US11788089B2 - Compositions and methods for modulating MECP2 expression - Google Patents
Compositions and methods for modulating MECP2 expression Download PDFInfo
- Publication number
- US11788089B2 US11788089B2 US16/876,271 US202016876271A US11788089B2 US 11788089 B2 US11788089 B2 US 11788089B2 US 202016876271 A US202016876271 A US 202016876271A US 11788089 B2 US11788089 B2 US 11788089B2
- Authority
- US
- United States
- Prior art keywords
- mecp2
- oligonucleotide
- nucleotide
- nucleotides
- single stranded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 101150083522 MECP2 gene Proteins 0.000 title claims abstract description 238
- 102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 title claims abstract description 192
- 238000000034 method Methods 0.000 title claims abstract description 84
- 230000014509 gene expression Effects 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title abstract description 69
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 400
- 125000003729 nucleotide group Chemical group 0.000 claims description 267
- 239000002773 nucleotide Substances 0.000 claims description 226
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 58
- 230000000295 complement effect Effects 0.000 claims description 58
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 45
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 31
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 27
- 230000001965 increasing effect Effects 0.000 claims description 16
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 12
- 208000006289 Rett Syndrome Diseases 0.000 claims description 10
- 239000002679 microRNA Substances 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 9
- 208000009575 Angelman syndrome Diseases 0.000 claims description 8
- 208000014644 Brain disease Diseases 0.000 claims description 8
- 208000032274 Encephalopathy Diseases 0.000 claims description 8
- 201000001875 X-linked intellectual disability-psychosis-macroorchidism syndrome Diseases 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 238000002473 ribonucleic acid immunoprecipitation Methods 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 238000012163 sequencing technique Methods 0.000 claims description 7
- 108700011259 MicroRNAs Proteins 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 108091028664 Ribonucleotide Proteins 0.000 claims description 4
- 239000012133 immunoprecipitate Substances 0.000 claims description 4
- 239000002336 ribonucleotide Substances 0.000 claims description 4
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 4
- 101100465401 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SCL1 gene Proteins 0.000 claims 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 119
- 230000003213 activating effect Effects 0.000 abstract description 12
- 230000002708 enhancing effect Effects 0.000 abstract description 8
- 108010000597 Polycomb Repressive Complex 2 Proteins 0.000 description 141
- 102000002272 Polycomb Repressive Complex 2 Human genes 0.000 description 141
- 108090000623 proteins and genes Proteins 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 43
- 230000004048 modification Effects 0.000 description 30
- 238000012986 modification Methods 0.000 description 30
- 108020004414 DNA Proteins 0.000 description 28
- 150000007523 nucleic acids Chemical class 0.000 description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 102000039446 nucleic acids Human genes 0.000 description 27
- 108020004707 nucleic acids Proteins 0.000 description 27
- 238000011282 treatment Methods 0.000 description 24
- 238000012384 transportation and delivery Methods 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 22
- 201000010099 disease Diseases 0.000 description 22
- -1 CPP Chemical compound 0.000 description 21
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 17
- 238000009472 formulation Methods 0.000 description 15
- 239000008194 pharmaceutical composition Substances 0.000 description 15
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 14
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 235000000346 sugar Nutrition 0.000 description 12
- 230000000692 anti-sense effect Effects 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 10
- 241000894007 species Species 0.000 description 10
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 9
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 229930024421 Adenine Natural products 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 8
- 108091093037 Peptide nucleic acid Proteins 0.000 description 7
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 7
- 229960000643 adenine Drugs 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 229940104302 cytosine Drugs 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 230000002685 pulmonary effect Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 235000020958 biotin Nutrition 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 108091070501 miRNA Proteins 0.000 description 6
- 239000002777 nucleoside Substances 0.000 description 6
- 150000003833 nucleoside derivatives Chemical class 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 229940035893 uracil Drugs 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940107161 cholesterol Drugs 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000007914 intraventricular administration Methods 0.000 description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 4
- 108010033040 Histones Proteins 0.000 description 4
- 108010071034 Retinoblastoma-Binding Protein 4 Proteins 0.000 description 4
- 102000007508 Retinoblastoma-Binding Protein 4 Human genes 0.000 description 4
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 150000001408 amides Chemical group 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 125000001921 locked nucleotide group Chemical group 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- RHCSKNNOAZULRK-APZFVMQVSA-N 2,2-dideuterio-2-(3,4,5-trimethoxyphenyl)ethanamine Chemical compound NCC([2H])([2H])C1=CC(OC)=C(OC)C(OC)=C1 RHCSKNNOAZULRK-APZFVMQVSA-N 0.000 description 3
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 3
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 3
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 102100033636 Histone H3.2 Human genes 0.000 description 3
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 3
- 101000866766 Homo sapiens Polycomb protein EED Proteins 0.000 description 3
- 101000584499 Homo sapiens Polycomb protein SUZ12 Proteins 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- 102100031338 Polycomb protein EED Human genes 0.000 description 3
- 102100030702 Polycomb protein SUZ12 Human genes 0.000 description 3
- 108091081021 Sense strand Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 229940014144 folate Drugs 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 229920000768 polyamine Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- QGVQZRDQPDLHHV-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3-thiol Chemical compound C1C=C2C[C@@H](S)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QGVQZRDQPDLHHV-DPAQBDIFSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 2
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 2
- HCGHYQLFMPXSDU-UHFFFAOYSA-N 7-methyladenine Chemical compound C1=NC(N)=C2N(C)C=NC2=N1 HCGHYQLFMPXSDU-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 2
- 229960005508 8-azaguanine Drugs 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 101150075175 Asgr1 gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 2
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 101001033726 Homo sapiens Methyl-CpG-binding protein 2 Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 2
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- XVIYCJDWYLJQBG-UHFFFAOYSA-N acetic acid;adamantane Chemical compound CC(O)=O.C1C(C2)CC3CC1CC2C3 XVIYCJDWYLJQBG-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000002214 arabinonucleotide Substances 0.000 description 2
- 230000037429 base substitution Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000003827 glycol group Chemical group 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 102000049101 human MECP2 Human genes 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000009437 off-target effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- ONTNXMBMXUNDBF-UHFFFAOYSA-N pentatriacontane-17,18,19-triol Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)C(O)CCCCCCCCCCCCCCCC ONTNXMBMXUNDBF-UHFFFAOYSA-N 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 150000004713 phosphodiesters Chemical group 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000003982 sigma receptor ligand Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- INEMUVRCEAELBK-UHFFFAOYSA-N 1,1,1,2-tetrafluoropropane Chemical compound CC(F)C(F)(F)F INEMUVRCEAELBK-UHFFFAOYSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
- UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- QSHACTSJHMKXTE-UHFFFAOYSA-N 2-(2-aminopropyl)-7h-purin-6-amine Chemical compound CC(N)CC1=NC(N)=C2NC=NC2=N1 QSHACTSJHMKXTE-UHFFFAOYSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- HBJGQJWNMZDFKL-UHFFFAOYSA-N 2-chloro-7h-purin-6-amine Chemical compound NC1=NC(Cl)=NC2=C1NC=N2 HBJGQJWNMZDFKL-UHFFFAOYSA-N 0.000 description 1
- HLLCNVLEVVFTJB-UHFFFAOYSA-N 2-fluoro-2-methylbutane Chemical compound CCC(C)(C)F HLLCNVLEVVFTJB-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- YNFSUOFXEVCDTC-UHFFFAOYSA-N 2-n-methyl-7h-purine-2,6-diamine Chemical compound CNC1=NC(N)=C2NC=NC2=N1 YNFSUOFXEVCDTC-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- JDBGXEHEIRGOBU-UHFFFAOYSA-N 5-hydroxymethyluracil Chemical compound OCC1=CNC(=O)NC1=O JDBGXEHEIRGOBU-UHFFFAOYSA-N 0.000 description 1
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- VKKXEIQIGGPMHT-UHFFFAOYSA-N 7h-purine-2,8-diamine Chemical class NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 description 1
- HRYKDUPGBWLLHO-UHFFFAOYSA-N 8-azaadenine Chemical compound NC1=NC=NC2=NNN=C12 HRYKDUPGBWLLHO-UHFFFAOYSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 241000023308 Acca Species 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100480489 Arabidopsis thaliana TAAC gene Proteins 0.000 description 1
- 102000008682 Argonaute Proteins Human genes 0.000 description 1
- 108010088141 Argonaute Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101100173970 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) fluG gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 102000011787 Histone Methyltransferases Human genes 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 1
- 101000651906 Homo sapiens Paired amphipathic helix protein Sin3a Proteins 0.000 description 1
- 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- FSNCEEGOMTYXKY-JTQLQIEISA-N Lycoperodine 1 Natural products N1C2=CC=CC=C2C2=C1CN[C@H](C(=O)O)C2 FSNCEEGOMTYXKY-JTQLQIEISA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 229910004679 ONO2 Inorganic materials 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100027334 Paired amphipathic helix protein Sin3a Human genes 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 101100271190 Plasmodium falciparum (isolate 3D7) ATAT gene Proteins 0.000 description 1
- 102100032442 Protein S100-A8 Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 230000026279 RNA modification Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 101710090029 Replication-associated protein A Proteins 0.000 description 1
- 108010071000 Retinoblastoma-Binding Protein 7 Proteins 0.000 description 1
- 102000007503 Retinoblastoma-Binding Protein 7 Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 108091007416 X-inactive specific transcript Proteins 0.000 description 1
- 108091035715 XIST (gene) Proteins 0.000 description 1
- WCDYMMVGBZNUGB-ORPFKJIMSA-N [(2r,3r,4s,5r,6r)-6-[[(1r,3r,4r,5r,6r)-4,5-dihydroxy-2,7-dioxabicyclo[4.2.0]octan-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl 3-hydroxy-2-tetradecyloctadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](COC(=O)C(CCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCC)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H]2OC[C@H]2O1 WCDYMMVGBZNUGB-ORPFKJIMSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000002215 arabinonucleoside Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000030303 breathing problems Diseases 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 238000009162 epigenetic therapy Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000009599 head growth Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- GZCNJTFELNTSAB-UHFFFAOYSA-N n'-(7h-purin-6-yl)hexane-1,6-diamine Chemical compound NCCCCCCNC1=NC=NC2=C1NC=N2 GZCNJTFELNTSAB-UHFFFAOYSA-N 0.000 description 1
- CJWXCNXHAIFFMH-AVZHFPDBSA-N n-[(2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy-3,5-dihydroxy-6-methyloxan-4-yl]acetamide Chemical compound C[C@H]1O[C@@H](O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)[C@H](O)[C@@H](NC(C)=O)[C@@H]1O CJWXCNXHAIFFMH-AVZHFPDBSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000025215 nuclear ribonucleic acid Diseases 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000008038 pharmaceutical propellant Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 101150054338 ref gene Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical group 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical group NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 150000003456 sulfonamides Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003457 sulfones Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000003977 synaptic function Effects 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
Definitions
- the invention relates to oligonucleotide based compositions, as well as methods of using oligonucleotide based compositions for treating disease.
- Rett syndrome is a developmental disorder of the brain occurring mostly in females characterized by normal early development, followed by a slowing of development resulting in loss of control of the hands, loss of speech, breathing problems, slowed brain and head growth, ambulatory problems, seizures, and mental retardation. Rett syndrome affects approximately 1 in 10,000 live female births. Most cases of Rett syndrome are caused by a mutation in the methyl CpG binding protein 2, or MECP2 gene, on the X chromosome that causes reduced activity or inactivation of MECP2.
- MECP2 is a transcriptional repressor that binds to methylated DNA and is present in large quantities in mature nerve cells.
- MECP2 represses transcription from methylated gene promoters through interaction with histone deacetylase and the corepressor SIN3A.
- Many of the genes that are known to be regulated by the MECP2 protein play a role in normal brain function, particularly the maintenance of synapses.
- Mouse studies have demonstrated MECP2 mutations cause defects in synaptic function, especially in synaptic plasticity.
- single stranded oligonucleotides are provided that target a PRC2-associated region of a MECP2 gene (e.g., human MECP2) and thereby cause upregulation of the gene.
- single stranded oligonucleotides are provided that target a PRC2-associated region of the gene encoding MECP2.
- these single stranded oligonucleotides activate or enhance expression of MECP2 by relieving or preventing PRC2 mediated repression of MECP2.
- Upregulation of MECP2 offers a treatment for diseases associated with decreased MECP2 activity.
- Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating MECP2 for the treatment and/or prevention of Rett Syndrome.
- MECP2 is also associated with MECP2-related severe neonatal encephalopathy, Angelman syndrome, and PPM-X syndrome. Accordingly, certain aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating MECP2 for the treatment and/or prevention of MECP2-related severe neonatal encephalopathy, Angelman syndrome, and PPM-X syndrome.
- Further aspects of the invention provide methods for selecting oligonucleotides for activating or enhancing expression of MECP2.
- methods are provided for selecting a set of oligonucleotides that is enriched in candidates (e.g., compared with a random selection of oligonucleotides) for activating or enhancing expression of MECP2. Accordingly, the methods may be used to establish sets of clinical candidates that are enriched in oligonucleotides that activate or enhance expression of MECP2.
- Such libraries may be utilized, for example, to identify lead oligonucleotides for developing therapeutics to treat MECP2.
- oligonucleotide chemistries are provided that are useful for controlling the pharmacokinetics, biodistribution, bioavailability and/or efficacy of the single stranded oligonucleotides for activating expression of MECP2.
- single stranded oligonucleotides that have a region of complementarity that is complementarity with (e.g., at least 8 consecutive nucleotides of) a PRC2-associated region of a MECP2 gene, e.g., a PRC2-associated region of the nucleotide sequence set forth as SEQ ID NO: 1 or 2.
- the oligonucleotide has at least one of the following features: a) a sequence that is 5′X-Y-Z, in which X is any nucleotide and in which X is at the 5′ end of the oligonucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a human seed sequence of a microRNA, and Z is a nucleotide sequence of 1 to 23 nucleotides in length; b) a sequence that does not comprise three or more consecutive guanosine nucleotides; c) a sequence that has less than a threshold level of sequence identity with every sequence of nucleotides, of equivalent length to the second nucleotide sequence, that are between 50 kilobases upstream of a 5′-end of an off-target gene and 50 kilobases downstream of a 3′-end of the off-target gene; d) a sequence that is complementary to a PRC2-
- the single stranded oligonucleotide has at least two of features a), b), c), d), and e), each independently selected. In some embodiments, the single stranded oligonucleotide has at least three of features a), b), c), d), and e), each independently selected. In some embodiments, the single stranded oligonucleotide has at least four of features a), b), c), d), and e), each independently selected. In some embodiments, the single stranded oligonucleotide has each of features a), b), c), d), and e). In certain embodiments, the oligonucleotide has the sequence 5′X-Y-Z, in which the oligonucleotide is 8-50 nucleotides in length.
- single stranded oligonucleotides have a sequence X-Y-Z, in which X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 1 to 23 nucleotides in length, in which the single stranded oligonucleotide is complementary with a PRC2-associated region of a MECP2 gene, e.g., a PRC2-associated region of the nucleotide sequence set forth as SEQ ID NO: 1 or 2.
- single stranded oligonucleotides have a sequence 5′-X-Y-Z, in which X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 1 to 23 nucleotides in length, in which the single stranded oligonucleotide is complementary with at least 8 consecutive nucleotides of a PRC2-associated region of a MECP2 gene, e.g., a PRC2-associated region of the nucleotide sequence set forth as SEQ ID NO: 1 or 2.
- Y is a sequence selected from Table 1.
- the PRC2-associated region is a sequence listed in any one of SEQ ID NOS: 5 to 118.
- the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 119 to 83660, or a fragment thereof that is at least 8 nucleotides.
- the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 119 to 83660, in which the 5′ end of the nucleotide sequence provided is the 5′ end of the oligonucleotide.
- the region of complementarity e.g., the at least 8 consecutive nucleotides is also present within the nucleotide sequence set forth as SEQ ID NO: 3 or 4.
- the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 119 to 83660. In some embodiments, the single stranded oligonucleotide comprises a fragment of at least 8 nucleotides of a nucleotide sequence as set forth in any one of SEQ ID NOS: 119 to 83660.
- the PRC2-associated region is a sequence listed in any one of SEQ ID NOS: 5 to 84.
- the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 119 to 47653 or a fragment thereof that is at least 8 nucleotides.
- the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 119 to 47653, wherein the 5′ end of the nucleotide sequence provided in any one of SEQ ID NOS: 119 to 47653 is the 5′ end of the oligonucleotide.
- the at least 8 consecutive nucleotides are also present within the nucleotide sequence set forth as SEQ ID NO: 3.
- the PRC2-associated region is a sequence listed in any one of SEQ ID NOS: 85 to 118.
- the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 47462 to 83660 or a fragment thereof that is at least 8 nucleotides.
- the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 47462 to 83660, wherein the 5′ end of the nucleotide sequence provided in any one of SEQ ID NOS: 47462 to 83660 is the 5′ end of the oligonucleotide.
- the at least 8 consecutive nucleotides are present within the nucleotide sequence set forth as SEQ ID NO: 4.
- a single stranded oligonucleotide comprises a nucleotide sequence as set forth in Table 3. In some embodiments, the single stranded oligonucleotide comprises a fragment of at least 8 nucleotides of a nucleotide sequence as set forth in Table 3. In some embodiments, a single stranded oligonucleotide consists of a nucleotide sequence as set forth in Table 3.
- the single stranded oligonucleotide does not comprise three or more consecutive guanosine nucleotides. In some embodiments, the single stranded oligonucleotide does not comprise four or more consecutive guanosine nucleotides.
- the single stranded oligonucleotide is 8 to 30 nucleotides in length. In some embodiments, the single stranded oligonucleotide is up to 50 nucleotides in length. In some embodiments, the single stranded oligonucleotide is 8 to 10 nucleotides in length and all but 1, 2, or 3 of the nucleotides of the complementary sequence of the PRC2-associated region are cytosine or guanosine nucleotides.
- the single stranded oligonucleotide is complementary with at least 8 consecutive nucleotides of a PRC2-associated region of a MECP2 gene, e.g., a PRC2-associated region of a nucleotide sequence set forth as SEQ ID NO: 1 or 2, in which the nucleotide sequence of the single stranded oligonucleotide comprises one or more of a nucleotide sequence selected from the group consisting of
- At least one nucleotide of the oligonucleotide is a nucleotide analogue.
- the at least one nucleotide analogue results in an increase in Tm of the oligonucleotide in a range of 1 to 5° C. compared with an oligonucleotide that does not have the at least one nucleotide analogue.
- At least one nucleotide of the oligonucleotide comprises a 2′ O-methyl. In some embodiments, each nucleotide of the oligonucleotide comprises a 2′ O-methyl. In some embodiments, the oligonucleotide comprises at least one ribonucleotide, at least one deoxyribonucleotide, or at least one bridged nucleotide. In some embodiments, the bridged nucleotide is a LNA nucleotide, a cEt nucleotide or a ENA modified nucleotide. In some embodiments, each nucleotide of the oligonucleotide is a LNA nucleotide.
- the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and 2′-fluoro-deoxyribonucleotides. In some embodiments, the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and 2′-O-methyl nucleotides. In some embodiments, the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and ENA nucleotide analogues. In some embodiments, the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and LNA nucleotides.
- the 5′ nucleotide of the oligonucleotide is a deoxyribonucleotide. In some embodiments, the nucleotides of the oligonucleotide comprise alternating LNA nucleotides and 2′-O-methyl nucleotides. In some embodiments, the 5′ nucleotide of the oligonucleotide is a LNA nucleotide. In some embodiments, the nucleotides of the oligonucleotide comprise deoxyribonucleotides flanked by at least one LNA nucleotide on each of the 5′ and 3′ ends of the deoxyribonucleotides.
- the single stranded oligonucleotide comprises modified internucleotide linkages (e.g., phosphorothioate internucleotide linkages or other linkages) between at least two, at least three, at least four, at least five or more nucleotides. In some embodiments, the single stranded oligonucleotide comprises modified internucleotide linkages (e.g., phosphorothioate internucleotide linkages or other linkages) between all nucleotides.
- modified internucleotide linkages e.g., phosphorothioate internucleotide linkages or other linkages
- the nucleotide at the 3′ position of the oligonucleotide has a 3′ hydroxyl group. In some embodiments, the nucleotide at the 3′ position of the oligonucleotide has a 3′ thiophosphate. In some embodiments, the single stranded oligonucleotide has a biotin moiety or other moiety conjugated to its 5′ or 3′ nucleotide.
- the single stranded oligonucleotide has cholesterol, Vitamin A, folate, sigma receptor ligands, aptamers, peptides, such as CPP, hydrophobic molecules, such as lipids, ASGPR or dynamic polyconjugates and variants thereof at its 5′ or 3′ end.
- compositions are provided that comprise any of the oligonucleotides disclosed herein, and a carrier.
- compositions are provided that comprise any of the oligonucleotides in a buffered solution.
- the oligonucleotide is conjugated to the carrier.
- the carrier is a peptide.
- the carrier is a steroid.
- pharmaceutical compositions are provided that comprise any of the oligonucleotides disclosed herein, and a pharmaceutically acceptable carrier.
- kits that comprise a container housing any of the compositions disclosed herein.
- methods of increasing expression of MECP2 in a cell involve delivering any one or more of the single stranded oligonucleotides disclosed herein into the cell.
- delivery of the single stranded oligonucleotide into the cell results in a level of expression of MECP2 that is greater (e.g., at least 50% greater) than a level of expression of MECP2 in a control cell that does not comprise the single stranded oligonucleotide.
- methods of increasing levels of MECP2 in a subject are provided.
- methods of treating a condition e.g., Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, PPM-X syndrome
- the methods involve administering any one or more of the single stranded oligonucleotides disclosed herein to the subject.
- Table 3 Formatted oligonucleotide sequences made for testing showing nucleotide modifications.
- the table shows the sequence of the modified nucleotides, where InaX represents an LNA nucleotide with 3′ phosphorothioate linkage, omeX is a 2′-O-methyl nucleotide, dX is a deoxy nucleotide.
- An s at the end of a nucleotide code indicates that the nucleotide had a 3′ phosphorothioate linkage.
- the “ ⁇ Sup” at the end of the sequence marks the fact that the 3′ end lacks either a phosphate or thiophosphate on the 3′ linkage.
- the Formatted Sequence column shows the sequence of the oligonucleotide, including modified nucleotides.
- Polycomb repressive complex 2 (PRC2) is a histone methyltransferase and a known epigenetic regulator involved in silencing of genomic regions through methylation of histone H3.
- PRC2 interacts with long noncoding RNAs (lncRNAs), such as RepA, Xist, and Tsix, to catalyze trimethylation of histone H3-lysine27.
- lncRNAs long noncoding RNAs
- RepA long noncoding RNAs
- Xist Xist
- Tsix long noncoding RNAs
- PRC2 contains four subunits, Eed, Suz12, RbAp48, and Ezh2.
- aspects of the invention relate to the recognition that single stranded oligonucleotides that bind to PRC2-associated regions of RNAs (e.g., lncRNAs) that are expressed from within a genomic region that encompasses or that is in functional proximity to the MECP2 gene can induce or enhance expression of MECP2. In some embodiments, this upregulation is believed to result from inhibition of PRC2 mediated repression of MECP2.
- RNAs e.g., lncRNAs
- PRC2-associated region refers to a region of a nucleic acid that comprises or encodes a sequence of nucleotides that interact directly or indirectly with a component of PRC2.
- a PRC2-associated region may be present in a RNA (e.g., a long non-coding RNA (lncRNA)) that that interacts with a PRC2.
- lncRNA long non-coding RNA
- a PRC2-associated region may be present in a DNA that encodes an RNA that interacts with PRC2. In some cases, the PRC2-associated region is equivalently referred to as a PRC2-interacting region.
- a PRC2-associated region is a region of an RNA that crosslinks to a component of PRC2 in response to in situ ultraviolet irradiation of a cell that expresses the RNA, or a region of genomic DNA that encodes that RNA region.
- a PRC2-associated region is a region of an RNA that immunoprecipitates with an antibody that targets a component of PRC2, or a region of genomic DNA that encodes that RNA region.
- a PRC2-associated region is a region of an RNA that immunoprecipitates with an antibody that binds specifically to SUZ12, EED, EZH2 or RBBP4 (which as noted above are components of PRC2), or a region of genomic DNA that encodes that RNA region.
- a PRC2-associated region is a region of an RNA that is protected from nucleases (e.g., RNases) in an RNA-immunoprecipitation assay that employs an antibody that targets a component of PRC2, or a region of genomic DNA that encodes that protected RNA region.
- a PRC2-associated region is a region of an RNA that is protected from nucleases (e.g., RNases) in an RNA-immunoprecipitation assay that employs an antibody that targets SUZ12, EED, EZH2 or RBBP4, or a region of genomic DNA that encodes that protected RNA region.
- a PRC2-associated region is a region of an RNA within which occur a relatively high frequency of sequence reads in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an antibody that targets a component of PRC2, or a region of genomic DNA that encodes that RNA region.
- a PRC2-associated region is a region of an RNA within which occur a relatively high frequency of sequence reads in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an antibody that binds specifically to SUZ12, EED, EZH2 or RBBP4, or a region of genomic DNA that encodes that protected RNA region.
- the PRC2-associated region may be referred to as a “peak.”
- a PRC2-associated region comprises a sequence of 40 to 60 nucleotides that interact with PRC2 complex. In some embodiments, a PRC2-associated region comprises a sequence of 40 to 60 nucleotides that encode an RNA that interacts with PRC2. In some embodiments, a PRC2-associated region comprises a sequence of up to 5 kb in length that comprises a sequence (e.g., of 40 to 60 nucleotides) that interacts with PRC2. In some embodiments, a PRC2-associated region comprises a sequence of up to 5 kb in length within which an RNA is encoded that has a sequence (e.g., of 40 to 60 nucleotides) that is known to interact with PRC2.
- a PRC2-associated region comprises a sequence of about 4 kb in length that comprise a sequence (e.g., of 40 to 60 nucleotides) that interacts with PRC2. In some embodiments, a PRC2-associated region comprises a sequence of about 4 kb in length within which an RNA is encoded that includes a sequence (e.g., of 40 to 60 nucleotides) that is known to interact with PRC2. In some embodiments, a PRC2-associated region has a sequence as set forth in any one of SEQ ID NOS: 5 to 118.
- single stranded oligonucleotides are provided that specifically bind to, or are complementary to, a PRC2-associated region in a genomic region that encompasses or that is in proximity to the MECP2 gene. In some embodiments, single stranded oligonucleotides are provided that specifically bind to, or are complementary to, a PRC2-associated region that has a sequence as set forth in any one of SEQ ID NOS: 5 to 118.
- single stranded oligonucleotides are provided that specifically bind to, or are complementary to, a PRC2-associated region that has a sequence as set forth in any one of SEQ ID NOS: 5 to 118 combined with up to 2 kb, up to 5 kb, or up to 10 kb of flanking sequences from a corresponding genomic region to which these SEQ IDs map (e.g., in a human genome).
- single stranded oligonucleotides have a sequence as set forth in any one of SEQ ID NOS: 119 to 83660.
- single stranded oligonucleotides have a sequence as set forth in Table 3.
- these oligonucleotides are able to interfere with the binding of and function of PRC2, by preventing recruitment of PRC2 to a specific chromosomal locus.
- a single administration of single stranded oligonucleotides designed to specifically bind a PRC2-associated region lncRNA can stably displace not only the lncRNA, but also the PRC2 that binds to the lncRNA, from binding chromatin. After displacement, the full complement of PRC2 is not recovered for up to 24 hours.
- lncRNA can recruit PRC2 in a cis fashion, repressing gene expression at or near the specific chromosomal locus from which the lncRNA was transcribed.
- Methods of modulating gene expression are provided, in some embodiments, that may be carried out in vitro, ex vivo, or in vivo. It is understood that any reference to uses of compounds throughout the description contemplates use of the compound in preparation of a pharmaceutical composition or medicament for use in the treatment of condition (e.g., Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, PPM-X syndrome) associated with decreased levels or activity of MECP2.
- condition e.g., Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, PPM-X syndrome
- this aspect of the invention includes use of such single stranded oligonucleotides in the preparation of a medicament for use in the treatment of disease, wherein the treatment involves upregulating expression of MECP2.
- methods are provided for selecting a candidate oligonucleotide for activating expression of MECP2.
- the methods generally involve selecting as a candidate oligonucleotide, a single stranded oligonucleotide comprising a nucleotide sequence that is complementary to a PRC2-associated region (e.g., a nucleotide sequence as set forth in any one of SEQ ID NOS: 5 to 118).
- sets of oligonucleotides may be selected that are enriched (e.g., compared with a random selection of oligonucleotides) in oligonucleotides that activate expression of MECP2.
- single stranded oligonucleotides complementary to the PRC2-associated regions are provided for modulating expression of MECP2 in a cell.
- expression of MECP2 is upregulated or increased.
- single stranded oligonucleotides complementary to these PRC2-associated regions inhibit the interaction of PRC2 with long RNA transcripts such that gene expression is upregulated or increased.
- single stranded oligonucleotides complementary to these PRC2-associated regions inhibit the interaction of PRC2 with long RNA transcripts, resulting in reduced methylation of histone H3 and reduced gene inactivation, such that gene expression is upregulated or increased.
- this interaction may be disrupted or inhibited due to a change in the structure of the long RNA that prevents or reduces binding to PRC2.
- the oligonucleotide may be selected using any of the methods disclosed herein for selecting a candidate oligonucleotide for activating expression of MECP2.
- the single stranded oligonucleotide may comprise a region of complementarity that is complementary with a PRC2-associated region of a nucleotide sequence set forth in any one of SEQ ID NOS: 1 to 4.
- the region of complementarity of the single stranded oligonucleotide may be complementary with at least 6, e.g., at least 7, at least 8, at least 9, at least 10, at least 15 or more consecutive nucleotides of the PRC2-associated region.
- the PRC2-associated region may map to a position in a chromosome between 50 kilobases upstream of a 5′-end of the MECP2 gene and 50 kilobases downstream of a 3′-end of the MECP2 gene.
- the PRC2-associated region may map to a position in a chromosome between 25 kilobases upstream of a 5′-end of the MECP2 gene and 25 kilobases downstream of a 3′-end of the MECP2 gene.
- the PRC2-associated region may map to a position in a chromosome between 12 kilobases upstream of a 5′-end of the MECP2 gene and 12 kilobases downstream of a 3′-end of the MECP2 gene.
- the PRC2-associated region may map to a position in a chromosome between 5 kilobases upstream of a 5′-end of the MECP2 gene and 5 kilobases downstream of a 3′-end of the ME
- the genomic position of the selected PRC2-associated region relative to the MECP2 gene may vary.
- the PRC2-associated region may be upstream of the 5′ end of the MECP2 gene.
- the PRC2-associated region may be downstream of the 3′ end of the MECP2 gene.
- the PRC2-associated region may be within an intron of the MECP2 gene.
- the PRC2-associated region may be within an exon of the MECP2 gene.
- the PRC2-associated region may traverse an intron-exon junction, a 5′-UTR-exon junction or a 3′-UTR-exon junction of the MECP2 gene.
- the single stranded oligonucleotide may comprise a sequence having the formula X-Y-Z, in which X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a human seed sequence of a microRNA, and Z is a nucleotide sequence of varying length.
- X is the 5′ nucleotide of the oligonucleotide.
- the oligonucleotide when X is anchored at the 5′ end of the oligonucleotide, the oligonucleotide does not have any nucleotides or nucleotide analogs linked 5′ to X.
- the single stranded oligonucleotide has a sequence 5′X-Y-Z and is 8-50 nucleotides in length. Oligonucleotides that have these sequence characteristics are predicted to avoid the miRNA pathway. Therefore, in some embodiments, oligonucleotides having these sequence characteristics are unlikely to have an unintended consequence of functioning in a cell as a miRNA molecule.
- the Y sequence may be a nucleotide sequence of 6 nucleotides in length set forth in Table 1.
- the single stranded oligonucleotide may have a sequence that does not contain guanosine nucleotide stretches (e.g., 3 or more, 4 or more, 5 or more, 6 or more consecutive guanosine nucleotides).
- guanosine nucleotide stretches e.g., 3 or more, 4 or more, 5 or more, 6 or more consecutive guanosine nucleotides.
- oligonucleotides having guanosine nucleotide stretches have increased non-specific binding and/or off-target effects, compared with oligonucleotides that do not have guanosine nucleotide stretches.
- the single stranded oligonucleotide may have a sequence that has less than a threshold level of sequence identity with every sequence of nucleotides, of equivalent length, that map to a genomic position encompassing or in proximity to an off-target gene.
- a threshold level of sequence identity may be 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity.
- the single stranded oligonucleotide may have a sequence that is complementary to a PRC2-associated region that encodes an RNA that forms a secondary structure comprising at least two single stranded loops.
- oligonucleotides that are complementary to a PRC2-associated region that encodes an RNA that forms a secondary structure comprising one or more single stranded loops e.g., at least two single stranded loops
- have a greater likelihood of being active e.g., of being capable of activating or enhancing expression of a target gene than a randomly selected oligonucleotide.
- the secondary structure may comprise a double stranded stem between the at least two single stranded loops.
- the region of complementarity between the oligonucleotide and the PRC2-associated region may be at a location of the PRC2 associated region that encodes at least a portion of at least one of the loops.
- the region of complementarity between the oligonucleotide and the PRC2-associated region may be at a location of the PRC2-associated region that encodes at least a portion of at least two of the loops.
- the region of complementarity between the oligonucleotide and the PRC2-associated region may be at a location of the PRC2 associated region that encodes at least a portion of the double stranded stem.
- a PRC2-associated region e.g., of an lncRNA
- the predicted secondary structure RNA (e.g., lncRNA) containing the PRC2-associated region is determined using RNA secondary structure prediction algorithms, e.g., RNAfold, mfold.
- oligonucleotides are designed to target a region of the RNA that forms a secondary structure comprising one or more single stranded loop (e.g., at least two single stranded loops) structures which may comprise a double stranded stem between the at least two single stranded loops.
- a single stranded loop e.g., at least two single stranded loops
- the single stranded oligonucleotide may have a sequence that is has greater than 30% G-C content, greater than 40% G-C content, greater than 50% G-C content, greater than 60% G-C content, greater than 70% G-C content, or greater than 80% G-C content.
- the single stranded oligonucleotide may have a sequence that has up to 100% G-C content, up to 95% G-C content, up to 90% G-C content, or up to 80% G-C content.
- the oligonucleotide is 8 to 10 nucleotides in length, all but 1, 2, 3, 4, or 5 of the nucleotides of the complementary sequence of the PRC2-associated region are cytosine or guanosine nucleotides.
- the sequence of the PRC2-associated region to which the single stranded oligonucleotide is complementary comprises no more than 3 nucleotides selected from adenine and uracil.
- the single stranded oligonucleotide may be complementary to a chromosome of a different species (e.g., a mouse, rat, rabbit, goat, monkey, etc.) at a position that encompasses or that is in proximity to that species' homolog of MECP2.
- the single stranded oligonucleotide may be complementary to a human genomic region encompassing or in proximity to the MECP2 gene and also be complementary to a mouse genomic region encompassing or in proximity to the mouse homolog of MECP2.
- the single stranded oligonucleotide may be complementary to a sequence as set forth in SEQ ID NO: 1 or 2, which is a human genomic region encompassing or in proximity to the MECP2 gene, and also be complementary to a sequence as set forth in SEQ ID NO: 3 or 4, which is a mouse genomic region encompassing or in proximity to the mouse homolog of the MECP2 gene. Oligonucleotides having these characteristics may be tested in vivo or in vitro for efficacy in multiple species (e.g., human and mouse). This approach also facilitates development of clinical candidates for treating human disease by selecting a species in which an appropriate animal exists for the disease.
- the region of complementarity of the single stranded oligonucleotide is complementary with at least 8 to 15, 8 to 30, 8 to 40, or 10 to 50, or 5 to 50, or 5 to 40 bases, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive nucleotides of a PRC2-associated region.
- the region of complementarity is complementary with at least 8 consecutive nucleotides of a PRC2-associated region.
- sequence of the single stranded oligonucleotide is based on an RNA sequence that binds to PRC2, or a portion thereof, said portion having a length of from 5 to 40 contiguous base pairs, or about 8 to 40 bases, or about 5 to 15, or about 5 to 30, or about 5 to 40 bases, or about 5 to 50 bases.
- Complementary refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of PRC2-associated region, then the single stranded nucleotide and PRC2-associated region are considered to be complementary to each other at that position.
- the single stranded nucleotide and PRC2-associated region are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides that can hydrogen bond with each other through their bases.
- complementary is a term which is used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the single stranded nucleotide and PRC2-associated region. For example, if a base at one position of a single stranded nucleotide is capable of hydrogen bonding with a base at the corresponding position of a PRC2-associated region, then the bases are considered to be complementary to each other at that position. 100% complementarity is not required.
- the single stranded oligonucleotide may be at least 80% complementary to (optionally one of at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% complementary to) the consecutive nucleotides of a PRC2-associated region.
- the single stranded oligonucleotide may contain 1, 2 or 3 base mismatches compared to the portion of the consecutive nucleotides of a PRC2-associated region.
- the single stranded oligonucleotide may have up to 3 mismatches over 15 bases, or up to 2 mismatches over 10 bases.
- a complementary nucleotide sequence need not be 100% complementary to that of its target to be specifically hybridizable.
- a complementary nucleic acid sequence for purposes of the present disclosure is specifically hybridizable when binding of the sequence to the target molecule (e.g., lncRNA) interferes with the normal function of the target (e.g., lncRNA) to cause a loss of activity (e.g., inhibiting PRC2-associated repression with consequent up-regulation of gene expression) and there is a sufficient degree of complementarity to avoid non-specific binding of the sequence to non-target sequences under conditions in which avoidance of non-specific binding is desired, e.g., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed under suitable conditions of stringency.
- the single stranded oligonucleotide is 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50 or more nucleotides in length. In a preferred embodiment, the oligonucleotide is 8 to 30 nucleotides in length.
- the PRC2-associated region occurs on the same DNA strand as a gene sequence (sense). In some embodiments, the PRC2-associated region occurs on the opposite DNA strand as a gene sequence (anti-sense). Oligonucleotides complementary to a PRC2-associated region can bind either sense or anti-sense sequences.
- Base pairings may include both canonical Watson-Crick base pairing and non-Watson-Crick base pairing (e.g., Wobble base pairing and Hoogsteen base pairing).
- adenosine-type bases are complementary to thymidine-type bases (T) or uracil-type bases (U), that cytosine-type bases (C) are complementary to guanosine-type bases (G), and that universal bases such as 3-nitropyrrole or 5-nitroindole can hybridize to and are considered complementary to any A, C, U, or T.
- Inosine (I) has also been considered in the art to be a universal base and is considered complementary to any A, C, U or T.
- any one or more thymidine (T) nucleotides (or modified nucleotide thereof) or uridine (U) nucleotides (or a modified nucleotide thereof) in a sequence provided herein, including a sequence provided in the sequence listing, may be replaced with any other nucleotide suitable for base pairing (e.g., via a Watson-Crick base pair) with an adenosine nucleotide.
- any one or more thymidine (T) nucleotides (or modified nucleotide thereof) or uridine (U) nucleotides (or a modified nucleotide thereof) in a sequence provided herein, including a sequence provided in the sequence listing, may be suitably replaced with a different pyrimidine nucleotide or vice versa.
- any one or more thymidine (T) nucleotides (or modified nucleotide thereof) in a sequence provided herein, including a sequence provided in the sequence listing may be suitably replaced with a uridine (U) nucleotide (or a modified nucleotide thereof) or vice versa.
- GC content of the single stranded oligonucleotide is preferably between about 30-60%. Contiguous runs of three or more Gs or Cs may not be preferable in some embodiments. Accordingly, in some embodiments, the oligonucleotide does not comprise a stretch of three or more guanosine nucleotides.
- the single stranded oligonucleotide specifically binds to, or is complementary to an RNA that is encoded in a genome (e.g., a human genome) as a single contiguous transcript (e.g., a non-spliced RNA).
- a genome e.g., a human genome
- a single contiguous transcript e.g., a non-spliced RNA
- the single stranded oligonucleotide specifically binds to, or is complementary to an RNA that is encoded in a genome (e.g., a human genome), in which the distance in the genome between the 5′end of the coding region of the RNA and the 3′ end of the coding region of the RNA is less than 1 kb, less than 2 kb, less than 3 kb, less than 4 kb, less than 5 kb, less than 7 kb, less than 8 kb, less than 9 kb, less than 10 kb, or less than 20 kb.
- a genome e.g., a human genome
- any oligonucleotide provided herein can be excluded.
- single stranded oligonucleotides disclosed herein may increase expression of mRNA corresponding to the gene by at least about 50% (i.e. 150% of normal or 1.5 fold), or by about 2 fold to about 5 fold.
- expression may be increased by at least about 15 fold, 20 fold, 30 fold, 40 fold, 50 fold or 100 fold, or any range between any of the foregoing numbers. It has also been found that increased mRNA expression has been shown to correlate to increased protein expression.
- the oligonucleotides will upregulate gene expression and may specifically bind or specifically hybridize or be complementary to the PRC2 binding RNA that is transcribed from the same strand as a protein coding reference gene.
- the oligonucleotide may bind to a region of the PRC2 binding RNA that originates within or overlaps an intron, exon, intron exon junction, 5′ UTR, 3′ UTR, a translation initiation region, or a translation termination region of a protein coding sense strand of a reference gene (refGene).
- the oligonucleotides will upregulate gene expression and may specifically bind or specifically hybridize or be complementary to a PRC2 binding RNA that transcribed from the opposite strand (the antisense strand) of a protein coding reference gene.
- the oligonucleotide may bind to a region of the PRC2 binding RNA that originates within or overlaps an intron, exon, intron exon junction, 5′ UTR, 3′ UTR, a translation initiation region, or a translation termination region of a protein coding antisense strand of a reference gene
- the oligonucleotides described herein may be modified, e.g., comprise a modified sugar moiety, a modified internucleoside linkage, a modified nucleotide and/or combinations thereof.
- the oligonucleotides can exhibit one or more of the following properties: do not induce substantial cleavage or degradation of the target RNA; do not cause substantially complete cleavage or degradation of the target RNA; do not activate the RNAse H pathway; do not activate RISC; do not recruit any Argonaute family protein; are not cleaved by Dicer; do not mediate alternative splicing; are not immune stimulatory; are nuclease resistant; have improved cell uptake compared to unmodified oligonucleotides; are not toxic to cells or mammals; may have improved endosomal exit; do interfere with interaction of lncRNA with PRC2, preferably the Ezh2 subunit but optionally the Suz12, Eed, RbAp46/48 sub
- Oligonucleotides that are designed to interact with RNA to modulate gene expression are a distinct subset of base sequences from those that are designed to bind a DNA target (e.g., are complementary to the underlying genomic DNA sequence from which the RNA is transcribed).
- oligonucleotides disclosed herein may be linked to one or more other oligonucleotides disclosed herein by a linker, e.g., a cleavable linker.
- a linker e.g., a cleavable linker.
- the target selection methods may generally involve steps for selecting single stranded oligonucleotides having any of the structural and functional characteristics disclosed herein.
- the methods involve one or more steps aimed at identifying oligonucleotides that target a PRC2-associated region that is functionally related to MECP2, for example a PRC2-associated region of a lncRNA that regulates expression of MECP2 by facilitating (e.g., in a cis-regulatory manner) the recruitment of PRC2 to the MECP2 gene.
- Such oligonucleotides are expected to be candidates for activating expression of MECP2 because of their ability to hybridize with the PRC2-associated region of a nucleic acid (e.g., a lncRNA).
- this hybridization event is understood to disrupt interaction of PRC2 with the nucleic acid (e.g., a lncRNA) and as a result disrupt recruitment of PRC2 and its associated co-repressors (e.g., chromatin remodeling factors) to the MECP2 gene locus.
- Methods of selecting a candidate oligonucleotide may involve selecting a PRC2-associated region (e.g., a nucleotide sequence as set forth in any one of SEQ ID NOS: 5 to 118) that maps to a chromosomal position encompassing or in proximity to the MECP2 gene (e.g., a chromosomal position having a sequence as set forth in any one of SEQ ID NOS: 1 to 4).
- the PRC2-associated region may map to the strand of the chromosome comprising the sense strand of the MECP2 gene, in which case the candidate oligonucleotide is complementary to the sense strand of the MECP2 gene (i.e., is antisense to the MECP2 gene).
- the PRC2-associated region may map to the strand of the first chromosome comprising the antisense strand of the MECP2 gene, in which case the oligonucleotide is complementary to the antisense strand (the template strand) of the MECP2 gene (i.e., is sense to the MECP2 gene).
- Methods for selecting a set of candidate oligonucleotides that is enriched in oligonucleotides that activate expression of MECP2 may involve selecting one or more PRC2-associated regions that map to a chromosomal position that encompasses or that is in proximity to the MECP2 gene and selecting a set of oligonucleotides, in which each oligonucleotide in the set comprises a nucleotide sequence that is complementary with the one or more PRC2-associated regions.
- a set of oligonucleotides that is enriched in oligonucleotides that activate expression of refers to a set of oligonucleotides that has a greater number of oligonucleotides that activate expression of a target gene (e.g., MECP2) compared with a random selection of oligonucleotides of the same physicochemical properties (e.g., the same GC content, T m , length etc.) as the enriched set.
- design and/or synthesis of a single stranded oligonucleotide involves design and/or synthesis of a sequence that is complementary to a nucleic acid or PRC2-associated region described by such sequence information
- the skilled person is readily able to determine the complementary sequence, e.g., through understanding of Watson Crick base pairing rules which form part of the common general knowledge in the field.
- design and/or synthesis of a single stranded oligonucleotide involves manufacture of an oligonucleotide from starting materials by techniques known to those of skill in the art, where the synthesis may be based on a sequence of a PRC2-associated region, or portion thereof.
- Methods of design and/or synthesis of a single stranded oligonucleotide may involve one or more of the steps of:
- Single stranded oligonucleotides so designed and/or synthesized may be useful in method of modulating gene expression as described herein.
- oligonucleotides of the invention are synthesized chemically.
- Oligonucleotides used to practice this invention can be synthesized in vitro by well-known chemical synthesis techniques.
- Oligonucleotides of the invention can be stabilized against nucleolytic degradation such as by the incorporation of a modification, e.g., a nucleotide modification.
- nucleic acid sequences of the invention include a phosphorothioate at least the first, second, or third internucleotide linkage at the 5′ or 3′ end of the nucleotide sequence.
- the nucleic acid sequence can include a 2′-modified nucleotide, e.g., a 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl (2′-O-MOE), 2′-O-aminopropyl (2′-O-AP), 2′-O-dimethylaminoethyl (2′-O-DMAOE), 2′-O-dimethylaminopropyl (2′-O-DMAP), 2′-O-dimethylaminoethyloxyethyl (2′-O-DMAEOE), or 2′-O—N-methylacetamido (2′-O-NMA).
- a 2′-modified nucleotide e.g., a 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl (2′-O-MO
- the nucleic acid sequence can include at least one 2′-O-methyl-modified nucleotide, and in some embodiments, all of the nucleotides include a 2′-O-methyl modification.
- the nucleic acids are “locked,” i.e., comprise nucleic acid analogues in which the ribose ring is “locked” by a methylene bridge connecting the 2′-O atom and the 4′-C atom.
- the method may further comprise the steps of amplifying the synthesized single stranded oligonucleotide, and/or purifying the single stranded oligonucleotide (or amplified single stranded oligonucleotide), and/or sequencing the single stranded oligonucleotide so obtained.
- the process of preparing a single stranded oligonucleotide may be a process that is for use in the manufacture of a pharmaceutical composition or medicament for use in the treatment of disease, optionally wherein the treatment involves modulating expression of a gene associated with a PRC2-associated region.
- a PRC2-associated region may be, or have been, identified, or obtained, by a method that involves identifying RNA that binds to PRC2.
- Such methods may involve the following steps: providing a sample containing nuclear ribonucleic acids, contacting the sample with an agent that binds specifically to PRC2 or a subunit thereof, allowing complexes to form between the agent and protein in the sample, partitioning the complexes, synthesizing nucleic acid that is complementary to nucleic acid present in the complexes.
- single stranded oligonucleotide is based on a PRC2-associated region, or a portion of such a sequence, it may be based on information about that sequence, e.g., sequence information available in written or electronic form, which may include sequence information contained in publicly available scientific publications or sequence databases.
- the oligonucleotide may comprise at least one ribonucleotide, at least one deoxyribonucleotide, and/or at least one bridged nucleotide.
- the oligonucleotide may comprise a bridged nucleotide, such as a locked nucleic acid (LNA) nucleotide, a constrained ethyl (cEt) nucleotide, or an ethylene bridged nucleic acid (ENA) nucleotide. Examples of such nucleotides are disclosed herein and known in the art.
- the oligonucleotide comprises a nucleotide analog disclosed in one of the following United States Patent or Patent Application Publications: U.S. Pat. Nos. 7,399,845, 7,741,457, 8,022,193, 7,569,686, 7,335,765, 7,314,923, 7,335,765, and U.S. Pat. No. 7,816,333, US 20110009471, the entire contents of each of which are incorporated herein by reference for all purposes.
- the oligonucleotide may have one or more 2′ O-methyl nucleotides.
- the oligonucleotide may consist entirely of 2′ O-methyl nucleotides.
- the single stranded oligonucleotide has one or more nucleotide analogues.
- the single stranded oligonucleotide may have at least one nucleotide analogue that results in an increase in T m of the oligonucleotide in a range of 1° C., 2° C., 3° C., 4° C., or 5° C. compared with an oligonucleotide that does not have the at least one nucleotide analogue.
- the single stranded oligonucleotide may have a plurality of nucleotide analogues that results in a total increase in T m of the oligonucleotide in a range of 2° C., 3° C., 4° C., 5° C., 6° C., 7° C., 8° C., 9° C., 10° C., 15° C., 20° C., 25° C., 30° C., 35° C., 40° C., 45° C. or more compared with an oligonucleotide that does not have the nucleotide analogue.
- the oligonucleotide may be of up to 50 nucleotides in length in which 2 to 10, 2 to 15, 2 to 16, 2 to 17, 2 to 18, 2 to 19, 2 to 20, 2 to 25, 2 to 30, 2 to 40, 2 to 45, or more nucleotides of the oligonucleotide are nucleotide analogues.
- the oligonucleotide may be of 8 to 30 nucleotides in length in which 2 to 10, 2 to 15, 2 to 16, 2 to 17, 2 to 18, 2 to 19, 2 to 20, 2 to 25, 2 to 30 nucleotides of the oligonucleotide are nucleotide analogues.
- the oligonucleotide may be of 8 to 15 nucleotides in length in which 2 to 4, 2 to 5, 2 to 6, 2 to 7, 2 to 8, 2 to 9, 2 to 10, 2 to 11, 2 to 12, 2 to 13, 2 to 14 nucleotides of the oligonucleotide are nucleotide analogues.
- the oligonucleotides may have every nucleotide except 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides modified.
- the oligonucleotide may consist entirely of bridged nucleotides (e.g., LNA nucleotides, cEt nucleotides, ENA nucleotides).
- the oligonucleotide may comprise alternating deoxyribonucleotides and 2′-fluoro-deoxyribonucleotides.
- the oligonucleotide may comprise alternating deoxyribonucleotides and 2′-O-methyl nucleotides.
- the oligonucleotide may comprise alternating deoxyribonucleotides and ENA nucleotide analogues.
- the oligonucleotide may comprise alternating deoxyribonucleotides and LNA nucleotides.
- the oligonucleotide may comprise alternating LNA nucleotides and 2′-O-methyl nucleotides.
- the oligonucleotide may have a 5′ nucleotide that is a bridged nucleotide (e.g., a LNA nucleotide, cEt nucleotide, ENA nucleotide).
- the oligonucleotide may have a 5′ nucleotide that is a deoxyribonucleotide.
- the oligonucleotide may comprise deoxyribonucleotides flanked by at least one bridged nucleotide (e.g., a LNA nucleotide, cEt nucleotide, ENA nucleotide) on each of the 5′ and 3′ ends of the deoxyribonucleotides.
- the oligonucleotide may comprise deoxyribonucleotides flanked by 1, 2, 3, 4, 5, 6, 7, 8 or more bridged nucleotides (e.g., LNA nucleotides, cEt nucleotides, ENA nucleotides) on each of the 5′ and 3′ ends of the deoxyribonucleotides.
- the 3′ position of the oligonucleotide may have a 3′ hydroxyl group.
- the 3′ position of the oligonucleotide may have a 3′ thiophosphate.
- the oligonucleotide may be conjugated with a label.
- the oligonucleotide may be conjugated with a biotin moiety, cholesterol, Vitamin A, folate, sigma receptor ligands, aptamers, peptides, such as CPP, hydrophobic molecules, such as lipids, ASGPR or dynamic polyconjugates and variants thereof at its 5′ or 3′ end.
- the single stranded oligonucleotide comprises one or more modifications comprising: a modified sugar moiety, and/or a modified internucleoside linkage, and/or a modified nucleotide and/or combinations thereof. It is not necessary for all positions in a given oligonucleotide to be uniformly modified, and in fact more than one of the modifications described herein may be incorporated in a single oligonucleotide or even at within a single nucleoside within an oligonucleotide.
- the single stranded oligonucleotides are chimeric oligonucleotides that contain two or more chemically distinct regions, each made up of at least one nucleotide.
- These oligonucleotides typically contain at least one region of modified nucleotides that confers one or more beneficial properties (such as, for example, increased nuclease resistance, increased uptake into cells, increased binding affinity for the target) and a region that is a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids.
- Chimeric single stranded oligonucleotides of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures comprise, but are not limited to, U.S. Pat. Nos.
- the single stranded oligonucleotide comprises at least one nucleotide modified at the 2′ position of the sugar, most preferably a 2′-O-alkyl, 2′-O-alkyl-O-alkyl or 2′-fluoro-modified nucleotide.
- RNA modifications include 2′-fluoro, 2′-amino and 2′ O-methyl modifications on the ribose of pyrimidines, abasic residues or an inverted base at the 3′ end of the RNA.
- modified oligonucleotides include those comprising modified backbones, for example, phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages.
- oligonucleotides with phosphorothioate backbones and those with heteroatom backbones particularly CH 2 —NH—O—CH 2 , CH, ⁇ N(CH 3 ) ⁇ O ⁇ CH 2 (known as a methylene(methylimino) or MMI backbone, CH 2 —O—N (CH 3 )—CH 2 , CH 2 —N (CH 3 )—N (CH 3 )—CH 2 and O—N (CH 3 )—CH 2 —CH 2 backbones, wherein the native phosphodiester backbone is represented as O— P— O— CH); amide backbones (see De Mesmaeker et al. Ace. Chem. Res.
- PNA peptide nucleic acid
- Phosphorus-containing linkages include, but are not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates comprising 3′alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′; see U.S.
- Morpholino-based oligomeric compounds are described in Dwaine A. Braasch and David R. Corey, Biochemistry, 2002, 41(14), 4503-4510); Genesis, volume 30, issue 3, 2001; Heasman, J., Dev. Biol., 2002, 243, 209-214; Nasevicius et al., Nat. Genet., 2000, 26, 216-220; Lacerra et al., Proc. Natl. Acad. Sci., 2000, 97, 9591-9596; and U.S. Pat. No. 5,034,506, issued Jul. 23, 1991.
- the morpholino-based oligomeric compound is a phosphorodiamidate morpholino oligomer (PMO) (e.g., as described in Iverson, Curr. Opin. Mol. Ther., 3:235-238, 2001; and Wang et al., J. Gene Med., 12:354-364, 2010; the disclosures of which are incorporated herein by reference in their entireties).
- PMO phosphorodiamidate morpholino oligomer
- Cyclohexenyl nucleic acid oligonucleotide mimetics are described in Wang et al., J. Am. Chem. Soc., 2000, 122, 8595-8602.
- Modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages.
- These comprise those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH2 component parts; see U.S. Pat. Nos.
- Modified oligonucleotides are also known that include oligonucleotides that are based on or constructed from arabinonucleotide or modified arabinonucleotide residues.
- Arabinonucleosides are stereoisomers of ribonucleosides, differing only in the configuration at the 2′-position of the sugar ring.
- a 2′-arabino modification is 2′-F arabino.
- the modified oligonucleotide is 2′-fluoro-D-arabinonucleic acid (FANA) (as described in, for example, Lon et al., Biochem., 41:3457-3467, 2002 and Min et al., Bioorg. Med. Chem. Lett., 12:2651-2654, 2002; the disclosures of which are incorporated herein by reference in their entireties). Similar modifications can also be made at other positions on the sugar, particularly the 3′ position of the sugar on a 3′ terminal nucleoside or in 2′-5′ linked oligonucleotides and the 5′ position of 5′ terminal nucleotide.
- FANA 2′-fluoro-D-arabinonucleic acid
- WO 99/67378 discloses arabinonucleic acids (ANA) oligomers and their analogues for improved sequence specific inhibition of gene expression via association to complementary messenger RNA.
- ENAs ethylene-bridged nucleic acids
- Preferred ENAs include, but are not limited to, 2′-O,4′-C-ethylene-bridged nucleic acids.
- LNAs examples include compounds of the following general formula.
- R is selected from hydrogen and C 1-4 -alkyl
- Z and Z* are independently selected among an internucleoside linkage, a terminal group or a protecting group
- B constitutes a natural or non-natural nucleotide base moiety
- the asymmetric groups may be found in either orientation.
- the LNA used in the oligonucleotides described herein comprises at least one LNA unit according any of the formulas
- Y is —O—, —S—, —NH—, or N(R H );
- Z and Z* are independently selected among an internucleoside linkage, a terminal group or a protecting group;
- B constitutes a natural or non-natural nucleotide base moiety, and
- RH is selected from hydrogen and C 1-4 -alkyl.
- the Locked Nucleic Acid (LNA) used in the oligonucleotides described herein comprises at least one Locked Nucleic Acid (LNA) unit according any of the formulas shown in Scheme 2 of PCT/DK2006/000512.
- the LNA used in the oligomer of the invention comprises internucleoside linkages selected from -0-P(O) 2 —O—, —O—P(O,S)—O—, —O—P(S) 2 —O—, —S—P(O) 2 —O—, —S—P(O,S)—O—, —S—P(S) 2 —O—, -0-P(O) 2 —S—, —O—P(O,S)—S—, —S—P(O) 2 —S—, —O—PO(R H )—O—, O—PO(OCH 3 )—O—, —O—PO(NR H )—O—, -0-PO(OCH 2 CH 2 S—R)—O—, —O—PO(BH 3 )—O—, —O—PO(NHR H )—O—, —O—P(O) 2 —NR H —
- thio-LNA comprises a locked nucleotide in which at least one of X or Y in the general formula above is selected from S or —CH 2 —S—.
- Thio-LNA can be in both beta-D and alpha-L-configuration.
- amino-LNA comprises a locked nucleotide in which at least one of X or Y in the general formula above is selected from —N(H)—, N(R)—, CH 2 —N(H)—, and —CH 2 —N(R)— where R is selected from hydrogen and C 1-4 -alkyl.
- Amino-LNA can be in both beta-D and alpha-L-configuration.
- Oxy-LNA comprises a locked nucleotide in which at least one of X or Y in the general formula above represents —O— or —CH 2 —O—. Oxy-LNA can be in both beta-D and alpha-L-configuration.
- ena-LNA comprises a locked nucleotide in which Y in the general formula above is —CH 2 —O— (where the oxygen atom of —CH 2 —O— is attached to the 2′-position relative to the base B).
- LNAs are described in additional detail herein.
- One or more substituted sugar moieties can also be included, e.g., one of the following at the 2′ position: OH, SH, SCH 3 , F, OCN, OCH 3 OCH 3 , OCH 3 O(CH 2 )n CH 3 , O(CH 2 )n NH 2 or O(CH 2 )n CH 3 where n is from 1 to about 10; C1 to C10 lower alkyl, alkoxyalkoxy, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF 3 ; OCF 3 ; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; SOCH 3 ; SO 2 CH 3 ; ONO 2 ; NO 2 ; N 3 ; NH2; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercal
- a preferred modification includes 2′-methoxyethoxy [2′-O—CH 2 CH 2 OCH 3 , also known as 2′-O-(2-methoxyethyl)] (Martin et al, HeIv. Chim. Acta, 1995, 78, 486).
- Other preferred modifications include 2′-methoxy (2′-O—CH 3 ), 2′-propoxy (2′-OCH 2 CH 2 CH 3 ) and 2′-fluoro (2′-F).
- Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3′ position of the sugar on the 3′ terminal nucleotide and the 5′ position of 5′ terminal nucleotide.
- Oligonucleotides may also have sugar mimetics such as cyclobutyls in place of the pentofuranosyl group.
- Single stranded oligonucleotides can also include, additionally or alternatively, nucleobase (often referred to in the art simply as “base”) modifications or substitutions.
- nucleobase often referred to in the art simply as “base”
- “unmodified” or “natural” nucleobases include adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U).
- Modified nucleobases include nucleobases found only infrequently or transiently in natural nucleic acids, e.g., hypoxanthine, 6-methyladenine, 5-Me pyrimidines, particularly 5-methylcytosine (also referred to as 5-methyl-2′ deoxycytosine and often referred to in the art as 5-Me-C), 5-hydroxymethylcytosine (HMC), glycosyl HMC and gentobiosyl HMC, isocytosine, pseudoisocytosine, as well as synthetic nucleobases, e.g., 2-aminoadenine, 2-(methylamino)adenine, 2-(imidazolylalkyl)adenine, 2-(aminoalklyamino)adenine or other heterosubstituted alkyladenines, 2-thiouracil, 2-thiothymine, 5-bromouracil, 5-hydroxymethyluracil, 5-propynyluracil, 8-azaguanine,
- both a sugar and an internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups.
- the base units are maintained for hybridization with an appropriate nucleic acid target compound.
- an oligomeric compound an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA).
- PNA peptide nucleic acid
- the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, for example, an aminoethylglycine backbone.
- the nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone.
- PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al, Science, 1991, 254, 1497-1500.
- Single stranded oligonucleotides can also include one or more nucleobase (often referred to in the art simply as “base”) modifications or substitutions.
- base any nucleobase (often referred to in the art simply as “base”) modifications or substitutions.
- “unmodified” or “natural” nucleobases comprise the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U).
- Modified nucleobases comprise other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudo-uracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substi
- nucleobases comprise those disclosed in U.S. Pat. No. 3,687,808, those disclosed in “The Concise Encyclopedia of Polymer Science And Engineering”, pages 858-859, Kroschwitz, ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., Angewandle Chemie, International Edition, 1991, 30, page 613, and those disclosed by Sanghvi, Chapter 15, Antisense Research and Applications,” pages 289-302, Crooke, and Lebleu, eds., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention.
- 5-substituted pyrimidines 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, comprising 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.
- 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2 ⁇ 0>C (Sanghvi, et al., eds, “Antisense Research and Applications,” CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2′-O-methoxyethyl sugar modifications. Modified nucleobases are described in U.S. Pat. No.
- the single stranded oligonucleotides are chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the oligonucleotide.
- one or more single stranded oligonucleotides, of the same or different types can be conjugated to each other; or single stranded oligonucleotides can be conjugated to targeting moieties with enhanced specificity for a cell type or tissue type.
- moieties include, but are not limited to, lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci.
- Acids Res., 1992, 20, 533-538 an aliphatic chain, e.g., dodecandiol or undecyl residues (Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl.
- a phospholipid e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-
- Acids Res., 1990, 18, 3777-3783 a polyamine or a polyethylene glycol chain (Mancharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-t oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp.
- conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers.
- Typical conjugate groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes.
- Groups that enhance the pharmacodynamic properties include groups that improve uptake, enhance resistance to degradation, and/or strengthen sequence-specific hybridization with the target nucleic acid.
- Groups that enhance the pharmacokinetic properties include groups that improve uptake, distribution, metabolism or excretion of the compounds of the present invention. Representative conjugate groups are disclosed in International Patent Application No. PCT/US92/09196, filed Oct. 23, 1992, and U.S. Pat. No. 6,287,860, which are incorporated herein by reference.
- Conjugate moieties include, but are not limited to, lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-5-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino-carbonyl-oxy cholesterol moiety.
- lipid moieties such as a cholesterol moiety, cholic acid, a thioether,
- single stranded oligonucleotide modification include modification of the 5′ or 3′ end of the oligonucleotide.
- the 3′ end of the oligonucleotide comprises a hydroxyl group or a thiophosphate.
- additional molecules e.g. a biotin moiety or a fluorophor
- the single stranded oligonucleotide comprises a biotin moiety conjugated to the 5′ nucleotide.
- the single stranded oligonucleotide comprises locked nucleic acids (LNA), ENA modified nucleotides, 2′-O-methyl nucleotides, or 2′-fluoro-deoxyribonucleotides.
- LNA locked nucleic acids
- ENA ENA modified nucleotides
- 2′-O-methyl nucleotides or 2′-fluoro-deoxyribonucleotides.
- the single stranded oligonucleotide comprises alternating deoxyribonucleotides and 2′-fluoro-deoxyribonucleotides.
- the single stranded oligonucleotide comprises alternating deoxyribonucleotides and 2′-O-methyl nucleotides.
- the single stranded oligonucleotide comprises alternating deoxyribonucleotides and ENA modified nucleotides. In some embodiments, the single stranded oligonucleotide comprises alternating deoxyribonucleotides and locked nucleic acid nucleotides. In some embodiments, the single stranded oligonucleotide comprises alternating locked nucleic acid nucleotides and 2′-O-methyl nucleotides.
- the 5′ nucleotide of the oligonucleotide is a deoxyribonucleotide. In some embodiments, the 5′ nucleotide of the oligonucleotide is a locked nucleic acid nucleotide. In some embodiments, the nucleotides of the oligonucleotide comprise deoxyribonucleotides flanked by at least one locked nucleic acid nucleotide on each of the 5′ and 3′ ends of the deoxyribonucleotides. In some embodiments, the nucleotide at the 3′ position of the oligonucleotide has a 3′ hydroxyl group or a 3′ thiophosphate.
- the single stranded oligonucleotide comprises phosphorothioate internucleotide linkages. In some embodiments, the single stranded oligonucleotide comprises phosphorothioate internucleotide linkages between at least two nucleotides. In some embodiments, the single stranded oligonucleotide comprises phosphorothioate internucleotide linkages between all nucleotides.
- the single stranded oligonucleotide can have any combination of modifications as described herein.
- the oligonucleotide may comprise a nucleotide sequence having one or more of the following modification patterns.
- the invention relates to methods for modulating gene expression in a cell (e.g., a cell for which MECP2 levels are reduced) for research purposes (e.g., to study the function of the gene in the cell).
- the invention relates to methods for modulating gene expression in a cell (e.g., a cell for which MECP2 levels are reduced) for gene or epigenetic therapy.
- the cells can be in vitro, ex vivo, or in vivo (e.g., in a subject who has a disease resulting from reduced expression or activity of MECP2.
- methods for modulating gene expression in a cell comprise delivering a single stranded oligonucleotide as described herein.
- delivery of the single stranded oligonucleotide to the cell results in a level of expression of gene that is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200% or more greater than a level of expression of gene in a control cell to which the single stranded oligonucleotide has not been delivered.
- delivery of the single stranded oligonucleotide to the cell results in a level of expression of gene that is at least 50% greater than a level of expression of gene in a control cell to which the single stranded oligonucleotide has not been delivered.
- methods comprise administering to a subject (e.g. a human) a composition comprising a single stranded oligonucleotide as described herein to increase protein levels in the subject.
- a subject e.g. a human
- the increase in protein levels is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, or more, higher than the amount of a protein in the subject before administering.
- the methods include introducing into the cell a single stranded oligonucleotide that is sufficiently complementary to a PRC2-associated region (e.g., of a long non-coding RNA) that maps to a genomic position encompassing or in proximity to the MECP2 gene.
- a PRC2-associated region e.g., of a long non-coding RNA
- a condition e.g., Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, PPM-X syndrome
- a condition e.g., Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, PPM-X syndrome
- administering a single stranded oligonucleotide as described herein.
- a subject can include a non-human mammal, e.g. mouse, rat, guinea pig, rabbit, cat, dog, goat, cow, or horse.
- a subject is a human.
- Single stranded oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals, including humans.
- Single stranded oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for the treatment of cells, tissues and animals, especially humans.
- an animal preferably a human, suspected of having Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, or PPM-X syndrome is treated by administering single stranded oligonucleotide in accordance with this invention.
- the methods comprise the step of administering to the animal in need of treatment, a therapeutically effective amount of a single stranded oligonucleotide as described herein.
- oligonucleotides described herein can be formulated for administration to a subject for treating a condition (e.g., Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, PPM-X syndrome) associated with decreased levels of MECP2. It should be understood that the formulations, compositions and methods can be practiced with any of the oligonucleotides disclosed herein.
- a condition e.g., Rett Syndrome, MECP2-related severe neonatal encephalopathy, Angelman syndrome, PPM-X syndrome
- the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
- the amount of active ingredient e.g., an oligonucleotide or compound of the invention
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration, e.g., intradermal or inhalation.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect, e.g. tumor regression.
- compositions of this invention can be prepared according to any method known to the art for the manufacture of pharmaceuticals. Such formulations can contain sweetening agents, flavoring agents, coloring agents and preserving agents. A formulation can be admixtured with nontoxic pharmaceutically acceptable excipients which are suitable for manufacture. Formulations may comprise one or more diluents, emulsifiers, preservatives, buffers, excipients, etc. and may be provided in such forms as liquids, powders, emulsions, lyophilized powders, sprays, creams, lotions, controlled release formulations, tablets, pills, gels, on patches, in implants, etc.
- a formulated single stranded oligonucleotide composition can assume a variety of states.
- the composition is at least partially crystalline, uniformly crystalline, and/or anhydrous (e.g., less than 80, 50, 30, 20, or 10% water).
- the single stranded oligonucleotide is in an aqueous phase, e.g., in a solution that includes water.
- the aqueous phase or the crystalline compositions can, e.g., be incorporated into a delivery vehicle, e.g., a liposome (particularly for the aqueous phase) or a particle (e.g., a microparticle as can be appropriate for a crystalline composition).
- the single stranded oligonucleotide composition is formulated in a manner that is compatible with the intended method of administration.
- the composition is prepared by at least one of the following methods: spray drying, lyophilization, vacuum drying, evaporation, fluid bed drying, or a combination of these techniques; or sonication with a lipid, freeze-drying, condensation and other self-assembly.
- a single stranded oligonucleotide preparation can be formulated or administered (together or separately) in combination with another agent, e.g., another therapeutic agent or an agent that stabilizes a single stranded oligonucleotide, e.g., a protein that complexes with single stranded oligonucleotide.
- another agent e.g., another therapeutic agent or an agent that stabilizes a single stranded oligonucleotide, e.g., a protein that complexes with single stranded oligonucleotide.
- Still other agents include chelators, e.g., EDTA (e.g., to remove divalent cations such as Mg 2+ ), salts, RNAse inhibitors (e.g., a broad specificity RNAse inhibitor such as RNAsin) and so forth.
- the single stranded oligonucleotide preparation includes another single stranded oligonucleotide, e.g., a second single stranded oligonucleotide that modulates expression of a second gene or a second single stranded oligonucleotide that modulates expression of the first gene. Still other preparation can include at least 3, 5, ten, twenty, fifty, or a hundred or more different single stranded oligonucleotide species. Such single stranded oligonucleotides can mediated gene expression with respect to a similar number of different genes.
- the single stranded oligonucleotide preparation includes at least a second therapeutic agent (e.g., an agent other than an oligonucleotide).
- a composition that includes a single stranded oligonucleotide can be delivered to a subject by a variety of routes.
- routes include: intravenous, intradermal, topical, rectal, parenteral, anal, intravaginal, intranasal, pulmonary, ocular.
- therapeutically effective amount is the amount of oligonucleotide present in the composition that is needed to provide the desired level of MECP2 expression in the subject to be treated to give the anticipated physiological response.
- physiologically effective amount is that amount delivered to a subject to give the desired palliative or curative effect.
- pharmaceutically acceptable carrier means that the carrier can be administered to a subject with no significant adverse toxicological effects to the subject.
- compositions suitable for administration can be incorporated into pharmaceutical compositions suitable for administration.
- Such compositions typically include one or more species of single stranded oligonucleotide and a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
- compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic, vaginal, rectal, intranasal, transdermal), oral or parenteral. Parenteral administration includes intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, or intrathecal or intraventricular administration.
- the route and site of administration may be chosen to enhance targeting.
- intramuscular injection into the muscles of interest would be a logical choice.
- Lung cells might be targeted by administering the single stranded oligonucleotide in aerosol form.
- the vascular endothelial cells could be targeted by coating a balloon catheter with the single stranded oligonucleotide and mechanically introducing the oligonucleotide.
- Topical administration refers to the delivery to a subject by contacting the formulation directly to a surface of the subject.
- the most common form of topical delivery is to the skin, but a composition disclosed herein can also be directly applied to other surfaces of the body, e.g., to the eye, a mucous membrane, to surfaces of a body cavity or to an internal surface.
- the most common topical delivery is to the skin.
- the term encompasses several routes of administration including, but not limited to, topical and transdermal. These modes of administration typically include penetration of the skin's permeability barrier and efficient delivery to the target tissue or stratum.
- Topical administration can be used as a means to penetrate the epidermis and dermis and ultimately achieve systemic delivery of the composition.
- Topical administration can also be used as a means to selectively deliver oligonucleotides to the epidermis or dermis of a subject, or to specific strata thereof, or to an underlying tissue.
- Formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
- Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
- Coated condoms, gloves and the like may also be useful.
- Transdermal delivery is a valuable route for the administration of lipid soluble therapeutics.
- the dermis is more permeable than the epidermis and therefore absorption is much more rapid through abraded, burned or denuded skin.
- Inflammation and other physiologic conditions that increase blood flow to the skin also enhance transdermal adsorption. Absorption via this route may be enhanced by the use of an oily vehicle (inunction) or through the use of one or more penetration enhancers.
- Other effective ways to deliver a composition disclosed herein via the transdermal route include hydration of the skin and the use of controlled release topical patches.
- the transdermal route provides a potentially effective means to deliver a composition disclosed herein for systemic and/or local therapy.
- iontophoresis transfer of ionic solutes through biological membranes under the influence of an electric field
- phonophoresis or sonophoresis use of ultrasound to enhance the absorption of various therapeutic agents across biological membranes, notably the skin and the cornea
- optimization of vehicle characteristics relative to dose position and retention at the site of administration may be useful methods for enhancing the transport of topically applied compositions across skin and mucosal sites.
- oligonucleotides administered through these membranes may have a rapid onset of action, provide therapeutic plasma levels, avoid first pass effect of hepatic metabolism, and avoid exposure of the oligonucleotides to the hostile gastrointestinal (GI) environment. Additional advantages include easy access to the membrane sites so that the oligonucleotide can be applied, localized and removed easily.
- GI gastrointestinal
- compositions can be targeted to a surface of the oral cavity, e.g., to sublingual mucosa which includes the membrane of ventral surface of the tongue and the floor of the mouth or the buccal mucosa which constitutes the lining of the cheek.
- the sublingual mucosa is relatively permeable thus giving rapid absorption and acceptable bioavailability of many agents. Further, the sublingual mucosa is convenient, acceptable and easily accessible.
- a pharmaceutical composition of single stranded oligonucleotide may also be administered to the buccal cavity of a human being by spraying into the cavity, without inhalation, from a metered dose spray dispenser, a mixed micellar pharmaceutical formulation as described above and a propellant.
- the dispenser is first shaken prior to spraying the pharmaceutical formulation and propellant into the buccal cavity.
- compositions for oral administration include powders or granules, suspensions or solutions in water, syrups, slurries, emulsions, elixirs or non-aqueous media, tablets, capsules, lozenges, or troches.
- carriers that can be used include lactose, sodium citrate and salts of phosphoric acid.
- Various disintegrants such as starch, and lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc, are commonly used in tablets.
- useful diluents are lactose and high molecular weight polyethylene glycols.
- the nucleic acid compositions can be combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents can be added.
- Parenteral administration includes intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, intrathecal or intraventricular administration.
- parental administration involves administration directly to the site of disease (e.g. injection into a tumor).
- Formulations for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.
- Intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir.
- the total concentration of solutes should be controlled to render the preparation isotonic.
- any of the single stranded oligonucleotides described herein can be administered to ocular tissue.
- the compositions can be applied to the surface of the eye or nearby tissue, e.g., the inside of the eyelid.
- ointments or droppable liquids may be delivered by ocular delivery systems known to the art such as applicators or eye droppers.
- Such compositions can include mucomimetics such as hyaluronic acid, chondroitin sulfate, hydroxypropyl methylcellulose or poly(vinyl alcohol), preservatives such as sorbic acid, EDTA or benzylchronium chloride, and the usual quantities of diluents and/or carriers.
- the single stranded oligonucleotide can also be administered to the interior of the eye, and can be introduced by a needle or other delivery device which can introduce it to a selected area or structure.
- Pulmonary delivery compositions can be delivered by inhalation by the patient of a dispersion so that the composition, preferably single stranded oligonucleotides, within the dispersion can reach the lung where it can be readily absorbed through the alveolar region directly into blood circulation. Pulmonary delivery can be effective both for systemic delivery and for localized delivery to treat diseases of the lungs.
- Pulmonary delivery can be achieved by different approaches, including the use of nebulized, aerosolized, micellular and dry powder-based formulations. Delivery can be achieved with liquid nebulizers, aerosol-based inhalers, and dry powder dispersion devices. Metered-dose devices are preferred. One of the benefits of using an atomizer or inhaler is that the potential for contamination is minimized because the devices are self-contained. Dry powder dispersion devices, for example, deliver agents that may be readily formulated as dry powders. A single stranded oligonucleotide composition may be stably stored as lyophilized or spray-dried powders by itself or in combination with suitable powder carriers.
- the delivery of a composition for inhalation can be mediated by a dosing timing element which can include a timer, a dose counter, time measuring device, or a time indicator which when incorporated into the device enables dose tracking, compliance monitoring, and/or dose triggering to a patient during administration of the aerosol medicament.
- a dosing timing element which can include a timer, a dose counter, time measuring device, or a time indicator which when incorporated into the device enables dose tracking, compliance monitoring, and/or dose triggering to a patient during administration of the aerosol medicament.
- the term “powder” means a composition that consists of finely dispersed solid particles that are free flowing and capable of being readily dispersed in an inhalation device and subsequently inhaled by a subject so that the particles reach the lungs to permit penetration into the alveoli.
- the powder is said to be “respirable.”
- the average particle size is less than about 10 ⁇ m in diameter preferably with a relatively uniform spheroidal shape distribution. More preferably the diameter is less than about 7.5 ⁇ m and most preferably less than about 5.0 ⁇ m.
- the particle size distribution is between about 0.1 ⁇ m and about 5 ⁇ m in diameter, particularly about 0.3 ⁇ m to about 5 ⁇ m.
- dry means that the composition has a moisture content below about 10% by weight (% w) water, usually below about 5% w and preferably less it than about 3% w.
- a dry composition can be such that the particles are readily dispersible in an inhalation device to form an aerosol.
- the types of pharmaceutical excipients that are useful as carrier include stabilizers such as human serum albumin (HSA), bulking agents such as carbohydrates, amino acids and polypeptides; pH adjusters or buffers; salts such as sodium chloride; and the like. These carriers may be in a crystalline or amorphous form or may be a mixture of the two.
- HSA human serum albumin
- bulking agents such as carbohydrates, amino acids and polypeptides
- pH adjusters or buffers such as sodium chloride
- salts such as sodium chloride
- Suitable pH adjusters or buffers include organic salts prepared from organic acids and bases, such as sodium citrate, sodium ascorbate, and the like; sodium citrate is preferred.
- Pulmonary administration of a micellar single stranded oligonucleotide formulation may be achieved through metered dose spray devices with propellants such as tetrafluoroethane, heptafluoroethane, dimethylfluoropropane, tetrafluoropropane, butane, isobutane, dimethyl ether and other non-CFC and CFC propellants.
- Exemplary devices include devices which are introduced into the vasculature, e.g., devices inserted into the lumen of a vascular tissue, or which devices themselves form a part of the vasculature, including stents, catheters, heart valves, and other vascular devices. These devices, e.g., catheters or stents, can be placed in the vasculature of the lung, heart, or leg.
- Other devices include non-vascular devices, e.g., devices implanted in the peritoneum, or in organ or glandular tissue, e.g., artificial organs.
- the device can release a therapeutic substance in addition to a single stranded oligonucleotide, e.g., a device can release insulin.
- unit doses or measured doses of a composition that includes single stranded oligonucleotide are dispensed by an implanted device.
- the device can include a sensor that monitors a parameter within a subject.
- the device can include pump, e.g., and, optionally, associated electronics.
- Tissue e.g., cells or organs can be treated with a single stranded oligonucleotide, ex vivo and then administered or implanted in a subject.
- the tissue can be autologous, allogeneic, or xenogeneic tissue.
- tissue can be treated to reduce graft v. host disease.
- the tissue is allogeneic and the tissue is treated to treat a disorder characterized by unwanted gene expression in that tissue.
- tissue e.g., hematopoietic cells, e.g., bone marrow hematopoietic cells, can be treated to inhibit unwanted cell proliferation.
- Introduction of treated tissue, whether autologous or transplant can be combined with other therapies.
- the single stranded oligonucleotide treated cells are insulated from other cells, e.g., by a semi-permeable porous barrier that prevents the cells from leaving the implant, but enables molecules from the body to reach the cells and molecules produced by the cells to enter the body.
- the porous barrier is formed from alginate.
- a contraceptive device is coated with or contains a single stranded oligonucleotide.
- exemplary devices include condoms, diaphragms, IUD (implantable uterine devices, sponges, vaginal sheaths, and birth control devices.
- the invention features a method of administering a single stranded oligonucleotide (e.g., as a compound or as a component of a composition) to a subject (e.g., a human subject).
- a subject e.g., a human subject.
- the unit dose is between about 10 mg and 25 mg per kg of bodyweight. In one embodiment, the unit dose is between about 1 mg and 100 mg per kg of bodyweight. In one embodiment, the unit dose is between about 0.1 mg and 500 mg per kg of bodyweight. In some embodiments, the unit dose is more than 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 2, 5, 10, 25, 50 or 100 mg per kg of bodyweight.
- the defined amount can be an amount effective to treat or prevent a disease or disorder, e.g., a disease or disorder associated with the MECP2.
- the unit dose for example, can be administered by injection (e.g., intravenous or intramuscular), an inhaled dose, or a topical application.
- the unit dose is administered daily. In some embodiments, less frequently than once a day, e.g., less than every 2, 4, 8 or 30 days. In another embodiment, the unit dose is not administered with a frequency (e.g., not a regular frequency). For example, the unit dose may be administered a single time. In some embodiments, the unit dose is administered more than once a day, e.g., once an hour, two hours, four hours, eight hours, twelve hours, etc.
- a subject is administered an initial dose and one or more maintenance doses of a single stranded oligonucleotide.
- the maintenance dose or doses are generally lower than the initial dose, e.g., one-half less of the initial dose.
- a maintenance regimen can include treating the subject with a dose or doses ranging from 0.0001 to 100 mg/kg of body weight per day, e.g., 100, 10, 1, 0.1, 0.01, 0.001, or 0.0001 mg per kg of bodyweight per day.
- the maintenance doses may be administered no more than once every 1, 5, 10, or 30 days. Further, the treatment regimen may last for a period of time which will vary depending upon the nature of the particular disease, its severity and the overall condition of the patient.
- the dosage may be delivered no more than once per day, e.g., no more than once per 24, 36, 48, or more hours, e.g., no more than once for every 5 or 8 days.
- the patient can be monitored for changes in his condition and for alleviation of the symptoms of the disease state.
- the dosage of the oligonucleotide may either be increased in the event the patient does not respond significantly to current dosage levels, or the dose may be decreased if an alleviation of the symptoms of the disease state is observed, if the disease state has been ablated, or if undesired side-effects are observed.
- the effective dose can be administered in a single dose or in two or more doses, as desired or considered appropriate under the specific circumstances. If desired to facilitate repeated or frequent infusions, implantation of a delivery device, e.g., a pump, semi-permanent stent (e.g., intravenous, intraperitoneal, intracisternal or intracapsular), or reservoir may be advisable.
- a delivery device e.g., a pump, semi-permanent stent (e.g., intravenous, intraperitoneal, intracisternal or intracapsular), or reservoir may be advisable.
- the oligonucleotide pharmaceutical composition includes a plurality of single stranded oligonucleotide species.
- the single stranded oligonucleotide species has sequences that are non-overlapping and non-adjacent to another species with respect to a naturally occurring target sequence (e.g., a PRC2-associated region).
- the plurality of single stranded oligonucleotide species is specific for different PRC2-associated regions.
- the single stranded oligonucleotide is allele specific. In some cases, a patient is treated with a single stranded oligonucleotide in conjunction with other therapeutic modalities.
- the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the compound of the invention is administered in maintenance doses, ranging from 0.0001 mg to 100 mg per kg of body weight.
- the concentration of the single stranded oligonucleotide composition is an amount sufficient to be effective in treating or preventing a disorder or to regulate a physiological condition in humans.
- concentration or amount of single stranded oligonucleotide administered will depend on the parameters determined for the agent and the method of administration, e.g. nasal, buccal, pulmonary.
- nasal formulations may tend to require much lower concentrations of some ingredients in order to avoid irritation or burning of the nasal passages. It is sometimes desirable to dilute an oral formulation up to 10-100 times in order to provide a suitable nasal formulation.
- treatment of a subject with a therapeutically effective amount of a single stranded oligonucleotide can include a single treatment or, preferably, can include a series of treatments.
- the effective dosage of a single stranded oligonucleotide used for treatment may increase or decrease over the course of a particular treatment.
- the subject can be monitored after administering a single stranded oligonucleotide composition. Based on information from the monitoring, an additional amount of the single stranded oligonucleotide composition can be administered.
- Dosing is dependent on severity and responsiveness of the disease condition to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of disease state is achieved.
- Optimal dosing schedules can be calculated from measurements of MECP2 expression levels in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual compounds, and can generally be estimated based on EC50s found to be effective in in vitro and in vivo animal models.
- the animal models include transgenic animals that express a human MECP2.
- the composition for testing includes a single stranded oligonucleotide that is complementary, at least in an internal region, to a sequence that is conserved between MECP2 in the animal model and the MECP2 in a human.
- the administration of the single stranded oligonucleotide composition is parenteral, e.g. intravenous (e.g., as a bolus or as a diffusible infusion), intradermal, intraperitoneal, intramuscular, intrathecal, intraventricular, intracranial, subcutaneous, transmucosal, buccal, sublingual, endoscopic, rectal, oral, vaginal, topical, pulmonary, intranasal, urethral or ocular.
- Administration can be provided by the subject or by another person, e.g., a health care provider.
- the composition can be provided in measured doses or in a dispenser which delivers a metered dose. Selected modes of delivery are discussed in more detail below.
- kits comprising a container housing a composition comprising a single stranded oligonucleotide.
- the composition is a pharmaceutical composition comprising a single stranded oligonucleotide and a pharmaceutically acceptable carrier.
- the individual components of the pharmaceutical composition may be provided in one container. Alternatively, it may be desirable to provide the components of the pharmaceutical composition separately in two or more containers, e.g., one container for single stranded oligonucleotides, and at least another for a carrier compound.
- the kit may be packaged in a number of different configurations such as one or more containers in a single box.
- the different components can be combined, e.g., according to instructions provided with the kit.
- the components can be combined according to a method described herein, e.g., to prepare and administer a pharmaceutical composition.
- the kit can also include a delivery device.
- RNA is harvested from the cells using Promega SV 96 Total RNA Isolation system or Trizol omitting the DNAse step. RNA harvested from cells is normalized so that equal RNA is input to each reverse transcription reaction. Reverse transcriptase reactions are performed using the Superscript II kit and real time PCR performed on cDNA samples using icycler SYBR green chemistry (Biorad). A baseline level of mRNA expression for MECP2 is determined through quantitative PCR as outlined above. Baseline levels are also determined for mRNA of various housekeeping genes which are constitutively expressed. A “control” housekeeping gene with approximately the same level of baseline expression as the target gene is chosen for comparison purposes.
- Human hepatocyte Hep3B, human hepatocyte HepG2 cells, mouse hepatoma Hepa1-6 cells, and human renal proximal tubule epithelial cells (RPTEC) are cultured using conditions known in the art (see, e.g. Current Protocols in Cell Biology).
- Oligonucleotides were designed within PRC2-interacting regions in order to upregulate MECP2.
- the sequence and structure of each oligonucleotide is shown in Table 3.
- the following table provides a description of the nucleotide analogs, modifications and intranucleotide linkages used for certain oligonucleotides tested and described in Table 2.
- Oligonucleotides are designed within PRC2-interacting regions in order to upregulate MECP2.
- Cells are seeded into each well of 24-well plates at a density of 25,000 cells per 500 uL and transfections are performed with Lipofectamine and the single stranded oligonucleotides.
- Control wells contain Lipofectamine alone.
- approximately 200 uL of cell culture supernatants are stored at ⁇ 80 C for ELISA.
- RNA is harvested from the cells and quantitative PCR is carried out as outlined above.
- the percent induction of target mRNA expression by each oligonucleotide is determined by normalizing mRNA levels in the presence of the oligonucleotide to the mRNA levels in the presence of control (Lipofectamine alone). This is compared side-by-side with the increase in mRNA expression of the “control” housekeeping gene.
- Oligonucleotides are designed as candidates for upregulating MECP2 expression.
- the single stranded oligonucleotides are designed to be complementary to a PRC2-interacting region within a sequence as set forth in SEQ ID NO: 1 or 2.
- the oligonucleotides are tested in at least duplicate. Briefly, cells are transfected in vitro with each of the oligonucleotides as described above. MECP2 expression in cells following treatment is evaluated by qRT-PCR. Oligonucleotides that upregulate MECP2 expression are identified.
Abstract
Description
TABLE |
Table 1: Hexamers that are not seed sequences of human miRNAs |
AAAAAA, AAAAAG, AAAACA, AAAAGA, AAAAGC, AAAAGG, AAAAUA, AAACAA, AAACAC, AAACAG, |
AAACAU, AAACCC, AAACCU, AAACGA, AAACGC, AAACGU, AAACUA, AAACUC, AAACUU, AAAGAU, |
AAAGCC, AAAGGA, AAAGGG, AAAGUC, AAAUAC, AAAUAU, AAAUCG, AAAUCU, AAAUGC, AAAUGU, |
AAAUUA, AAAUUG, AACAAC, AACAAG, AACAAU, AACACA, AACACG, AACAGA, AACAGC, AACAGG, |
AACAUC, AACAUG, AACCAA, AACCAC, AACCAG, AACCAU, AACCCC, AACCCG, AACCGA, AACCGC, |
AACCGG, AACCUA, AACCUU, AACGAA, AACGAC, AACGAG, AACGAU, AACGCU, AACGGG, AACGGU, |
AACGUA, AACGUC, AACGUG, AACGUU, AACUAU, AACUCA, AACUCC, AACUCG, AACUGA, AACUGC, |
AACUGU, AACUUA, AACUUC, AACUUG, AACUUU, AAGAAA, AAGAAG, AAGAAU, AAGACG, AAGAGA, |
AAGAGC, AAGAGG, AAGAGU, AAGAUU, AAGCAA, AAGCAC, AAGCAG, AAGCAU, AAGCCA, AAGCCC, |
AAGCCG, AAGCCU, AAGCGA, AAGCGG, AAGCGU, AAGCUA, AAGGAA, AAGGAC, AAGGCU, AAGGGC, |
AAGGGU, AAGGUU, AAGUAA, AAGUAC, AAGUAU, AAGUCC, AAGUCG, AAGUGA, AAGUGG, AAGUUA, |
AAGUUU, AAUAAA, AAUAAC, AAUAAG, AAUAAU, AAUACA, AAUACC, AAUACG, AAUAGA, AAUAGC, |
AAUAGG, AAUAGU, AAUAUC, AAUAUU, AAUCAA, AAUCAU, AAUCCA, AAUCCC, AAUCCG, AAUCGA, |
AAUCGC, AAUCGU, AAUCUA, AAUCUG, AAUCUU, AAUGAA, AAUGAC, AAUGAG, AAUGAU, AAUGCG, |
AAUGCU, AAUGGA, AAUGGU, AAUGUA, AAUGUC, AAUGUG, AAUUAA, AAUUAC, AAUUAG, AAUUCC, |
AAUUCG, AAUUGA, AAUUGG, AAUUGU, AAUUUC, AAUUUG, ACAAAA, ACAAAC, ACAAAG, ACAAAU, |
ACAACC, ACAACG, ACAACU, ACAAGA, ACAAGC, ACAAGU, ACAAUC, ACAAUG, ACAAUU, ACACAG, |
ACACCA, ACACCC, ACACCG, ACACCU, ACACGA, ACACGC, ACACGU, ACACUC, ACACUG, ACACUU, |
ACAGAA, ACAGAC, ACAGCC, ACAGCG, ACAGCU, ACAGGG, ACAGUC, ACAGUG, ACAGUU, ACAUAA, |
ACAUAC, ACAUCC, ACAUCG, ACAUCU, ACAUGA, ACAUGC, ACAUGU, ACAUUG, ACAUUU, ACCAAA, |
ACCAAC, ACCAAG, ACCAAU, ACCACC, ACCACG, ACCAGA, ACCAGU, ACCAUA, ACCAUG, ACCAUU, |
ACCCAA, ACCCAC, ACCCCA, ACCCCG, ACCCGA, ACCCGC, ACCCUA, ACCCUC, ACCCUU, ACCGAA, |
ACCGAC, ACCGAU, ACCGCA, ACCGCC, ACCGCG, ACCGCU, ACCGGA, ACCGGC, ACCGGU, ACCGUA, |
ACCGUC, ACCGUG, ACCGUU, ACCUAA, ACCUAC, ACCUAG, ACCUAU, ACCUCA, ACCUCC, ACCUCG, |
ACCUCU, ACCUGA, ACCUGC, ACCUGU, ACCUUA, ACCUUC, ACCUUU, ACGAAA, ACGAAC, ACGAAG, |
ACGAAU, ACGACA, ACGACC, ACGACG, ACGACU, ACGAGA, ACGAGC, ACGAGG, ACGAGU, ACGAUA, |
ACGAUC, ACGAUG, ACGAUU, ACGCAA, ACGCAG, ACGCAU, ACGCCC, ACGCCG, ACGCCU, ACGCGA, |
ACGCGG, ACGCGU, ACGCUA, ACGCUG, ACGCUU, ACGGAA, ACGGAC, ACGGAG, ACGGAU, ACGGCC, |
ACGGCG, ACGGCU, ACGGGC, ACGGGG, ACGGGU, ACGGUA, ACGGUC, ACGGUG, ACGGUU, ACGUAA, |
ACGUAC, ACGUAU, ACGUCC, ACGUCG, ACGUCU, ACGUGA, ACGUGC, ACGUGG, ACGUGU, ACGUUA, |
ACGUUC, ACGUUG, ACGUUU, ACUAAA, ACUAAG, ACUAAU, ACUACA, ACUACC, ACUACG, ACUACU, |
ACUAGG, ACUAUC, ACUAUG, ACUAUU, ACUCAU, ACUCCC, ACUCCG, ACUCCU, ACUCGA, ACUCGC, |
ACUCGG, ACUCUC, ACUCUU, ACUGAG, ACUGAU, ACUGCC, ACUGCG, ACUGCU, ACUGGG, ACUGGU, |
ACUGUC, ACUUAA, ACUUAC, ACUUAU, ACUUCA, ACUUCC, ACUUCG, ACUUCU, ACUUGA, ACUUGC, |
ACUUGU, ACUUUA, ACUUUC, ACUUUG, AGAAAA, AGAAAC, AGAAAG, AGAACC, AGAACG, AGAACU, |
AGAAGC, AGAAGU, AGAAUA, AGAAUC, AGAAUG, AGAAUU, AGACAA, AGACAC, AGACAU, AGACCA, |
AGACCC, AGACCG, AGACCU, AGACGA, AGACGC, AGACGU, AGACUA, AGACUC, AGACUU, AGAGAC, |
AGAGAG, AGAGAU, AGAGCC, AGAGCG, AGAGCU, AGAGGC, AGAGGG, AGAGGU, AGAGUA, AGAGUU, |
AGAUAC, AGAUAG, AGAUAU, AGAUCC, AGAUCG, AGAUCU, AGAUGA, AGAUGC, AGAUGG, AGAUUA, |
AGAUUC, AGAUUG, AGAUUU, AGCAAC, AGCACA, AGCACG, AGCACU, AGCAGA, AGCAUA, AGCAUC, |
AGCAUG, AGCCAA, AGCCAU, AGCCCA, AGCCGA, AGCCGC, AGCCGG, AGCCGU, AGCCUA, AGCCUC, |
AGCGAA, AGCGAG, AGCGAU, AGCGCA, AGCGCC, AGCGCG, AGCGCU, AGCGGA, AGCGGC, AGCGGU, |
AGCGUA, AGCGUC, AGCGUG, AGCGUU, AGCUAA, AGCUAC, AGCUAG, AGCUAU, AGCUCA, AGCUCC, |
AGCUCG, AGCUCU, AGCUGA, AGCUGG, AGCUGU, AGCUUC, AGCUUU, AGGAAU, AGGACC, AGGACG, |
AGGAGA, AGGAGU, AGGAUA, AGGCAA, AGGCAU, AGGCCG, AGGCGA, AGGCGC, AGGCGG, AGGCUA, |
AGGCUC, AGGCUU, AGGGAC, AGGGAU, AGGGGA, AGGGGU, AGGGUA, AGGGUG, AGGUAA, |
AGGUAC, AGGUCA, AGGUCC, AGGUCU, AGGUGA, AGGUGC, AGGUGG, AGGUGU, AGGUUC, |
AGGUUG, AGUAAA, AGUAAG, AGUAAU, AGUACA, AGUACG, AGUAGC, AGUAGG, AGUAUA, AGUAUC, |
AGUAUG, AGUAUU, AGUCAA, AGUCAC, AGUCAG, AGUCAU, AGUCCA, AGUCCG, AGUCCU, AGUCGA, |
AGUCGC, AGUCGG, AGUCGU, AGUCUA, AGUCUC, AGUCUG, AGUCUU, AGUGAA, AGUGAC, AGUGCG, |
AGUGGG, AGUGUC, AGUUAA, AGUUAC, AGUUAG, AGUUCC, AGUUCG, AGUUGA, AGUUGC, |
AGUUGU, AGUUUA, AGUUUC, AGUUUG, AGUUUU, AUAAAC, AUAAAU, AUAACA, AUAACC, AUAACG, |
AUAACU, AUAAGA, AUAAGC, AUAAGG, AUAAGU, AUAAUC, AUAAUG, AUAAUU, AUACAC, AUACAG, |
AUACAU, AUACCA, AUACCC, AUACCG, AUACGA, AUACGC, AUACGG, AUACGU, AUACUA, AUACUC, |
AUACUG, AUACUU, AUAGAA, AUAGAC, AUAGAU, AUAGCA, AUAGCG, AUAGCU, AUAGGA, AUAGGU, |
AUAGUA, AUAGUC, AUAGUG, AUAGUU, AUAUAC, AUAUAG, AUAUCC, AUAUCG, AUAUCU, AUAUGA, |
AUAUGC, AUAUGG, AUAUGU, AUAUUC, AUAUUG, AUAUUU, AUCAAA, AUCAAC, AUCAAG, AUCAAU, |
AUCACA, AUCACC, AUCACG, AUCAGC, AUCAGG, AUCCAA, AUCCAU, AUCCCC, AUCCCG, AUCCGA, |
AUCCGC, AUCCGG, AUCCUA, AUCCUC, AUCCUG, AUCGAA, AUCGAC, AUCGAG, AUCGAU, AUCGCA, |
AUCGCC, AUCGCG, AUCGCU, AUCGGC, AUCGGG, AUCGGU, AUCGUC, AUCGUG, AUCGUU, AUCUAA, |
AUCUAC, AUCUAG, AUCUAU, AUCUCC, AUCUCG, AUCUGU, AUCUUG, AUCUUU, AUGAAA, AUGAAC, |
AUGAAG, AUGAAU, AUGACC, AUGACU, AUGAGG, AUGAGU, AUGAUA, AUGAUC, AUGAUU, AUGCAA, |
AUGCAG, AUGCCA, AUGCCC, AUGCCG, AUGCGA, AUGCGG, AUGCGU, AUGCUC, AUGCUU, AUGGAC, |
AUGGCC, AUGGGA, AUGGGC, AUGGGU, AUGGUC, AUGGUG, AUGUAC, AUGUAU, AUGUCA, |
AUGUCC, AUGUCG, AUGUGU, AUGUUA, AUGUUC, AUUAAA, AUUAAC, AUUAAG, AUUAAU, AUUACA, |
AUUACC, AUUACG, AUUACU, AUUAGA, AUUAGC, AUUAGG, AUUAGU, AUUAUA, AUUAUC, AUUAUG, |
AUUCAC, AUUCCA, AUUCCG, AUUCCU, AUUCGA, AUUCGC, AUUCGG, AUUCGU, AUUCUA, AUUCUC, |
AUUCUU, AUUGAA, AUUGAC, AUUGAU, AUUGCC, AUUGCG, AUUGCU, AUUGGA, AUUGGC, |
AUUGGG, AUUGGU, AUUGUA, AUUGUC, AUUGUG, AUUGUU, AUUUAA, AUUUAG, AUUUAU, |
AUUUCC, AUUUCG, AUUUCU, AUUUGA, AUUUGC, AUUUGU, AUUUUA, AUUUUC, AUUUUG, |
AUUUUU, CAAAAG, CAAACA, CAAACC, CAAACG, CAAACU, CAAAGA, CAAAGG, CAAAUA, CAAAUU, |
CAACAC, CAACAU, CAACCA, CAACCC, CAACCG, CAACGA, CAACGC, CAACGG, CAACGU, CAACUA, |
CAACUC, CAACUG, CAACUU, CAAGAA, CAAGAC, CAAGAU, CAAGCA, CAAGCC, CAAGCG, CAAGCU, |
CAAGGA, CAAGGG, CAAGUC, CAAGUG, CAAGUU, CAAUAA, CAAUAC, CAAUAG, CAAUCC, CAAUCG, |
CAAUCU, CAAUGA, CAAUGC, CAAUGG, CAAUGU, CAAUUC, CAAUUG, CAAUUU, CACAAU, CACACA, |
CACACG, CACACU, CACAGA, CACAGC, CACAGG, CACAUA, CACAUC, CACAUU, CACCAA, CACCAC, |
CACCAU, CACCCA, CACCCC, CACCCG, CACCGA, CACCGC, CACCGG, CACCGU, CACCUA, CACCUU, |
CACGAA, CACGAC, CACGAG, CACGAU, CACGCA, CACGCC, CACGCU, CACGGA, CACGGC, CACGGG, |
CACGGU, CACGUA, CACGUC, CACGUG, CACGUU, CACUAA, CACUAG, CACUAU, CACUCA, CACUCG, |
CACUGA, CACUGC, CACUGG, CACUUA, CACUUC, CACUUU, CAGAAA, CAGAAG, CAGAAU, CAGACC, |
CAGACG, CAGAGC, CAGAUA, CAGAUC, CAGCCG, CAGCCU, CAGCGA, CAGCGC, CAGCGG, CAGCGU, |
CAGCUC, CAGCUU, CAGGAU, CAGGGG, CAGGGU, CAGGUA, CAGGUC, CAGGUU, CAGUAC, CAGUCG, |
CAGUUG, CAUAAA, CAUAAC, CAUAAG, CAUAAU, CAUACA, CAUACC, CAUACG, CAUACU, CAUAGA, |
CAUAGG, CAUAGU, CAUAUA, CAUAUC, CAUAUG, CAUCAA, CAUCAC, CAUCAG, CAUCAU, CAUCCA, |
CAUCCC, CAUCCG, CAUCGA, CAUCGC, CAUCGG, CAUCGU, CAUCUA, CAUCUC, CAUCUG, CAUCUU, |
CAUGAA, CAUGAC, CAUGAG, CAUGAU, CAUGCA, CAUGCC, CAUGCG, CAUGCU, CAUGGC, CAUGGG, |
CAUGGU, CAUGUA, CAUGUC, CAUGUU, CAUUAA, CAUUAC, CAUUAG, CAUUCA, CAUUCC, CAUUCG, |
CAUUCU, CAUUGA, CAUUGG, CAUUUC, CAUUUG, CAUUUU, CCAAAA, CCAAAC, CCAAAG, CCAAAU, |
CCAACA, CCAACC, CCAACG, CCAACU, CCAAGA, CCAAGC, CCAAGG, CCAAUC, CCAAUG, CCAAUU, |
CCACAA, CCACAC, CCACAG, CCACAU, CCACCA, CCACCC, CCACCG, CCACCU, CCACGA, CCACGC, |
CCACGG, CCACGU, CCACUA, CCACUC, CCACUU, CCAGAA, CCAGAC, CCAGAG, CCAGCC, CCAGGU, |
CCAGUC, CCAGUU, CCAUAA, CCAUAC, CCAUAG, CCAUAU, CCAUCA, CCAUCC, CCAUCU, CCAUGA, |
CCAUGC, CCAUGG, CCAUUC, CCAUUG, CCAUUU, CCCAAC, CCCAAG, CCCAAU, CCCACA, CCCAGA, |
CCCAGC, CCCAGU, CCCAUA, CCCAUC, CCCAUG, CCCAUU, CCCCAA, CCCCAG, CCCCAU, CCCCCC, |
CCCCCG, CCCCCU, CCCCGA, CCCCGC, CCCCGU, CCCCUA, CCCCUC, CCCGAA, CCCGAC, CCCGAU, |
CCCGCA, CCCGCU, CCCGGA, CCCGGC, CCCGUA, CCCGUG, CCCGUU, CCCUAA, CCCUAG, CCCUCA, |
CCCUCU, CCCUGC, CCCUUA, CCCUUC, CCCUUU, CCGAAA, CCGAAC, CCGAAU, CCGACA, CCGACC, |
CCGACG, CCGACU, CCGAGA, CCGAGG, CCGAGU, CCGAUA, CCGAUC, CCGAUG, CCGAUU, CCGCAA, |
CCGCAC, CCGCAG, CCGCAU, CCGCCA, CCGCCC, CCGCCG, CCGCCU, CCGCGA, CCGCGC, CCGCGG, |
CCGCGU, CCGCUA, CCGCUC, CCGCUG, CCGCUU, CCGGAA, CCGGAU, CCGGCA, CCGGCC, CCGGCG, |
CCGGCU, CCGGGA, CCGGGC, CCGGGG, CCGGGU, CCGGUA, CCGGUC, CCGGUG, CCGUAA, CCGUAG, |
CCGUAU, CCGUCA, CCGUCC, CCGUCG, CCGUGA, CCGUGU, CCGUUA, CCGUUC, CCGUUG, CCGUUU, |
CCUAAC, CCUAAG, CCUAAU, CCUACA, CCUACC, CCUACG, CCUACU, CCUAGA, CCUAGC, CCUAGG, |
CCUAGU, CCUAUA, CCUAUC, CCUAUG, CCUAUU, CCUCAA, CCUCAC, CCUCAG, CCUCAU, CCUCCA, |
CCUCCC, CCUCCG, CCUCGA, CCUCGC, CCUCGG, CCUCGU, CCUCUA, CCUCUG, CCUGAC, CCUGAU, |
CCUGCA, CCUGGG, CCUGGU, CCUGUU, CCUUAA, CCUUAC, CCUUAG, CCUUAU, CCUUCG, CCUUGA, |
CCUUGU, CCUUUA, CCUUUC, CCUUUU, CGAAAA, CGAAAC, CGAAAG, CGAAAU, CGAACA, CGAACC, |
CGAACG, CGAACU, CGAAGA, CGAAGC, CGAAGG, CGAAGU, CGAAUA, CGAAUC, CGAAUG, CGAAUU, |
CGACAA, CGACAC, CGACAU, CGACCA, CGACCU, CGACGA, CGACGC, CGACGG, CGACGU, CGACUA, |
CGACUG, CGACUU, CGAGAA, CGAGAC, CGAGAG, CGAGAU, CGAGCA, CGAGCC, CGAGCG, CGAGCU, |
CGAGGC, CGAGGG, CGAGGU, CGAGUA, CGAGUC, CGAGUG, CGAGUU, CGAUAA, CGAUAC, CGAUAG, |
CGAUAU, CGAUCA, CGAUCC, CGAUCG, CGAUCU, CGAUGA, CGAUGC, CGAUGG, CGAUGU, CGAUUA, |
CGAUUC, CGAUUG, CGAUUU, CGCAAA, CGCAAC, CGCAAG, CGCAAU, CGCACA, CGCACC, CGCACG, |
CGCAGA, CGCAGC, CGCAGG, CGCAGU, CGCAUA, CGCAUC, CGCAUG, CGCAUU, CGCCAA, CGCCAC, |
CGCCAG, CGCCAU, CGCCCA, CGCCCC, CGCCCG, CGCCGA, CGCCGC, CGCCGG, CGCCGU, CGCCUA, |
CGCCUG, CGCCUU, CGCGAA, CGCGAC, CGCGAG, CGCGAU, CGCGCA, CGCGCC, CGCGCG, CGCGCU, |
CGCGGA, CGCGGC, CGCGGG, CGCGGU, CGCGUA, CGCGUC, CGCGUG, CGCGUU, CGCUAA, CGCUAC, |
CGCUAG, CGCUAU, CGCUCA, CGCUCC, CGCUCG, CGCUCU, CGCUGA, CGCUGC, CGCUGG, CGCUGU, |
CGCUUA, CGCUUC, CGCUUG, CGGAAA, CGGAAC, CGGAAG, CGGACA, CGGACC, CGGACG, CGGACU, |
CGGAGC, CGGAGG, CGGAGU, CGGAUA, CGGAUU, CGGCAA, CGGCAC, CGGCAG, CGGCCA, CGGCCC, |
CGGCCG, CGGCGC, CGGCGG, CGGCGU, CGGCUA, CGGCUC, CGGCUG, CGGCUU, CGGGAA, CGGGAC, |
CGGGAG, CGGGAU, CGGGCA, CGGGCC, CGGGCG, CGGGCU, CGGGGU, CGGGUA, CGGGUC, CGGGUG, |
CGGUAA, CGGUAC, CGGUAG, CGGUAU, CGGUCA, CGGUCG, CGGUCU, CGGUGA, CGGUGG, CGGUGU, |
CGGUUA, CGGUUC, CGGUUG, CGGUUU, CGUAAA, CGUAAC, CGUAAG, CGUAAU, CGUACA, CGUACG, |
CGUACU, CGUAGA, CGUAGC, CGUAGG, CGUAGU, CGUAUA, CGUAUC, CGUAUG, CGUAUU, CGUCAA, |
CGUCAC, CGUCAG, CGUCAU, CGUCCA, CGUCCC, CGUCCG, CGUCCU, CGUCGA, CGUCGG, CGUCGU, |
CGUCUA, CGUCUC, CGUCUG, CGUCUU, CGUGAA, CGUGAC, CGUGAG, CGUGAU, CGUGCC, CGUGCG, |
CGUGCU, CGUGGA, CGUGGG, CGUGGU, CGUGUA, CGUGUG, CGUUAA, CGUUAC, CGUUAG, |
CGUUAU, CGUUCA, CGUUCC, CGUUCG, CGUUCU, CGUUGA, CGUUGC, CGUUGU, CGUUUA, CGUUUC, |
CGUUUU, CUAAAA, CUAAAC, CUAAAU, CUAACA, CUAACC, CUAACG, CUAACU, CUAAGA, CUAAGC, |
CUAAGU, CUAAUA, CUAAUC, CUAAUG, CUACAC, CUACAU, CUACCA, CUACCC, CUACCG, CUACCU, |
CUACGA, CUACGC, CUACGG, CUACGU, CUACUA, CUACUC, CUACUG, CUAGAA, CUAGAG, CUAGAU, |
CUAGCA, CUAGCC, CUAGCG, CUAGCU, CUAGGA, CUAGGG, CUAGGU, CUAGUG, CUAGUU, CUAUAA, |
CUAUAG, CUAUAU, CUAUCA, CUAUCC, CUAUCG, CUAUCU, CUAUGA, CUAUGC, CUAUGG, CUAUGU, |
CUAUUA, CUAUUG, CUCAAC, CUCAAG, CUCAAU, CUCACC, CUCACG, CUCAGC, CUCAUA, CUCAUC, |
CUCAUG, CUCAUU, CUCCAC, CUCCCC, CUCCCG, CUCCGA, CUCCGC, CUCCGG, CUCCUA, CUCCUC, |
CUCCUU, CUCGAA, CUCGAC, CUCGAG, CUCGAU, CUCGCA, CUCGCC, CUCGCG, CUCGGG, CUCGGU, |
CUCGUA, CUCGUC, CUCGUG, CUCGUU, CUCUAA, CUCUAC, CUCUAU, CUCUCA, CUCUCC, CUCUCU, |
CUCUGC, CUCUGU, CUCUUA, CUCUUG, CUGAAG, CUGACC, CUGACG, CUGAGC, CUGAUA, CUGAUC, |
CUGCCG, CUGCCU, CUGCGA, CUGCUA, CUGCUU, CUGGAG, CUGGAU, CUGGCG, CUGGGU, CUGUAC, |
CUGUCA, CUGUCC, CUGUCG, CUGUGG, CUGUGU, CUGUUA, CUGUUU, CUUAAC, CUUAAG, CUUAAU, |
CUUACC, CUUACG, CUUAGA, CUUAGC, CUUAGG, CUUAGU, CUUAUA, CUUAUC, CUUAUG, CUUAUU, |
CUUCAG, CUUCAU, CUUCCA, CUUCCC, CUUCCG, CUUCCU, CUUCGA, CUUCGC, CUUCGG, CUUCGU, |
CUUCUA, CUUGAC, CUUGAG, CUUGAU, CUUGCA, CUUGCC, CUUGCG, CUUGCU, CUUGGC, CUUGGU, |
CUUGUU, CUUUAC, CUUUAG, CUUUAU, CUUUCA, CUUUCG, CUUUCU, CUUUGA, CUUUGC, CUUUGU, |
CUUUUA, CUUUUC, CUUUUG, CUUUUU, GAAAAA, GAAAAG, GAAAAU, GAAACC, GAAACG, GAAAGA, |
GAAAGC, GAAAGU, GAAAUA, GAAAUC, GAAAUG, GAAAUU, GAACAA, GAACAC, GAACAG, GAACAU, |
GAACCA, GAACCC, GAACCG, GAACCU, GAACGA, GAACGC, GAACGG, GAACGU, GAACUA, GAACUG, |
GAACUU, GAAGAC, GAAGAG, GAAGCA, GAAGCG, GAAGCU, GAAGUC, GAAUAA, GAAUAC, GAAUAG, |
GAAUAU, GAAUCC, GAAUCG, GAAUCU, GAAUGA, GAAUGC, GAAUGU, GAAUUA, GAAUUC, GAAUUU, |
GACAAA, GACAAG, GACAAU, GACACC, GACAGA, GACAGG, GACAUA, GACAUG, GACAUU, GACCAA, |
GACCAC, GACCAG, GACCCA, GACCCC, GACCCG, GACCGC, GACCGG, GACCGU, GACCUA, GACCUC, |
GACCUU, GACGAA, GACGAC, GACGAG, GACGAU, GACGCA, GACGCC, GACGCG, GACGCU, GACGGA, |
GACGGC, GACGGG, GACGGU, GACGUA, GACGUC, GACGUG, GACGUU, GACUAA, GACUAC, GACUAG, |
GACUAU, GACUCA, GACUCC, GACUCG, GACUGG, GACUGU, GACUUA, GACUUG, GACUUU, GAGAAU, |
GAGAGA, GAGAGC, GAGAGG, GAGAUA, GAGAUC, GAGCAA, GAGCAU, GAGCCA, GAGCGA, GAGCGG, |
GAGCGU, GAGGGU, GAGGUC, GAGGUG, GAGUAA, GAGUAG, GAGUCC, GAGUUC, GAGUUU, |
GAUAAA, GAUAAC, GAUAAG, GAUAAU, GAUACA, GAUACC, GAUACG, GAUACU, GAUAGA, GAUAGC, |
GAUAGG, GAUAGU, GAUAUA, GAUCAA, GAUCAC, GAUCAU, GAUCCA, GAUCCC, GAUCCU, GAUCGC, |
GAUCGG, GAUCGU, GAUCUA, GAUCUG, GAUCUU, GAUGAA, GAUGAC, GAUGAG, GAUGCA, GAUGCC, |
GAUGCG, GAUGCU, GAUGGC, GAUGGG, GAUGGU, GAUGUG, GAUGUU, GAUUAA, GAUUAC, |
GAUUAG, GAUUAU, GAUUCA, GAUUCG, GAUUCU, GAUUGA, GAUUGC, GAUUUA, GAUUUC, |
GAUUUG, GAUUUU, GCAAAC, GCAAAG, GCAAAU, GCAACA, GCAACC, GCAAGC, GCAAGU, GCAAUA, |
GCAAUC, GCAAUG, GCAAUU, GCACAA, GCACAC, GCACAG, GCACCC, GCACCG, GCACCU, GCACGA, |
GCACGC, GCACGU, GCACUA, GCACUC, GCACUG, GCACUU, GCAGAU, GCAGCC, GCAGCG, GCAGGC, |
GCAGUA, GCAGUC, GCAGUG, GCAGUU, GCAUAA, GCAUAG, GCAUAU, GCAUCG, GCAUCU, GCAUGA, |
GCAUGC, GCAUGG, GCAUGU, GCAUUA, GCAUUC, GCAUUG, GCAUUU, GCCAAA, GCCAAC, GCCAAU, |
GCCACA, GCCACC, GCCACG, GCCAGA, GCCAGU, GCCAUA, GCCAUC, GCCAUG, GCCAUU, GCCCAA, |
GCCCAC, GCCCAG, GCCCCG, GCCCGA, GCCCGG, GCCCGU, GCCGAA, GCCGAC, GCCGAG, GCCGAU, |
GCCGCA, GCCGCU, GCCGGA, GCCGGC, GCCGGG, GCCGGU, GCCGUA, GCCGUC, GCCGUG, GCCGUU, |
GCCUAA, GCCUAU, GCCUCA, GCCUCC, GCCUCG, GCCUGA, GCCUUA, GCCUUU, GCGAAA, GCGAAC, |
GCGAAG, GCGAAU, GCGACC, GCGACG, GCGACU, GCGAGA, GCGAGC, GCGAGG, GCGAGU, GCGAUA, |
GCGAUC, GCGAUG, GCGAUU, GCGCAA, GCGCAC, GCGCAG, GCGCAU, GCGCCA, GCGCCC, GCGCCU, |
GCGCGA, GCGCGU, GCGCUA, GCGCUC, GCGCUG, GCGCUU, GCGGAA, GCGGAC, GCGGAU, GCGGCA, |
GCGGCC, GCGGCU, GCGGGA, GCGGUA, GCGGUC, GCGGUU, GCGUAA, GCGUAC, GCGUAG, GCGUAU, |
GCGUCA, GCGUCC, GCGUCG, GCGUCU, GCGUGA, GCGUGC, GCGUGG, GCGUGU, GCGUUA, GCGUUC, |
GCGUUG, GCGUUU, GCUAAA, GCUAAC, GCUAAG, GCUAAU, GCUACC, GCUACG, GCUACU, GCUAGA, |
GCUAGG, GCUAGU, GCUAUA, GCUAUC, GCUAUU, GCUCAA, GCUCAC, GCUCAG, GCUCAU, GCUCCA, |
GCUCCC, GCUCCG, GCUCGA, GCUCGC, GCUCGU, GCUCUA, GCUCUC, GCUCUU, GCUGAA, GCUGAC, |
GCUGAU, GCUGCA, GCUGCC, GCUGCG, GCUGCU, GCUGUG, GCUGUU, GCUUAC, GCUUAG, GCUUAU, |
GCUUCA, GCUUCG, GCUUGA, GCUUGG, GCUUGU, GCUUUA, GCUUUG, GGAAAG, GGAACA, GGAACC, |
GGAACG, GGAACU, GGAAGU, GGAAUA, GGAAUC, GGAAUU, GGACAA, GGACAC, GGACAG, GGACAU, |
GGACCG, GGACGA, GGACGC, GGACGU, GGACUA, GGACUC, GGACUU, GGAGAC, GGAGCA, GGAGCG, |
GGAGGG, GGAGUA, GGAUAA, GGAUAC, GGAUCA, GGAUCC, GGAUCG, GGAUCU, GGAUGC, GGAUUA, |
GGAUUG, GGCAAU, GGCACA, GGCACU, GGCAGA, GGCAUA, GGCAUC, GGCCAC, GGCCAG, GGCCCC, |
GGCCGA, GGCCGC, GGCCGU, GGCCUA, GGCCUG, GGCCUU, GGCGAA, GGCGAG, GGCGAU, GGCGCA, |
GGCGCU, GGCGGU, GGCGUA, GGCGUC, GGCGUG, GGCGUU, GGCUAA, GGCUAC, GGCUAG, GGCUAU, |
GGCUCC, GGCUCG, GGCUGA, GGCUUA, GGCUUC, GGCUUG, GGGAAU, GGGACA, GGGAGA, GGGAGU, |
GGGAUA, GGGAUU, GGGCAA, GGGCAC, GGGCAG, GGGCCG, GGGCGG, GGGGCC, GGGGGG, |
GGGGGU, GGGGUA, GGGUAC, GGGUAU, GGGUCA, GGGUCC, GGGUCG, GGGUGA, GGGUGC, |
GGGUUA, GGGUUG, GGUAAA, GGUAAC, GGUAAG, GGUAAU, GGUACA, GGUACC, GGUACG, |
GGUACU, GGUAGC, GGUAGG, GGUAGU, GGUAUA, GGUAUC, GGUAUG, GGUCAA, GGUCAC, |
GGUCAG, GGUCAU, GGUCCA, GGUCCG, GGUCCU, GGUCGA, GGUCGC, GGUCGG, GGUCGU, GGUCUC, |
GGUCUU, GGUGAA, GGUGAC, GGUGAU, GGUGCA, GGUGCC, GGUGGC, GGUGUA, GGUGUC, |
GGUUAA, GGUUAG, GGUUAU, GGUUCA, GGUUCC, GGUUCG, GGUUGC, GGUUUC, GGUUUU, |
GUAAAA, GUAAAG, GUAAAU, GUAACC, GUAACG, GUAACU, GUAAGA, GUAAGC, GUAAGG, GUAAGU, |
GUAAUA, GUAAUC, GUAAUG, GUAAUU, GUACAA, GUACAC, GUACAG, GUACAU, GUACCA, GUACCC, |
GUACCG, GUACCU, GUACGA, GUACGC, GUACGG, GUACGU, GUACUA, GUACUC, GUACUG, GUACUU, |
GUAGAA, GUAGAC, GUAGCA, GUAGCC, GUAGCG, GUAGCU, GUAGGA, GUAGGC, GUAGGG, |
GUAGGU, GUAGUA, GUAGUC, GUAUAA, GUAUAC, GUAUAG, GUAUAU, GUAUCA, GUAUCG, |
GUAUCU, GUAUGA, GUAUGC, GUAUGG, GUAUUA, GUAUUG, GUAUUU, GUCAAA, GUCAAG, |
GUCAAU, GUCACA, GUCACC, GUCACG, GUCAGA, GUCAGC, GUCAGG, GUCAUA, GUCAUC, GUCAUG, |
GUCCAA, GUCCAC, GUCCAU, GUCCCC, GUCCCU, GUCCGA, GUCCGC, GUCCGG, GUCCGU, GUCCUA, |
GUCCUG, GUCCUU, GUCGAA, GUCGAC, GUCGAG, GUCGAU, GUCGCA, GUCGCC, GUCGCG, GUCGCU, |
GUCGGA, GUCGGC, GUCGGG, GUCGGU, GUCGUA, GUCGUC, GUCGUU, GUCUAA, GUCUAG, GUCUCA, |
GUCUCC, GUCUCG, GUCUGA, GUCUGG, GUCUGU, GUCUUC, GUCUUU, GUGAAA, GUGAAC, GUGAAG, |
GUGACC, GUGACG, GUGAGA, GUGAGC, GUGAGU, GUGAUC, GUGAUG, GUGAUU, GUGCAC, |
GUGCAU, GUGCCC, GUGCCG, GUGCGA, GUGCGG, GUGCGU, GUGCUA, GUGCUC, GUGCUG, |
GUGGAG, GUGGCG, GUGGCU, GUGGGU, GUGGUC, GUGGUG, GUGUAA, GUGUAG, GUGUCG, |
GUGUGA, GUGUGC, GUGUGU, GUGUUG, GUGUUU, GUUAAA, GUUAAC, GUUAAG, GUUACA, |
GUUACC, GUUACG, GUUACU, GUUAGA, GUUAGC, GUUAGU, GUUAUA, GUUAUC, GUUAUG, |
GUUAUU, GUUCAA, GUUCAC, GUUCAG, GUUCCA, GUUCCG, GUUCGA, GUUCGC, GUUCGG, GUUCGU, |
GUUCUA, GUUCUG, GUUGAA, GUUGAC, GUUGAG, GUUGAU, GUUGCG, GUUGCU, GUUGGA, |
GUUGGC, GUUGGU, GUUGUC, GUUGUG, GUUGUU, GUUUAA, GUUUAC, GUUUAG, GUUUAU, |
GUUUCA, GUUUCC, GUUUCU, GUUUGA, GUUUGC, GUUUGG, GUUUGU, GUUUUA, GUUUUC, |
GUUUUU, UAAAAA, UAAAAC, UAAAAG, UAAAAU, UAAACA, UAAACC, UAAACG, UAAACU, UAAAGA, |
UAAAGG, UAAAGU, UAAAUA, UAAAUC, UAAAUG, UAAAUU, UAACAA, UAACAC, UAACAG, UAACCA, |
UAACCC, UAACCG, UAACCU, UAACGA, UAACGC, UAACGG, UAACGU, UAACUA, UAACUG, UAACUU, |
UAAGAG, UAAGAU, UAAGCA, UAAGCC, UAAGCG, UAAGCU, UAAGGA, UAAGGC, UAAGGG, UAAGGU, |
UAAGUA, UAAGUC, UAAGUG, UAAGUU, UAAUAA, UAAUCA, UAAUCC, UAAUCG, UAAUCU, UAAUGA, |
UAAUGG, UAAUGU, UAAUUA, UAAUUC, UAAUUG, UACAAC, UACAAG, UACAAU, UACACC, UACACG, |
UACACU, UACAGA, UACAGC, UACAUA, UACAUC, UACAUU, UACCAA, UACCAC, UACCAG, UACCAU, |
UACCCC, UACCCG, UACCCU, UACCGA, UACCGC, UACCGG, UACCGU, UACCUA, UACCUG, UACGAA, |
UACGAC, UACGAG, UACGAU, UACGCA, UACGCC, UACGCG, UACGCU, UACGGC, UACGGG, UACGGU, |
UACGUA, UACGUC, UACGUG, UACGUU, UACUAA, UACUAC, UACUAG, UACUAU, UACUCA, UACUCC, |
UACUCG, UACUCU, UACUGA, UACUGC, UACUGG, UACUUA, UACUUG, UACUUU, UAGAAA, UAGAAG, |
UAGAAU, UAGACA, UAGACG, UAGAGA, UAGAGC, UAGAGU, UAGAUA, UAGAUC, UAGAUG, UAGCAU, |
UAGCCC, UAGCCG, UAGCCU, UAGCGA, UAGCGC, UAGCGU, UAGCUA, UAGCUC, UAGCUG, UAGGAA, |
UAGGAU, UAGGCG, UAGGCU, UAGGGU, UAGGUC, UAGGUG, UAGGUU, UAGUAA, UAGUAC, |
UAGUAG, UAGUAU, UAGUCA, UAGUCG, UAGUGU, UAGUUA, UAGUUC, UAGUUG, UAGUUU, |
UAUAAC, UAUAAG, UAUACU, UAUAGA, UAUAGC, UAUAGG, UAUAGU, UAUAUA, UAUAUC, UAUAUG, |
UAUAUU, UAUCAA, UAUCAC, UAUCAU, UAUCCA, UAUCCC, UAUCCG, UAUCCU, UAUCGA, UAUCGC, |
UAUCGG, UAUCGU, UAUCUA, UAUCUC, UAUCUG, UAUCUU, UAUGAA, UAUGAC, UAUGAG, |
UAUGAU, UAUGCA, UAUGCG, UAUGCU, UAUGGA, UAUGGC, UAUGUC, UAUGUG, UAUGUU, |
UAUUAG, UAUUCA, UAUUCC, UAUUCG, UAUUCU, UAUUGA, UAUUGG, UAUUUA, UAUUUC, |
UAUUUG, UAUUUU, UCAAAA, UCAAAC, UCAAAG, UCAACC, UCAACU, UCAAGA, UCAAGC, UCAAUA, |
UCAAUC, UCAAUG, UCAAUU, UCACCC, UCACCG, UCACCU, UCACGA, UCACGC, UCACGG, UCACGU, |
UCACUA, UCACUC, UCACUU, UCAGAA, UCAGAC, UCAGAG, UCAGCG, UCAGCU, UCAGGA, UCAGGC, |
UCAGGU, UCAGUC, UCAGUU, UCAUAA, UCAUCA, UCAUCC, UCAUCG, UCAUGC, UCAUGG, UCAUGU, |
UCAUUA, UCAUUG, UCCAAA, UCCAAC, UCCAAG, UCCAAU, UCCACA, UCCACC, UCCACG, UCCAGC, |
UCCAGG, UCCAUA, UCCAUC, UCCAUU, UCCCAA, UCCCAG, UCCCAU, UCCCCC, UCCCCG, UCCCCU, |
UCCCGA, UCCCGC, UCCCGG, UCCCGU, UCCCUA, UCCCUC, UCCGAA, UCCGAC, UCCGAG, UCCGAU, |
UCCGCA, UCCGCC, UCCGGA, UCCGGC, UCCGGU, UCCGUA, UCCGUC, UCCGUG, UCCUAA, UCCUCA, |
UCCUCG, UCCUCU, UCCUGC, UCCUGU, UCCUUA, UCCUUC, UCCUUU, UCGAAA, UCGAAC, UCGAAG, |
UCGAAU, UCGACA, UCGACC, UCGACG, UCGACU, UCGAGA, UCGAGC, UCGAGG, UCGAUA, UCGAUC, |
UCGAUG, UCGAUU, UCGCAA, UCGCAC, UCGCAG, UCGCAU, UCGCCA, UCGCCC, UCGCCG, UCGCCU, |
UCGCGA, UCGCGC, UCGCGU, UCGCUA, UCGCUC, UCGGAA, UCGGAC, UCGGAG, UCGGAU, UCGGCA, |
UCGGCU, UCGGGG, UCGGGU, UCGGUC, UCGGUG, UCGGUU, UCGUAA, UCGUAC, UCGUAG, |
UCGUAU, UCGUCA, UCGUCC, UCGUCG, UCGUCU, UCGUGA, UCGUGU, UCGUUA, UCGUUC, UCGUUG, |
UCGUUU, UCUAAC, UCUAAG, UCUAAU, UCUACA, UCUACC, UCUACG, UCUACU, UCUAGC, UCUAGG, |
UCUAGU, UCUAUA, UCUAUC, UCUAUG, UCUAUU, UCUCAG, UCUCAU, UCUCCG, UCUCGC, UCUCGG, |
UCUCGU, UCUCUC, UCUGAA, UCUGAU, UCUGCA, UCUGCG, UCUGCU, UCUGGC, UCUGGU, UCUGUC, |
UCUGUG, UCUGUU, UCUUAA, UCUUAC, UCUUAG, UCUUAU, UCUUCA, UCUUCC, UCUUCG, UCUUCU, |
UCUUGC, UCUUGG, UCUUGU, UCUUUA, UCUUUC, UCUUUG, UCUUUU, UGAAAA, UGAAAC, |
UGAACA, UGAACC, UGAAGG, UGAAUC, UGAAUG, UGACAA, UGACAC, UGACAG, UGACCA, UGACCC, |
UGACCG, UGACGA, UGACGC, UGACGG, UGACGU, UGACUA, UGACUC, UGACUU, UGAGAG, UGAGAU, |
UGAGCA, UGAGCC, UGAGCU, UGAGGC, UGAGGU, UGAGUA, UGAGUU, UGAUAC, UGAUAG, |
UGAUAU, UGAUCA, UGAUCG, UGAUCU, UGAUGA, UGAUGC, UGAUGG, UGAUGU, UGAUUA, |
UGAUUC, UGAUUG, UGAUUU, UGCAAC, UGCAAG, UGCACA, UGCACG, UGCAGG, UGCAGU, UGCAUC, |
UGCCCA, UGCCCC, UGCCCG, UGCCGA, UGCCGC, UGCCGG, UGCCGU, UGCCUA, UGCCUC, UGCCUG, |
UGCCUU, UGCGAA, UGCGAC, UGCGAU, UGCGCC, UGCGCG, UGCGCU, UGCGGC, UGCGGG, UGCGGU, |
UGCGUA, UGCGUC, UGCGUG, UGCGUU, UGCUAC, UGCUAU, UGCUCC, UGCUCG, UGCUGC, UGCUGG, |
UGCUGU, UGCUUA, UGCUUU, UGGAAC, UGGAAG, UGGAGC, UGGAUC, UGGAUU, UGGCAA, |
UGGCAC, UGGCAG, UGGCCG, UGGCCU, UGGCGA, UGGCGC, UGGCGU, UGGCUA, UGGCUC, UGGCUU, |
UGGGAA, UGGGCA, UGGGCC, UGGGGC, UGGGUC, UGGUAA, UGGUAG, UGGUAU, UGGUCC, |
UGGUCG, UGGUCU, UGGUGA, UGGUGC, UGGUGG, UGGUGU, UGGUUA, UGGUUG, UGUAAA, |
UGUAAC, UGUAAG, UGUACC, UGUACG, UGUACU, UGUAGA, UGUAGC, UGUAGU, UGUAUC, |
UGUAUU, UGUCAA, UGUCAC, UGUCAG, UGUCAU, UGUCCA, UGUCCC, UGUCCG, UGUCGA, UGUCGC, |
UGUCGG, UGUCGU, UGUCUA, UGUCUC, UGUGAC, UGUGAG, UGUGAU, UGUGCA, UGUGGU, |
UGUGUA, UGUGUU, UGUUAC, UGUUAG, UGUUAU, UGUUCA, UGUUCC, UGUUCG, UGUUGG, |
UGUUGU, UGUUUA, UGUUUC, UGUUUG, UGUUUU, UUAAAA, UUAAAC, UUAAAG, UUAAAU, |
UUAACC, UUAACG, UUAACU, UUAAGU, UUAAUA, UUAAUC, UUAAUG, UUAAUU, UUACAA, UUACAC, |
UUACAG, UUACAU, UUACCA, UUACCC, UUACCG, UUACCU, UUACGA, UUACGC, UUACGG, UUACGU, |
UUACUA, UUACUC, UUACUG, UUACUU, UUAGAA, UUAGAC, UUAGCC, UUAGCG, UUAGCU, UUAGGC, |
UUAGGU, UUAGUA, UUAGUC, UUAGUU, UUAUAA, UUAUAC, UUAUAG, UUAUAU, UUAUCC, |
UUAUCG, UUAUCU, UUAUGA, UUAUGG, UUAUGU, UUAUUA, UUAUUC, UUAUUG, UUAUUU, |
UUCAAC, UUCAAU, UUCACA, UUCACC, UUCACG, UUCACU, UUCAGC, UUCAGG, UUCAGU, UUCAUA, |
UUCAUC, UUCAUG, UUCAUU, UUCCAA, UUCCCA, UUCCCG, UUCCGA, UUCCGU, UUCCUU, UUCGAA, |
UUCGAC, UUCGAG, UUCGAU, UUCGCA, UUCGCC, UUCGCG, UUCGCU, UUCGGA, UUCGGC, UUCGGG, |
UUCGGU, UUCGUA, UUCGUC, UUCGUG, UUCGUU, UUCUAC, UUCUAG, UUCUCA, UUCUCG, |
UUCUGG, UUCUUA, UUCUUU, UUGAAA, UUGAAC, UUGAAG, UUGAAU, UUGACC, UUGACG, |
UUGACU, UUGAGA, UUGAGC, UUGAGU, UUGAUA, UUGAUC, UUGAUG, UUGAUU, UUGCAA, |
UUGCAC, UUGCAG, UUGCAU, UUGCCC, UUGCCG, UUGCGA, UUGCGC, UUGCGG, UUGCGU, UUGCUA, |
UUGCUC, UUGCUG, UUGCUU, UUGGAA, UUGGAG, UUGGCC, UUGGCG, UUGGCU, UUGGGC, |
UUGGGU, UUGGUA, UUGGUG, UUGUAA, UUGUAC, UUGUCA, UUGUCG, UUGUCU, UUGUGC, |
UUGUGG, UUGUUA, UUGUUG, UUGUUU, UUUAAA, UUUAAC, UUUAAG, UUUAAU, UUUACA, |
UUUACC, UUUACG, UUUACU, UUUAGA, UUUAGC, UUUAGG, UUUAGU, UUUAUA, UUUAUC, |
UUUAUG, UUUAUU, UUUCAU, UUUCCA, UUUCCG, UUUCCU, UUUCGA, UUUCGC, UUUCGG, |
UUUCGU, UUUCUA, UUUCUC, UUUCUG, UUUCUU, UUUGAA, UUUGAC, UUUGAG, UUUGAU, |
UUUGCC, UUUGCU, UUUGGA, UUUGGC, UUUGGG, UUUGGU, UUUGUA, UUUGUC, UUUGUU, |
UUUUAA, UUUUAG, UUUUAU, UUUUCC, UUUUCG, UUUUCU, UUUUGA, UUUUGC, UUUUGG, |
UUUUGU, UUUUUA, UUUUUC, UUUUUU |
TABLE 2 |
A listing of oligonucleotide modifications |
Symbol | Feature Description | ||
bio | 5′ biotin | ||
dAs | DNA w/3′ thiophosphate | ||
dCs | DNA w/3′ thiophosphate | ||
dGs | DNA w/3′ thiophosphate | ||
dTs | DNA w/3′ thiophosphate | ||
dG | DNA | ||
enaAs | ENA w/3′ thiophosphate | ||
enaCs | ENA w/3′ thiophosphate | ||
enaGs | ENA w/3′ thiophosphate | ||
enaTs | ENA w/3′ thiophosphate | ||
fluAs | 2′-fluoro w/3′ thiophosphate | ||
fluCs | 2′-fluoro w/3′ thiophosphate | ||
fluGs | 2′-fluoro w/3′ thiophosphate | ||
fluUs | 2′-fluoro w/3′ thiophosphate | ||
InaAs | LNA w/3′ thiophosphate | ||
InaCs | LNA w/3′ thiophosphate | ||
InaGs | LNA w/3′ thiophosphate | ||
InaTs | LNA w/3′ thiophosphate | ||
omeAs | 2′-Ome w/3′ thiophosphate | ||
omeCs | 2′-Ome w/3′ thiophosphate | ||
omeGs | 2′-Ome w/3′ thiophosphate | ||
omeTs | 2′-Ome w/3′ thiophosphate | ||
InaAs-Sup | LNA w/3′ thiophosphate at 3′ terminus | ||
InaCs-Sup | LNA w/3′ thiophosphate at 3′ terminus | ||
InaGs-Sup | LNA w/3′ thiophosphate at 3′ terminus | ||
InaTs-Sup | LNA w/3′ thiophosphate at 3′ terminus | ||
InaA-Sup | LNA w/3′ OH at 3′ terminus | ||
InaC-Sup | LNA w/3′ OH at 3′ terminus | ||
InaG-Sup | LNA w/3′ OH at 3′ terminus | ||
InaT-Sup | LNA w/3′ OH at 3′ terminus | ||
omeA-Sup | 2′-Ome w/3′ OH at 3′ terminus | ||
omeC-Sup | 2′-Ome w/3′ OH at 3′ terminus | ||
omeG-Sup | 2′-Ome w/3′ OH at 3′ terminus | ||
omeU-Sup | 2′-Ome w/3′ OH at 3′ terminus | ||
dAs-Sup | DNA w/3′ thiophosphate at 3′ terminus | ||
dCs-Sup | DNA w/3′ thiophosphate at 3′ terminus | ||
dGs-Sup | DNA w/3′ thiophosphate at 3′ terminus | ||
dTs-Sup | DNA w/3′ thiophosphate at 3′ terminus | ||
dA-Sup | DNA w/3′ OH at 3′ terminus | ||
dC-Sup | DNA w/3′ OH at 3′ terminus | ||
dG-Sup | DNA w/3′ OH at 3′ terminus | ||
dT-Sup | DNA w/3′ OH at 3′ terminus | ||
TABLE 3 |
Formatted oligonucleotide sequences made for |
testing showing nucleotide modifications. |
Oligo | Base | Seq | |
Name | Sequence | RaNA Sequence | ID |
MECP2- | CGACGTCGCGC | InaCs;omeGs;InaAs;omeCs;InaGs;omeUs;InaCs;omeGs; | 1438 |
01 m01 | CCCG | InaCs;omeGs;InaCs;omeCs;InaCs;omeCs;InaG-Sup | |
MECP2- | CCGACGTCGCG | InaCs;omeCs;InaGs;omeAs;InaCs;omeGs;InaTs;omeCs; | 1439 |
02 m01 | CCCC | InaGs;omeCs;InaGs;omeCs;InaCs;omeCs;InaC-Sup | |
MECP2- | CCATTTTCCGG | InaCs;omeCs;InaAs;omeUs;InaTs;omeUs;InaTs;omeCs; | 1521 |
03 m01 | ACGG | InaCs;omeGs;InaGs;omeAs;InaCs;omeGs;InaG-Sup | |
MECP2- | GCCATTTTCCG | InaGs;omeCs;InaCs;omeAs;InaTs;omeUs;InaTs;omeUs; | 1522 |
04 m01 | GACG | InaCs;omeCs;InaGs;omeGs;InaAs;omeCs;InaG-Sup | |
MECP2- | GCGGCCATTTT | InaGs;omeCs;InaGs;omeGs;InaCs;omeCs;InaAs;omeUs; | 1525 |
05 m01 | CCGG | InaTs;omeUs;InaTs;omeCs;InaCs;omeGs;InaG-Sup | |
MECP2- | GGCGGCCATTT | InaGs;omeGs;InaCs;omeGs;InaGs;omeCs;InaCs;omeAs; | 1526 |
06 m01 | TCCG | InaTs;omeUs;InaTs;omeUs;InaCs;omeCs;InaG-Sup | |
MECP2- | GCCAGCCGTGT | InaGs;omeCs;InaCs;omeAs;InaGs;omeCs;InaCs;omeGs; | 1683 |
07 m01 | CGTC | InaTs;omeGs;InaTs;omeCs;InaGs;omeUs;InaC-Sup | |
MECP2- | ATCCGCCAGCC | InaAs;omeUs;InaCs;omeCs;InaGs;omeCs;InaCs;omeAs; | 1687 |
08 m01 | GTGT | InaGs;omeCs;InaCs;omeGs;InaTs;omeGs;InaT-Sup | |
MECP2- | GATCGCCGGCG | InaGs;omeAs;InaTs;omeCs;InaGs;omeCs;InaCs;omeGs; | 2463 |
09 m01 | AAGG | InaGs;omeCs;InaGs;omeAs;InaAs;omeGs;InaG-Sup | |
MECP2- | GATCCCGAGCG | InaGs;omeAs;InaTs;omeCs;InaCs;omeCs;InaGs;omeAs; | 2532 |
10 m01 | CTCC | InaGs;omeCs;InaGs;omeCs;InaTs;omeCs;InaC-Sup | |
MECP2- | TGTGGCGACCA | InaTs;omeGs;InaTs;omeGs;InaGs;omeCs;InaGs;omeAs; | 7070 |
11 m01 | AGTA | InaCs;omeCs;InaAs;omeAs;InaGs;omeUs;InaA-Sup | |
MECP2- | AGATCACCAGT | InaAs;omeGs;InaAs;omeUs;InaCs;omeAs;InaCs;omeCs; | 7117 |
12 m01 | TCCG | InaAs;omeGs;InaTs;omeUs;InaCs;omeCs;InaG-Sup | |
MECP2- | TTGTACCTATA | InaTs;omeUs;InaGs;omeUs;InaAs;omeCs;InaCs;omeUs; | 14460 |
13 m01 | CGCA | InaAs;omeUs;InaAs;omeCs;InaGs;omeCs;InaA-Sup | |
MECP2- | TTTGTACCTAT | InaTs;omeUs;InaTs;omeGs;InaTs;omeAs;InaCs;omeCs; | 14461 |
14 m01 | ACGC | InaTs;omeAs;InaTs;omeAs;InaCs;omeGs;InaC-Sup | |
MECP2- | CCCAAACAGCG | InaCs;omeCs;InaCs;omeAs;InaAs;omeAs;InaCs;omeAs; | 65064 |
15 m01 | GCGC | InaGs;omeCs;InaGs;omeGs;InaCs;omeGs;InaC-Sup | |
MECP2- | CCAAACAGCGG | InaCs;omeCs;InaAs;omeAs;InaAs;omeCs;InaAs;omeGs; | 65065 |
16 m01 | CGCT | InaCs;omeGs;InaGs;omeCs;InaGs;omeCs;InaT-Sup | |
MECP2- | CAAACAGCGGC | InaCs;omeAs;InaAs;omeAs;InaCs;omeAs;InaGs;omeCs; | 65066 |
17 m01 | GCTC | InaGs;omeGs;InaCs;omeGs;InaCs;omeUs;InaC-Sup | |
MECP2- | AAACAGCGGCG | InaAs;omeAs;InaAs;omeCs;InaAs;omeGs;InaCs;omeGs; | 65067 |
18 m01 | CTCC | InaGs;omeCs;InaGs;omeCs;InaTs;omeCs;InaC-Sup | |
MECP2- | AACAGCGGCGC | InaAs;omeAs;InaCs;omeAs;InaGs;omeCs;InaGs;omeGs; | 65068 |
19 m01 | TCCA | InaCs;omeGs;InaCs;omeUs;InaCs;omeCs;InaA-Sup | |
MECP2- | TCCATCATCCG | InaTs;omeCs;InaCs;omeAs;InaTs;omeCs;InaAs;omeUs; | 65079 |
20 m01 | TGAC | InaCs;omeCs;InaGs;omeUs;InaGs;omeAs;InaC-Sup | |
MECP2- | GGACCCATGTA | InaGs;omeGs;InaAs;omeCs;InaCs;omeCs;InaAs;omeUs; | 65097 |
21 m01 | TGAT | InaGs;omeUs;InaAs;omeUs;InaGs;omeAs;InaT-Sup | |
MECP2- | CTTTCGCTCTA | InaCs;omeUs;InaTs;omeUs;InaCs;omeGs;InaCs;omeUs; | 65972 |
22 m01 | AAGT | InaCs;omeUs;InaAs;omeAs;InaAs;omeGs;InaT-Sup | |
MECP2- | TCGCTCTAAAG | InaTs;omeCs;InaGs;omeCs;InaTs;omeCs;InaTs;omeAs; | 65975 |
23 m01 | TGGA | InaAs;omeAs;InaGs;omeUs;InaGs;omeGs;InaA-Sup | |
MECP2- | GACTTCACGGT | InaGs;omeAs;InaCs;omeUs;InaTs;omeCs;InaAs;omeCs; | 66045 |
24 m01 | AACT | InaGs;omeGs;InaTs;omeAs;InaAs;omeCs;InaT-Sup | |
MECP2- | CTTCACGGTAA | InaCs;omeUs;InaTs;omeCs;InaAs;omeCs;InaGs;omeGs; | 66047 |
25 m01 | CTGG | InaTs;omeAs;InaAs;omeCs;InaTs;omeGs;InaG-Sup | |
MECP2- | CAAACGCCCCG | InaCs;omeAs;InaAs;omeAs;InaCs;omeGs;InaCs;omeCs; | 66323 |
26 m01 | GCAG | InaCs;omeCs;InaGs;omeGs;InaCs;omeAs;InaG-Sup | |
MECP2- | GAAGCGAAAAG | InaGs;omeAs;InaAs;omeGs;InaCs;omeGs;InaAs;omeAs; | 66338 |
27 m01 | CTGA | InaAs;omeAs;InaGs;omeCs;InaTs;omeGs;InaA-Sup | |
MECP2- | AAGAAAGCCGT | InaAs;omeAs;InaGs;omeAs;InaAs;omeAs;InaGs;omeCs; | 66432 |
28 m01 | GAAG | InaCs;omeGs;InaTs;omeGs;InaAs;omeAs;InaG-Sup | |
MECP2- | CATCAAGAAGC | InaCs;omeAs;InaTs;omeCs;InaAs;omeAs;InaGs;omeAs; | 66485 |
29 m01 | GCAA | InaAs;omeGs;InaCs;omeGs;InaCs;omeAs;InaA-Sup | |
MECP2- | CAATGTCTTTG | InaCs;omeAs;InaAs;omeUs;InaGs;omeUs;InaCs;omeUs; | 27322 |
30 m01 | CGCT | InaTs;omeUs;InaGs;omeCs;InaGs;omeCs;InaT-Sup | |
MECP2- | GGCGTCCGGCT | InaGs;omeGs;InaCs;omeGs;InaTs;omeCs;InaCs;omeGs; | 27377 |
31 m01 | GTCC | InaGs;omeCs;InaTs;omeGs;InaTs;omeCs;InaC-Sup | |
MECP2- | TTTGCAATCCG | InaTs;omeUs;InaTs;omeGs;InaCs;omeAs;InaAs;omeUs; | 27422 |
32 m01 | CTCC | InaCs;omeCs;InaGs;omeCs;InaTs;omeCs;InaC-Sup | |
MECP2- | GCCACGAAACT | InaGs;omeCs;InaCs;omeAs;InaCs;omeGs;InaAs;omeAs; | 27548 |
33 m01 | CTAA | InaAs;omeCs;InaTs;omeCs;InaTs;omeAs;InaA-Sup | |
MECP2- | AGCGCAGGTAT | InaAs;omeGs;InaCs;omeGs;InaCs;omeAs;InaGs;omeGs; | 28519 |
34 m01 | ATAT | InaTs;omeAs;InaTs;omeAs;InaTs;omeAs;InaT-Sup | |
MECP2- | TTCGGAGCTTC | InaTs;omeUs;InaCs;omeGs;InaGs;omeAs;InaGs;omeCs; | 28565 |
35 m01 | GTGG | InaTs;omeUs;InaCs;omeGs;InaTs;omeGs;InaG-Sup | |
MECP2- | GACAAACACGG | InaGs;omeAs;InaCs;omeAs;InaAs;omeAs;InaCs;omeAs; | 29761 |
36 m01 | TTTT | InaCs;omeGs;InaGs;omeUs;InaTs;omeUs;InaT-Sup | |
MECP2- | TTGCTACCACG | InaTs;omeUs;InaGs;omeCs;InaTs;omeAs;InaCs;omeCs; | 72740 |
37 m01 | GCCT | InaAs;omeCs;InaGs;omeGs;InaCs;omeCs;InaT-Sup | |
MECP2- | TGCTACCACGG | InaTs;omeGs;InaCs;omeUs;InaAs;omeCs;InaCs;omeAs; | 72741 |
38 m01 | CCTC | InaCs;omeGs;InaGs;omeCs;InaCs;omeUs;InaC-Sup | |
MECP2- | ATCAATAACAG | InaAs;omeUs;InaCs;omeAs;InaAs;omeUs;InaAs;omeAs; | 72783 |
39 m01 | CCGC | InaCs;omeAs;InaGs;omeCs;InaCs;omeGs;InaC-Sup | |
MECP2- | CAATAACAGCC | InaCs;omeAs;InaAs;omeUs;InaAs;omeAs;InaCs;omeAs; | 72785 |
40 m01 | GCTC | InaGs;omeCs;InaCs;omeGs;InaCs;omeUs;InaC-Sup | |
MECP2- | ACTCAATGTGT | InaAs;omeCs;InaTs;omeCs;InaAs;omeAs;InaTs;omeGs; | 72848 |
41 m01 | GCCG | InaTs;omeGs;InaTs;omeGs;InaCs;omeCs;InaG-Sup | |
MECP2- | CAATGTGTGCC | InaCs;omeAs;InaAs;omeUs;InaGs;omeUs;InaGs;omeUs; | 72851 |
42 m01 | GAGC | InaGs;omeCs;InaCs;omeGs;InaAs;omeGs;InaC-Sup | |
MECP2- | CAAACGCGTCA | InaCs;omeAs;InaAs;omeAs;InaCs;omeGs;InaCs;omeGs; | 36117 |
43 m01 | CTTA | InaTs;omeCs;InaAs;omeCs;InaTs;omeUs;InaA-Sup | |
MECP2- | ATCGAGAATGC | InaAs;omeUs;InaCs;omeGs;InaAs;omeGs;InaAs;omeAs; | 36165 |
44 m01 | TAAC | InaTs;omeGs;InaCs;omeUs;InaAs;omeAs;InaC-Sup | |
MECP2- | CGCACGAGGCC | InaCs;omeGs;InaCs;omeAs;InaCs;omeGs;InaAs;omeGs; | 76153 |
45 m01 | GGCT | InaGs;omeCs;InaCs;omeGs;InaGs;omeCs;InaT-Sup | |
MECP2- | GAGTCAGTGTC | InaGs;omeAs;InaGs;omeUs;InaCs;omeAs;InaGs;omeUs; | 76180 |
46 m01 | CGCG | InaGs;omeUs;InaCs;omeCs;InaGs;omeCs;InaG-Sup | |
MECP2- | GTGTCCGCGGA | InaGs;omeUs;InaGs;omeUs;InaCs;omeCs;InaGs;omeCs; | 76186 |
47 m01 | CCCG | InaGs;omeGs;InaAs;omeCs;InaCs;omeCs;InaG-Sup | |
MECP2- | AGCACTTCTTG | InaAs;omeGs;InaCs;omeAs;InaCs;omeUs;InaTs;omeCs; | 76316 |
48 m01 | TACG | InaTs;omeUs;InaGs;omeUs;InaAs;omeCs;InaG-Sup | |
MECP2- | TTCTTGTACGA | InaTs;omeUs;InaCs;omeUs;InaTs;omeGs;InaTs;omeAs; | 76321 |
49 m01 | GGTG | InaCs;omeGs;InaAs;omeGs;InaGs;omeUs;InaG-Sup | |
MECP2- | TGTGCCGCTTC | InaTs;omeGs;InaTs;omeGs;InaCs;omeCs;InaGs;omeCs; | 76349 |
50 m01 | TACA | InaTs;omeUs;InaCs;omeUs;InaAs;omeCs;InaA-Sup | |
MECP2- | CCGCCGACTGG | InaCs;omeCs;InaGs;omeCs;InaCs;omeGs;InaAs;omeCs; | 76385 |
51 m01 | TGCC | InaTs;omeGs;InaGs;omeUs;InaGs;omeCs;InaC-Sup | |
MECP2- | TGGTGCCAGTT | InaTs;omeGs;InaGs;omeUs;InaGs;omeCs;InaCs;omeAs; | 76393 |
52 m01 | CGGT | InaGs;omeUs;InaTs;omeCs;InaGs;omeGs;InaT-Sup | |
MECP2- | TGATCGTGCGC | InaTs;omeGs;InaAs;omeUs;InaCs;omeGs;InaTs;omeGs; | 76490 |
53 m01 | GACC | InaCs;omeGs;InaCs;omeGs;InaAs;omeCs;InaC-Sup | |
MECP2- | GATCGTGCGCG | InaGs;omeAs;InaTs;omeCs;InaGs;omeUs;InaGs;omeCs; | 76491 |
54 m01 | ACCA | InaGs;omeCs;InaGs;omeAs;InaCs;omeCs;InaA-Sup | |
MECP2- | TCGTGCGCGAC | InaTs;omeCs;InaGs;omeUs;InaGs;omeCs;InaGs;omeCs; | 76493 |
55 m01 | CAGA | InaGs;omeAs;InaCs;omeCs;InaAs;omeGs;InaA-Sup | |
MECP2- | GCGGCTGTGCG | InaGs;omeCs;InaGs;omeGs;InaCs;omeUs;InaGs;omeUs; | 76515 |
56 m01 | AGCG | InaGs;omeCs;InaGs;omeAs;InaGs;omeCs;InaG-Sup | |
MECP2- | GGATCAACCGC | InaGs;omeGs;InaAs;omeUs;InaCs;omeAs;InaAs;omeCs; | 76565 |
57 m01 | AACG | InaCs;omeGs;InaCs;omeAs;InaAs;omeCs;InaG-Sup | |
MECP2- | GATCAACCGCA | InaGs;omeAs;InaTs;omeCs;InaAs;omeAs;InaCs;omeCs; | 76566 |
58 m01 | ACGC | InaGs;omeCs;InaAs;omeAs;InaCs;omeGs;InaC-Sup | |
MECP2- | CGACTGGACAT | InaCs;omeGs;InaAs;omeCs;InaTs;omeGs;InaGs;omeAs; | 78887 |
59 m01 | CCTT | InaCs;omeAs;InaTs;omeCs;InaCs;omeUs;InaT-Sup | |
MECP2- | CCCGAGGAGTA | InaCs;omeCs;InaCs;omeGs;InaAs;omeGs;InaGs;omeAs; | 79422 |
60 m01 | CATC | InaGs;omeUs;InaAs;omeCs;InaAs;omeUs;InaC-Sup | |
SEQ ID | Chrom | Gene | Chr. Start | Chr. End | Strand |
1 | chrX | MECP2 | 153275263 | 153375188 | − |
2 | chrX | MECP2 | 153275263 | 153375188 | + |
3 | chrX | Mecp2 | 71260160 | 71342932 | − |
4 | chrX | Mecp2 | 71260160 | 71342932 | + |
5 | chrX | MECP2 | 153278064 | 153278111 | − |
6 | chrX | MECP2 | 153278111 | 153278156 | − |
7 | chrX | MECP2 | 153278706 | 153278747 | − |
8 | chrX | MECP2 | 153279512 | 153279556 | − |
9 | chrX | MECP2 | 153279613 | 153279658 | − |
10 | chrX | MECP2 | 153281486 | 153281531 | − |
11 | chrX | MECP2 | 153283707 | 153283737 | − |
12 | chrX | MECP2 | 153284059 | 153284105 | − |
13 | chrX | MECP2 | 153287944 | 153287992 | − |
14 | chrX | MECP2 | 153288681 | 153288722 | − |
15 | chrX | MECP2 | 153290087 | 153290134 | − |
16 | chrX | MECP2 | 153290216 | 153290263 | − |
17 | chrX | MECP2 | 153290364 | 153290414 | − |
18 | chrX | MECP2 | 153291585 | 153291633 | − |
19 | chrX | MECP2 | 153292312 | 153292362 | − |
20 | chrX | MECP2 | 153292731 | 153292774 | − |
21 | chrX | MECP2 | 153293138 | 153293185 | − |
22 | chrX | MECP2 | 153293331 | 153293377 | − |
23 | chrX | MECP2 | 153293427 | 153293469 | − |
24 | chrX | MECP2 | 153293568 | 153293614 | − |
25 | chrX | MECP2 | 153293715 | 153293764 | − |
26 | chrX | MECP2 | 153293792 | 153293878 | − |
27 | chrX | MECP2 | 153293901 | 153293948 | − |
28 | chrX | MECP2 | 153294420 | 153294467 | − |
29 | chrX | MECP2 | 153297927 | 153297972 | − |
30 | chrX | MECP2 | 153315466 | 153315571 | − |
31 | chrX | MECP2 | 153343401 | 153343447 | − |
32 | chrX | MECP2 | 153344298 | 153344339 | − |
33 | chrX | MECP2 | 153348654 | 153348702 | − |
34 | chrX | MECP2 | 153348997 | 153349021 | − |
35 | chrX | MECP2 | 153349179 | 153349222 | − |
36 | chrX | MECP2 | 153349694 | 153349734 | − |
37 | chrX | MECP2 | 153350493 | 153350518 | − |
38 | chrX | MECP2 | 153356667 | 153356713 | − |
39 | chrX | MECP2 | 153356742 | 153356795 | − |
40 | chrX | MECP2 | 153357047 | 153357106 | − |
41 | chrX | MECP2 | 153357161 | 153357204 | − |
42 | chrX | MECP2 | 153361085 | 153361163 | − |
43 | chrX | MECP2 | 153361423 | 153361467 | − |
44 | chrX | MECP2 | 153362464 | 153362527 | − |
45 | chrX | MECP2 | 153276064 | 153280111 | − |
46 | chrX | MECP2 | 153276111 | 153280156 | − |
47 | chrX | MECP2 | 153276706 | 153280747 | − |
48 | chrX | MECP2 | 153277512 | 153281556 | − |
49 | chrX | MECP2 | 153277613 | 153281658 | − |
50 | chrX | MECP2 | 153279486 | 153283531 | − |
51 | chrX | MECP2 | 153281707 | 153285737 | − |
52 | chrX | MECP2 | 153282059 | 153286105 | − |
53 | chrX | MECP2 | 153285944 | 153289992 | − |
54 | chrX | MECP2 | 153286681 | 153290722 | − |
55 | chrX | MECP2 | 153288087 | 153292134 | − |
56 | chrX | MECP2 | 153288216 | 153292263 | − |
57 | chrX | MECP2 | 153288364 | 153292414 | − |
58 | chrX | MECP2 | 153289585 | 153293633 | − |
59 | chrX | MECP2 | 153290312 | 153294362 | − |
60 | chrX | MECP2 | 153290731 | 153294774 | − |
61 | chrX | MECP2 | 153291138 | 153295185 | − |
62 | chrX | MECP2 | 153291331 | 153295377 | − |
63 | chrX | MECP2 | 153291427 | 153295469 | − |
64 | chrX | MECP2 | 153291568 | 153295614 | − |
65 | chrX | MECP2 | 153291715 | 153295764 | − |
66 | chrX | MECP2 | 153291792 | 153295878 | − |
67 | chrX | MECP2 | 153291901 | 153295948 | − |
68 | chrX | MECP2 | 153292420 | 153296467 | − |
69 | chrX | MECP2 | 153295927 | 153299972 | − |
70 | chrX | MECP2 | 153313466 | 153317571 | − |
71 | chrX | MECP2 | 153341401 | 153345447 | − |
72 | chrX | MECP2 | 153342298 | 153346339 | − |
73 | chrX | MECP2 | 153346654 | 153350702 | − |
74 | chrX | MECP2 | 153346997 | 153351021 | − |
75 | chrX | MECP2 | 153347179 | 153351222 | − |
76 | chrX | MECP2 | 153347694 | 153351734 | − |
77 | chrX | MECP2 | 153348493 | 153352518 | − |
78 | chrX | MECP2 | 153354667 | 153358713 | − |
79 | chrX | MECP2 | 153354742 | 153358795 | − |
80 | chrX | MECP2 | 153355047 | 153359106 | − |
81 | chrX | MECP2 | 153355161 | 153359204 | − |
82 | chrX | MECP2 | 153359085 | 153363163 | − |
83 | chrX | MECP2 | 153359423 | 153363467 | − |
84 | chrX | MECP2 | 153360464 | 153364527 | − |
85 | chrX | MECP2 | 153279614 | 153279660 | + |
86 | chrX | MECP2 | 153281662 | 153281720 | + |
87 | chrX | MECP2 | 153281946 | 153281988 | + |
88 | chrX | MECP2 | 153284367 | 153284448 | + |
89 | chrX | MECP2 | 153284489 | 153284534 | + |
90 | chrX | MECP2 | 153288786 | 153288832 | + |
91 | chrX | MECP2 | 153289895 | 153289940 | + |
92 | chrX | MECP2 | 153292315 | 153292365 | + |
93 | chrX | MECP2 | 153292496 | 153292548 | + |
94 | chrX | MECP2 | 153297642 | 153297688 | + |
95 | chrX | MECP2 | 153297723 | 153297765 | + |
96 | chrX | MECP2 | 153300816 | 153300879 | + |
97 | chrX | MECP2 | 153315579 | 153315621 | + |
98 | chrX | MECP2 | 153316595 | 153316640 | + |
99 | chrX | MECP2 | 153348783 | 153348830 | + |
100 | chrX | MECP2 | 153349199 | 153349250 | + |
101 | chrX | MECP2 | 153358221 | 153358285 | + |
102 | chrX | MECP2 | 153277614 | 153281660 | + |
103 | chrX | MECP2 | 153279662 | 153283720 | + |
104 | chrX | MECP2 | 153279946 | 153283988 | + |
105 | chrX | MECP2 | 153282367 | 153286448 | + |
106 | chrX | MECP2 | 153282489 | 153286534 | + |
107 | chrX | MECP2 | 153286786 | 153290832 | + |
108 | chrX | MECP2 | 153287895 | 153291940 | + |
109 | chrX | MECP2 | 153290315 | 153294365 | + |
110 | chrX | MECP2 | 153290496 | 153294548 | + |
111 | chrX | MECP2 | 153295642 | 153299688 | + |
112 | chrX | MECP2 | 153295723 | 153299765 | + |
113 | chrX | MECP2 | 153298816 | 153302879 | + |
114 | chrX | MECP2 | 153313579 | 153317621 | + |
115 | chrX | MECP2 | 153314595 | 153318640 | + |
116 | chrX | MECP2 | 153346783 | 153350830 | + |
117 | chrX | MECP2 | 153347199 | 153351250 | + |
118 | chrX | MECP2 | 153356221 | 153360285 | + |
Single Strand Oligonucleotides (Sense Strand of Target Gene)
SeqID range: 47462-83660
SeqIDs w/o G Runs:
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/876,271 US11788089B2 (en) | 2012-05-16 | 2020-05-18 | Compositions and methods for modulating MECP2 expression |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261648051P | 2012-05-16 | 2012-05-16 | |
PCT/US2013/041394 WO2013173608A1 (en) | 2012-05-16 | 2013-05-16 | Compositions and methods for modulating mecp2 expression |
US201414401237A | 2014-11-14 | 2014-11-14 | |
US15/787,876 US10655128B2 (en) | 2012-05-16 | 2017-10-19 | Compositions and methods for modulating MECP2 expression |
US16/876,271 US11788089B2 (en) | 2012-05-16 | 2020-05-18 | Compositions and methods for modulating MECP2 expression |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/787,876 Continuation US10655128B2 (en) | 2012-05-16 | 2017-10-19 | Compositions and methods for modulating MECP2 expression |
Publications (2)
Publication Number | Publication Date |
---|---|
US20210102203A1 US20210102203A1 (en) | 2021-04-08 |
US11788089B2 true US11788089B2 (en) | 2023-10-17 |
Family
ID=49584296
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/401,237 Abandoned US20150152410A1 (en) | 2012-05-16 | 2013-05-16 | Compositions and methods for modulating mecp2 expression |
US15/787,876 Active US10655128B2 (en) | 2012-05-16 | 2017-10-19 | Compositions and methods for modulating MECP2 expression |
US16/876,271 Active 2034-09-14 US11788089B2 (en) | 2012-05-16 | 2020-05-18 | Compositions and methods for modulating MECP2 expression |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/401,237 Abandoned US20150152410A1 (en) | 2012-05-16 | 2013-05-16 | Compositions and methods for modulating mecp2 expression |
US15/787,876 Active US10655128B2 (en) | 2012-05-16 | 2017-10-19 | Compositions and methods for modulating MECP2 expression |
Country Status (8)
Country | Link |
---|---|
US (3) | US20150152410A1 (en) |
EP (1) | EP2850190B1 (en) |
JP (1) | JP2015518712A (en) |
CN (1) | CN104583402A (en) |
AU (1) | AU2013262709A1 (en) |
CA (1) | CA2873779A1 (en) |
EA (1) | EA201492116A1 (en) |
WO (1) | WO2013173608A1 (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
DK2638163T3 (en) | 2010-11-12 | 2017-07-24 | Massachusetts Gen Hospital | POLYCOMB-ASSOCIATED NON-CODING RNAs |
DK2756080T3 (en) | 2011-09-14 | 2019-05-20 | Translate Bio Ma Inc | MULTIMERIC OILONCLEOTID CONNECTIONS |
JP2015523853A (en) | 2012-05-16 | 2015-08-20 | ラナ セラピューティクス インコーポレイテッド | Compositions and methods for modulating ATP2A2 expression |
BR112014028634A2 (en) | 2012-05-16 | 2017-06-27 | Rana Therapeutics Inc | compositions and methods for modulating utrn expression |
JP2015518710A (en) | 2012-05-16 | 2015-07-06 | ラナ セラピューティクス インコーポレイテッド | Compositions and methods for regulating hemoglobin gene family expression |
US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
CA2873779A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating mecp2 expression |
KR20150030205A (en) | 2012-05-16 | 2015-03-19 | 라나 테라퓨틱스, 인크. | Compositions and methods for modulating smn gene family expression |
WO2014025887A1 (en) | 2012-08-07 | 2014-02-13 | The General Hospital Corporation | Selective reactivation of genes on the inactive x chromosome |
JP2015529469A (en) | 2012-09-14 | 2015-10-08 | ラナ セラピューティクス インコーポレイテッド | Multimeric oligonucleotide compounds |
EP2906258A4 (en) | 2012-10-15 | 2016-08-10 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
EP2906697A4 (en) | 2012-10-15 | 2016-06-22 | Ionis Pharmaceuticals Inc | Methods for monitoring c9orf72 expression |
JP2016531570A (en) | 2013-08-16 | 2016-10-13 | ラナ セラピューティクス インコーポレイテッド | Oligonucleotides targeting the euchromatin region |
EP3055414A4 (en) | 2013-10-11 | 2017-07-19 | Ionis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
US20150376612A1 (en) | 2014-06-10 | 2015-12-31 | The General Hospital Corporation | CCCTC-Binding Factor (CTCF) RNA Interactome |
CA2958524A1 (en) * | 2014-08-20 | 2016-02-25 | Lifesplice Pharma Llc | Splice modulating oligonucleotides and methods of use thereof |
CA2966044A1 (en) | 2014-10-30 | 2016-05-06 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
WO2016130943A1 (en) | 2015-02-13 | 2016-08-18 | Rana Therapeutics, Inc. | Hybrid oligonucleotides and uses thereof |
US11129844B2 (en) | 2015-03-03 | 2021-09-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating MECP2 expression |
EP3265564B1 (en) * | 2015-03-03 | 2022-01-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating mecp2 expression |
EP3271460A4 (en) | 2015-03-17 | 2019-03-13 | The General Hospital Corporation | The rna interactome of polycomb repressive complex 1 (prc1) |
WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
JP6866379B2 (en) | 2016-01-26 | 2021-04-28 | アナベックス ライフ サイエンシズ コーポレイション | Neurodevelopmental disorder therapy |
CN109563516B (en) * | 2016-07-28 | 2023-10-27 | 雷杰纳荣制药公司 | GPR156 variants and uses thereof |
CA3042401A1 (en) | 2016-11-01 | 2018-05-11 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
EP3604531A4 (en) * | 2017-03-31 | 2020-12-23 | Aichi Medical University | Antisense nucleic acid for inhibiting biosynthesis of chondroitin sulfate |
EP3679139B1 (en) | 2017-09-08 | 2022-11-02 | MiNA Therapeutics Limited | Stabilized hnf4a sarna compositions and methods of use |
EP3679140B1 (en) | 2017-09-08 | 2022-11-16 | MiNA Therapeutics Limited | Stabilized cebpa sarna compositions and methods of use |
EP3773618A1 (en) * | 2018-04-06 | 2021-02-17 | Camp4 Therapeutics Corporation | Treating diseases via targeted modulation of gene signaling networks |
MX2020013667A (en) | 2018-06-14 | 2021-03-02 | Ovid Therapeutics Inc | Use of mir-92a or mir-145 in the treatment of angelman syndrome. |
CA3110289A1 (en) * | 2018-08-30 | 2020-03-05 | The University Of North Carolina At Chapel Hill | Feedback enabled synthetic genes, target seed match cassettes, and their uses |
WO2020081764A1 (en) * | 2018-10-18 | 2020-04-23 | Synerk Inc. | Compositions and methods for inhibiting tigit gene expression |
WO2020097414A1 (en) | 2018-11-08 | 2020-05-14 | Greenlight Biosciences, Inc. | Control of insect infestation |
CN114585633A (en) | 2019-08-19 | 2022-06-03 | 米纳治疗有限公司 | Oligonucleotide conjugate compositions and methods of use |
WO2021178557A1 (en) * | 2020-03-03 | 2021-09-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Rational design of upstream enhancement rna for circuit dynamics regulation and viral diagnostics optimization |
EP4347837A2 (en) * | 2021-06-04 | 2024-04-10 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity |
Citations (305)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4725677A (en) | 1983-08-18 | 1988-02-16 | Biosyntech Gmbh | Process for the preparation of oligonucleotides |
WO1989005358A1 (en) | 1987-11-30 | 1989-06-15 | University Of Iowa Research Foundation | Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes |
WO1992000386A1 (en) | 1990-06-27 | 1992-01-09 | The Trustees Of Columbia University In The City Of New York | Methods for detecting spinal muscular atrophy type i and types ii/iii and marker therefor |
JPH04320700A (en) | 1991-04-17 | 1992-11-11 | Nippon Shoji Kk | Method for testing apolipoprotein e genotype and primer and probe suitable for its testing |
WO1993013121A1 (en) | 1991-12-24 | 1993-07-08 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
WO1994002499A1 (en) | 1992-07-27 | 1994-02-03 | Hybridon, Inc. | Oligonucleotide alkylphosphonothioates |
WO1994017093A1 (en) | 1993-01-25 | 1994-08-04 | Hybridon, Inc. | Oligonucleotide alkylphosphonates and alkylphosphonothioates |
WO1995033852A1 (en) | 1994-06-03 | 1995-12-14 | Institut National De La Sante Et De La Recherche Medicale | Method and probes for detecting markers bound to the locus of child spinal muscular atrophies |
US5576208A (en) | 1991-06-14 | 1996-11-19 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide inhibition of the RAS gene |
US5623065A (en) | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
US5661134A (en) | 1991-10-15 | 1997-08-26 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity |
US5734039A (en) | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
US5766903A (en) | 1995-08-23 | 1998-06-16 | University Technology Corporation | Circular RNA and uses thereof |
JPH1133863A (en) | 1997-07-23 | 1999-02-09 | Howa Mach Ltd | Tool replacing device and extruding device for replacing tool |
US5912332A (en) | 1996-07-26 | 1999-06-15 | Hybridon, Inc. | Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides |
US5914396A (en) | 1990-01-11 | 1999-06-22 | Isis Pharmaceuticals, Inc. | 2'-O-modified nucleosides and phosphoramidites |
US5919619A (en) | 1981-10-23 | 1999-07-06 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and methods of making same |
US5965722A (en) | 1991-05-21 | 1999-10-12 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ras gene with chimeric and alternating oligonucleotides |
US5976879A (en) | 1993-05-11 | 1999-11-02 | The University Of North Carolina At Chapel Hill | Antisense oligonucleotides which combat aberrant splicing and methods of using the same |
US6015710A (en) | 1996-04-09 | 2000-01-18 | The University Of Texas System | Modulation of mammalian telomerase by peptide nucleic acids |
WO2000020645A1 (en) | 1998-10-05 | 2000-04-13 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-α (TNF-α) EXPRESSION |
EP0999270A1 (en) | 1998-10-09 | 2000-05-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method of regulating SMN gene expression |
US6063400A (en) | 1997-07-02 | 2000-05-16 | Sdg, Inc. | Targeted liposomal constructs for diagnostic and therapeutic uses |
US6080577A (en) | 1994-10-19 | 2000-06-27 | Institut National De La Sante Et De La Recherche Medicale | Survival motor neuron (SMN) gene: a gene for spinal muscular atrophy |
US6107094A (en) | 1996-06-06 | 2000-08-22 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides and ribonucleases for cleaving RNA |
US6143881A (en) | 1992-07-23 | 2000-11-07 | University Of Massachusetts Worcester | Hybrid oligonucleotide phosphorothioates |
WO2001007662A1 (en) | 1999-07-22 | 2001-02-01 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the prostaglandin-endoperoxide synthase 2 gene |
US6187545B1 (en) | 2000-01-19 | 2001-02-13 | Isis Pharmaceuticals Inc. | Antisense modulation of pepck-cytosolic expression |
US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
WO2001036627A2 (en) | 1999-11-16 | 2001-05-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders |
US6284458B1 (en) | 1992-09-10 | 2001-09-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
WO2001066129A1 (en) | 2000-03-10 | 2001-09-13 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Substances for the treatment of spinal muscular atrophy |
WO2001072765A1 (en) | 2000-03-28 | 2001-10-04 | Isis Pharmaceuticals, Inc. | ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING |
WO2001090341A1 (en) | 2000-05-24 | 2001-11-29 | Isis Pharmaceuticals, Inc. | Antisense modulation of pten expression |
US6346614B1 (en) | 1992-07-23 | 2002-02-12 | Hybridon, Inc. | Hybrid oligonucleotide phosphorothioates |
WO2002022635A1 (en) | 2000-09-11 | 2002-03-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of clusterin expression |
WO2002038738A2 (en) | 2000-11-09 | 2002-05-16 | Cold Spring Harbor Laboratory | Chimeric molecules to modulate gene expression |
US6395492B1 (en) | 1990-01-11 | 2002-05-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US6451991B1 (en) | 1996-02-14 | 2002-09-17 | Isis Pharmaceuticals, Inc. | Sugar-modified gapped oligonucleotides |
WO2002103015A2 (en) | 2001-06-14 | 2002-12-27 | Active Pass Pharmaceuticals, Inc. | Abca10 transporter |
US6503754B1 (en) | 2000-09-07 | 2003-01-07 | Isis Pharmaceuticals, Inc. | Antisense modulation of BH3 interacting domain death agonist expression |
US6531584B1 (en) | 1990-01-11 | 2003-03-11 | Isis Pharmaceuticals, Inc. | 2'modified oligonucleotides |
JP3420984B2 (en) | 1999-02-12 | 2003-06-30 | 三共株式会社 | New nucleoside and oligonucleotide analogs |
US6602857B1 (en) | 2000-01-18 | 2003-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
US6608035B1 (en) | 1994-10-25 | 2003-08-19 | Hybridon, Inc. | Method of down-regulating gene expression |
US20030198983A1 (en) | 2002-02-01 | 2003-10-23 | Affymetrix, Inc. | Methods of genetic analysis of human genes |
US20030208061A1 (en) | 2001-03-30 | 2003-11-06 | Muthiah Manoharan | Labeled oligonucleotides, methods for making same, and compounds useful therefor |
US20030219770A1 (en) | 2001-11-08 | 2003-11-27 | Eshleman James R. | Methods and systems of nucleic acid sequencing |
US20030228690A1 (en) | 2002-06-10 | 2003-12-11 | Isis Pharmaceuticals Inc. | Antisense modulation of IL-1 receptor-associated kinase-1 expression |
US20030235822A1 (en) | 1998-04-03 | 2003-12-25 | Epoch Biosciences, Inc. | Systems and methods for predicting oligonucleotide melting temperature (TmS) |
US20040002153A1 (en) | 1999-07-21 | 2004-01-01 | Monia Brett P. | Modulation of PTEN expression via oligomeric compounds |
US6677445B1 (en) | 1999-08-27 | 2004-01-13 | Chiron Corporation | Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
WO2004011613A2 (en) | 2002-07-29 | 2004-02-05 | Epigenesis Pharmaceuticals, Inc. | Composition & methods for treatment and screening |
US6727355B2 (en) | 2000-08-25 | 2004-04-27 | Jcr Pharmaceuticals Co., Ltd. | Pharmaceutical composition for treatment of Duchenne muscular dystrophy |
US20040096848A1 (en) | 2002-04-05 | 2004-05-20 | Thrue Charlotte Albaek | Oligomeric compounds for the modulation HIF-1alpha expression |
US6753423B1 (en) | 1990-01-11 | 2004-06-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
WO2004092356A2 (en) | 2003-04-14 | 2004-10-28 | Aventis Pharma S.A. | Method for obtaining mastocyte lines from porcine tissue and method for production of heparin type molecules |
WO2004099382A2 (en) | 2003-04-30 | 2004-11-18 | Genpathway, Inc. | Methods for global profiling gene regulatory element activity |
US20040241651A1 (en) | 2000-04-07 | 2004-12-02 | Alexander Olek | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
US20040248840A1 (en) | 2003-02-10 | 2004-12-09 | Santaris Pharma A/S | Oligomeric compounds for the modulation of ras expression |
US6831166B2 (en) | 1992-10-23 | 2004-12-14 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
WO2004113867A2 (en) | 2003-06-16 | 2004-12-29 | University Of Massachusetts | Exon analysis |
US20050003369A1 (en) | 2002-10-10 | 2005-01-06 | Affymetrix, Inc. | Method for depleting specific nucleic acids from a mixture |
US20050026160A1 (en) | 2002-11-05 | 2005-02-03 | Charles Allerson | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
WO2005042018A2 (en) | 2003-10-30 | 2005-05-12 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
US20050100923A1 (en) | 1998-09-17 | 2005-05-12 | Trustees Of The University Of Pennsylvania | Compositions, methods, and kits useful for the diagnosis and treatment of spinal muscular atrophy |
US20050108783A1 (en) | 2003-09-23 | 2005-05-19 | Chihiro Koike | Porcine invariant chain protein, full length cDNA, genomic organization, and regulatory region |
WO2005044981A2 (en) | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
US20050130924A1 (en) | 2002-06-26 | 2005-06-16 | Monia Brett P. | Antisense inhibition via RNAse H-independent reduction in mRNA |
WO2005061710A1 (en) | 2003-12-23 | 2005-07-07 | Santaris Pharma A/S | Oligomeric compounds for the modulation of bcl-2 |
US20050164209A1 (en) | 2004-01-23 | 2005-07-28 | Bennett C. F. | Hepatocyte free uptake assays |
US20050176025A1 (en) | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
WO2005089169A2 (en) | 2004-03-12 | 2005-09-29 | Exelixis, Inc. | Mptens as modifiers of the pten pathway and methods of use |
WO2005094370A2 (en) | 2004-03-29 | 2005-10-13 | The General Hospital Corporation | Oligonucleotide complex compositions and methods of use as gene alteration tools |
US20050226848A1 (en) | 2003-05-29 | 2005-10-13 | Tomoko Kuwabara | Transcriptional regulation of gene expression by small double-stranded modulatory RNA |
US20050233455A1 (en) | 2001-10-29 | 2005-10-20 | Damha Masad J | Acyclic linker-containing oligonucleotides and uses thereof |
US20050246794A1 (en) | 2002-11-14 | 2005-11-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
US20050244851A1 (en) | 2004-01-13 | 2005-11-03 | Affymetrix, Inc. | Methods of analysis of alternative splicing in human |
US20050272080A1 (en) | 2004-05-03 | 2005-12-08 | Affymetrix, Inc. | Methods of analysis of degraded nucleic acid samples |
US20060003322A1 (en) | 2002-11-14 | 2006-01-05 | Isaac Bentwich | Bioinformatically detectable group of novel regulatory genes and uses thereof |
US20060046260A1 (en) | 2004-09-01 | 2006-03-02 | Viral Therapeutics, Inc | Amplified Bioassay |
US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
US7041816B2 (en) | 1999-02-04 | 2006-05-09 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligomeric compounds |
WO2006063356A1 (en) | 2004-12-10 | 2006-06-15 | Isis Phamaceuticals, Inc. | Regulation of epigenetic control of gene expression |
US20060128646A1 (en) | 2002-11-18 | 2006-06-15 | Santaris Pharma A/S | Antisense design |
US20060135458A1 (en) | 2002-09-13 | 2006-06-22 | Andrew Vaillant | Antiviral oligonucleotides |
WO2006069584A2 (en) | 2004-12-29 | 2006-07-06 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs |
US20060270624A1 (en) | 1991-12-24 | 2006-11-30 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
WO2006130201A1 (en) | 2005-03-14 | 2006-12-07 | Board Of Regents, The University Of Texas System | Antigene oligomers inhibit transcription |
WO2007002390A2 (en) | 2005-06-23 | 2007-01-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of smn2 splicing |
WO2007004977A1 (en) | 2005-07-01 | 2007-01-11 | Index Pharmaceuticals Ab | Immunostimulatory method |
EP1752536A1 (en) | 2004-05-11 | 2007-02-14 | RNAi Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
US20070042380A1 (en) | 2003-08-13 | 2007-02-22 | Rosetta Genomics | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
US20070111963A1 (en) | 2005-11-17 | 2007-05-17 | Board Of Regents, The University Of Texas System | Modulation of gene expression by oligomers targeted to chromosomal DNA |
US20070123484A1 (en) | 2004-06-03 | 2007-05-31 | Balkrishen Bhat | Double strand compositions comprising differentially modified strands for use in gene modulation |
US7226785B2 (en) | 2000-03-27 | 2007-06-05 | University Of Delaware | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
WO2007076328A2 (en) | 2005-12-19 | 2007-07-05 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of hepatitis c virus |
US20070191294A1 (en) | 2003-03-21 | 2007-08-16 | Santaris Pharma A/S | Short interfering rna (sirna) analogues |
US20070219244A1 (en) | 2005-11-11 | 2007-09-20 | The Scripps Research Institute | Histone deacetylase inhibitors as therapeutics for neurological diseases |
WO2007112753A2 (en) | 2006-04-03 | 2007-10-11 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
WO2007115578A1 (en) | 2006-04-07 | 2007-10-18 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts | Synthetic mecp2 sequence for protein substitution therapy |
WO2007131237A2 (en) | 2006-05-05 | 2007-11-15 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of ptp1b |
WO2007133812A2 (en) | 2005-12-30 | 2007-11-22 | Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine | Improved carriers for delivery of nucleic acid agents to cells and tissues |
US20070269815A1 (en) | 2005-11-21 | 2007-11-22 | Rivory Laurent P | Multitargeting interfering RNAs having two active strands and methods for their design and use |
US20070292408A1 (en) | 2004-12-03 | 2007-12-20 | University Of Massachusetts | Spinal Muscular Atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
WO2008024499A2 (en) | 2006-08-25 | 2008-02-28 | Duke University | Methods for in vivo identification of endogenous mrna targets of micrornas |
JP2008044958A (en) | 2000-11-20 | 2008-02-28 | Board Of Trustees Of The Univ Of Illinois | Membrane scaffold protein |
WO2008025069A1 (en) | 2006-08-28 | 2008-03-06 | The Walter And Eliza Hall Institute Of Medical Research | Methods of modulating cellular activity and compositions therefor |
WO2008029619A1 (en) | 2006-09-07 | 2008-03-13 | Daiichi Sankyo Company, Limited | Ena antisense oligonucleotide having sequence-specific action |
WO2008061537A2 (en) | 2006-11-23 | 2008-05-29 | Querdenker Aps | Oligonucleotides for modulating target rna activity |
US20080139472A1 (en) | 2006-10-06 | 2008-06-12 | The Regents Of The University Of California | Upregulating bdnf levels to mitigate mental retardation |
US20080176793A1 (en) | 2006-09-18 | 2008-07-24 | The Regents Of The University Of California | Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects |
US20080194463A1 (en) | 2005-07-13 | 2008-08-14 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
WO2008103763A2 (en) | 2007-02-20 | 2008-08-28 | Sequenom, Inc. | Methods and compositions for cancer diagnosis and treatment based on nucleic acid methylation |
EP1967525A2 (en) | 2001-05-08 | 2008-09-10 | Darwin Molecular Corporation | A method for regulating immune function in primates using the foxp3 protein |
WO2008113832A2 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
US20080242629A1 (en) | 2001-08-01 | 2008-10-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein b expression |
US20080249039A1 (en) | 2004-01-30 | 2008-10-09 | Santaris Pharma A/S | Modified Short Interfering Rna (Modified Sirna) |
WO2008132234A2 (en) | 2007-05-01 | 2008-11-06 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of beta-catenin |
US7449297B2 (en) | 2005-04-14 | 2008-11-11 | Euclid Diagnostics Llc | Methods of copying the methylation pattern of DNA during isothermal amplification and microarrays |
WO2008141282A2 (en) | 2007-05-11 | 2008-11-20 | The Regents Of The University Of Michigan | Materials and methods for foxp3 tumor suppression |
WO2008138904A2 (en) | 2007-05-11 | 2008-11-20 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of her3 |
US20080293655A1 (en) | 2006-02-08 | 2008-11-27 | Huseyin Aygun | Novel tandem siRNAS |
US20080311039A1 (en) | 2004-09-09 | 2008-12-18 | The Regents Of The University Of California | Therapeutic and Prognostic Factor Yy1 in Human Cancer |
US20080318895A1 (en) | 2004-05-17 | 2008-12-25 | Yale University | Intranasal delivery of nucleic acid molecules |
US20090082297A1 (en) | 2007-06-25 | 2009-03-26 | Lioy Daniel T | Compositions and Methods for Regulating Gene Expression |
WO2009046397A2 (en) | 2007-10-04 | 2009-04-09 | Board Of Regents, The University Of Texas System | Modulating gene expression with agrna and gapmers targeting antisense transcripts |
WO2009043353A2 (en) | 2007-10-04 | 2009-04-09 | Santaris Pharma A/S | Micromirs |
WO2009044383A1 (en) | 2007-10-05 | 2009-04-09 | Consiglio Nazionale Delle Ricerche | Nucleic acid codifying for a utrophin transcription specific regulating protein, protein codified thereby and uses thereof |
US20090099109A1 (en) | 2007-02-26 | 2009-04-16 | Shames David S | Interfering rnas against the promoter region of p53 |
US20090099066A1 (en) | 2007-06-29 | 2009-04-16 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
WO2009061851A2 (en) | 2007-11-09 | 2009-05-14 | Isis Pharmaceuticals, Inc. | Modulation of factor 7 expression |
US20090123467A1 (en) | 2007-07-31 | 2009-05-14 | The Johns Hopkins University | Polypeptide-Nucleic Acid Conjugate for Immunoprophylaxis or Immunotherapy for Neoplastic or Infectious Disorders |
WO2009064920A2 (en) | 2007-11-13 | 2009-05-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating protein expression |
US20090156538A1 (en) | 2002-12-12 | 2009-06-18 | Isis Pharmaceuticals, Inc. | Modulation of endothelial lipase expression |
US20090155910A1 (en) | 2007-12-18 | 2009-06-18 | E.I.Du Pont De Nemours And Company | Down-regulation of gene expression using artificial micrornas |
WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
US20090221685A1 (en) | 2006-01-27 | 2009-09-03 | Isis Pharmaceuticals, Inc | Oligomeric compounds and compositions for the use in modulation of micrornas |
US20090258925A1 (en) | 2005-12-28 | 2009-10-15 | Claes Wahlestedt | Natural antisense and non-coding rna transcripts as drug targets |
WO2009124341A1 (en) | 2008-04-07 | 2009-10-15 | The University Of Queensland | Rna molecules and uses thereof |
WO2009127680A1 (en) | 2008-04-16 | 2009-10-22 | Santaris Pharma A/S | Pharmaceutical composition comprising anti pcsk9 oligomers |
WO2009134710A2 (en) | 2008-04-28 | 2009-11-05 | The Trustees Of The University Of Pennsylvania | Methods for enhancing utrophin production via inhibition of microrna |
WO2009149182A1 (en) | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
WO2009151546A2 (en) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
US20090324549A1 (en) | 2007-01-29 | 2009-12-31 | Fondazione I.R.C.C.S. Istituto Neurologico "Carlo Besta" | Proteins and/or peptides for the prevention and/or treatment of neurodegenerative diseases |
WO2010000665A1 (en) | 2008-06-30 | 2010-01-07 | Santaris Pharma A/S | Antidote oligomers |
US20100004314A1 (en) | 2008-03-07 | 2010-01-07 | Senesco Technologies, Inc. | Use of sirna to achieve down regulation of an endogenous gene in combination with the use of a sense construct to achieve expression of a polynucleotide |
WO2010007522A1 (en) | 2008-07-15 | 2010-01-21 | Santaris Pharma A/S | Rna antagonists targeting gli2 |
US7655785B1 (en) | 2002-11-14 | 2010-02-02 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
WO2010014592A1 (en) | 2008-07-29 | 2010-02-04 | The Board Of Regents Of The University Of Texas Sytem | Selective inhibition of polyglutamine protein expression |
JP2010507579A (en) | 2006-10-18 | 2010-03-11 | アイシス ファーマシューティカルズ, インコーポレーテッド | Antisense compound |
US7687616B1 (en) | 2004-05-14 | 2010-03-30 | Rosetta Genomics Ltd | Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof |
WO2010040112A2 (en) | 2008-10-03 | 2010-04-08 | Curna, Inc. | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1 |
US20100111982A1 (en) | 2006-06-27 | 2010-05-06 | Shanghai Institutes For Biological Sciences | Rheumatoid arthritis t cell vaccine |
US20100112042A1 (en) | 2008-10-16 | 2010-05-06 | Mdrna, Inc. | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics |
JP2010516256A (en) | 2007-01-19 | 2010-05-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ADRB2 cancer marker |
US20100124547A1 (en) | 2008-11-17 | 2010-05-20 | Birgit Bramlage | Compositions and methods for inhibiting expression of factor vii genes |
WO2010065787A2 (en) | 2008-12-04 | 2010-06-10 | Curna, Inc. | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
US20100143359A1 (en) | 2006-11-27 | 2010-06-10 | Ludwig Institute For Cancer Research Ltd. | Expression of foxp3 by cancer cells |
WO2010065671A2 (en) | 2008-12-04 | 2010-06-10 | Curna, Inc. | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
WO2010076248A1 (en) | 2008-12-31 | 2010-07-08 | Santaris Pharma A/S | Use of lna apob antisense oligomers for the treatment of acute coronary syndromes |
WO2010083615A1 (en) | 2009-01-26 | 2010-07-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein c-iii expression |
US20100210707A1 (en) | 2005-04-15 | 2010-08-19 | Longcheng Li | Small Activating RNA Molecules and Methods of Use |
WO2010093860A2 (en) | 2009-02-13 | 2010-08-19 | The General Hospital Corporation | Isolation of factors that associate directly or indirectly with chromatin |
WO2010093904A2 (en) | 2009-02-12 | 2010-08-19 | Curna, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
WO2010102058A2 (en) | 2009-03-04 | 2010-09-10 | Curna, Inc. | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1 |
WO2010107733A2 (en) | 2009-03-16 | 2010-09-23 | Curna, Inc. | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
US20100247543A1 (en) | 2007-08-24 | 2010-09-30 | Oryzon Genomics, S.A. | Treatment and prevention of neurodegenerative diseases |
US20100256223A1 (en) | 2007-06-14 | 2010-10-07 | Querdenker Aps | Oligonucleotides for modulating target rna activity |
WO2010124231A2 (en) | 2009-04-24 | 2010-10-28 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions |
WO2010122538A1 (en) | 2009-04-24 | 2010-10-28 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon |
US20100280100A1 (en) | 2009-05-01 | 2010-11-04 | Curna, Inc. | Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg |
WO2010129799A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene |
WO2010129861A2 (en) | 2009-05-08 | 2010-11-11 | Curna, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
US20100286234A1 (en) | 2006-04-03 | 2010-11-11 | Joacim Elmen | Pharmaceutical Composition Comprising Anti-Mirna Antisense Oligonucleotides |
WO2010129746A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
US20100286141A1 (en) | 2000-05-30 | 2010-11-11 | Durden Donald L | Compositions and Methods for Identifying Agents Which Modulate PTEN Function and PI-3 Kinase Pathways |
WO2010135695A2 (en) | 2009-05-22 | 2010-11-25 | Curna, Inc. | TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 |
WO2010135329A2 (en) | 2009-05-18 | 2010-11-25 | Curna, Inc. | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
WO2010138806A2 (en) | 2009-05-28 | 2010-12-02 | Curna, Inc. | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
US20100317606A1 (en) | 2005-04-27 | 2010-12-16 | Pacific Arrow Limited | Novel triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents |
WO2010148065A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1 |
WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
WO2010151674A2 (en) | 2009-06-26 | 2010-12-29 | Curna, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
WO2010151671A2 (en) | 2009-06-24 | 2010-12-29 | Curna, Inc. | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
WO2011005786A2 (en) | 2009-07-06 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for enhancing production of a biological product |
WO2011009624A1 (en) | 2009-07-22 | 2011-01-27 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
WO2011010706A1 (en) | 2009-07-23 | 2011-01-27 | 武田薬品工業株式会社 | Fgf21 cis-element binding substance |
US7879992B2 (en) | 2005-01-31 | 2011-02-01 | Isis Pharmaceuticals, Inc. | Modification of MyD88 splicing using modified oligonucleotides |
WO2011017516A2 (en) | 2009-08-05 | 2011-02-10 | Curna, Inc. | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
US7888012B2 (en) | 2005-02-09 | 2011-02-15 | Avi Biopharma, Inc. | Antisense composition and method for treating muscle atrophy |
US20110039910A1 (en) | 2003-06-02 | 2011-02-17 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein (a) expression |
WO2011019815A2 (en) | 2009-08-11 | 2011-02-17 | Curna, Inc. | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
WO2011022606A2 (en) | 2009-08-21 | 2011-02-24 | Curna, Inc. | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
WO2011025862A2 (en) | 2009-08-28 | 2011-03-03 | Curna, Inc. | Treatment of atp-binding cassette sub-family b member 1 (abcb1) related diseases by inhibition of natural antisense transcript to abcb1 |
WO2011031482A2 (en) | 2009-08-25 | 2011-03-17 | Curna, Inc. | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
WO2011032109A1 (en) | 2009-09-11 | 2011-03-17 | Sma Foundation | Biomarkers for spinal muscular atrophy |
WO2011038205A2 (en) | 2009-09-25 | 2011-03-31 | Curna, Inc. | Treatment of growth hormone (gh) related diseases by inhibition of natural antisense transcript to gh |
WO2011038210A2 (en) | 2009-09-25 | 2011-03-31 | Curna, Inc. | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
US20110077286A1 (en) | 2008-06-05 | 2011-03-31 | Damha Masad J | Oligonucleotide duplexes comprising dna-like and rna-like nucleotides and uses thereof |
WO2011048125A1 (en) | 2009-10-20 | 2011-04-28 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
KR20110050134A (en) | 2009-11-06 | 2011-05-13 | 성균관대학교산학협력단 | Novel peptides upregulating bdnf expression and pharmaceutical composition for protection and therapy against alzheimer's disease and parkinson's disease comprising the same |
US7960541B2 (en) | 2004-06-28 | 2011-06-14 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US20110150868A1 (en) | 2003-11-05 | 2011-06-23 | Board Of Regents Of The University Of Texas System | Diagnostic and therapeutic methods and compositions involving pten and breast cancer |
WO2011079261A2 (en) | 2009-12-23 | 2011-06-30 | Curna, Inc. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
WO2011079263A2 (en) | 2009-12-23 | 2011-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2 |
WO2011082409A2 (en) | 2010-01-04 | 2011-07-07 | Curna, Inc. | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
WO2011085066A2 (en) | 2010-01-06 | 2011-07-14 | Curna, Inc. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene |
WO2011084455A2 (en) | 2009-12-16 | 2011-07-14 | Opko Curna, Llc. | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
US20110191912A1 (en) | 2000-04-26 | 2011-08-04 | Nickolai Alexandrov | Promoter, promoter control elements, and combinations, and uses thereof |
WO2011097641A1 (en) | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Methods and compositions useful in treatment of diseases or conditions related to repeat expansion |
WO2011097582A2 (en) | 2010-02-08 | 2011-08-11 | Opko Curna Llc | Treatment of arachidonate 12-lipoxygenase, 12r type (alox12b) related diseases by inhibition of natural antisense transcript to alox12b |
WO2011097388A1 (en) | 2010-02-03 | 2011-08-11 | Alnylam Pharmaceuticals, Inc. | Selective inhibition of polyglutamine protein expression |
US20110237606A1 (en) | 2008-09-26 | 2011-09-29 | Agency Of Science, Technology And Research | 3-Deazaneplanocin Derivatives |
US20110237649A1 (en) | 2008-12-04 | 2011-09-29 | Opko Curna, Llc | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1 |
US20110237651A1 (en) | 2008-12-04 | 2011-09-29 | Opko Curna, Llc | Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo |
WO2011123745A2 (en) | 2010-04-02 | 2011-10-06 | Opko Curna Llc | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
US20110251261A1 (en) | 2010-04-13 | 2011-10-13 | Life Technologies Corporation | Compositions and methods for inhibition of nucleic acids function |
WO2011139387A1 (en) | 2010-05-03 | 2011-11-10 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
WO2011139917A1 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Modulation of transthyretin expression |
WO2011146675A2 (en) | 2010-05-19 | 2011-11-24 | Opko Curna Llc | Treatment of lim homeobox 2 (lhx2) related diseases by inhibition of natural antisense transcript to lhx2 |
WO2011146674A2 (en) | 2010-05-19 | 2011-11-24 | Opko Curna Llc | Treatment of bcl2-like 11 (bcl2l11) related diseases by inhibition of natural antisense transcript to bcl2l11 |
US8067569B2 (en) | 2000-05-04 | 2011-11-29 | Avi Biopharma, Inc. | Splice-region antisense composition and method |
WO2011150005A2 (en) | 2010-05-26 | 2011-12-01 | Opko Curna Llc | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
WO2011159836A2 (en) | 2010-06-15 | 2011-12-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating interaction between proteins and target nucleic acids |
US20110319283A1 (en) | 2008-11-24 | 2011-12-29 | Trillion Genomics Limited | Oligonucleotides capable of discriminating between nucleic acid sequences that comprise a conserved sequence |
WO2011163499A2 (en) | 2010-06-23 | 2011-12-29 | Opko Curna, Llc | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
US20110319476A1 (en) | 2009-02-12 | 2011-12-29 | Opko Curna, Llc | Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf |
WO2011161460A2 (en) | 2010-06-23 | 2011-12-29 | Mina Therapeutics Limited | Rna molecules and uses thereof |
US20120004278A1 (en) | 2010-06-18 | 2012-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Linc rnas in cancer diagnosis and treatment |
US20120010156A1 (en) | 2009-03-17 | 2012-01-12 | OPKP CuRNA, LLC | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
WO2012009347A2 (en) | 2010-07-12 | 2012-01-19 | Opko Curna Llc | Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3 |
WO2012009402A2 (en) | 2010-07-14 | 2012-01-19 | Opko Curna Llc | Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg |
WO2012012467A2 (en) | 2010-07-19 | 2012-01-26 | Isis Pharmaceuticals, Inc. | Modulation of nuclear-retained rna |
WO2012018881A2 (en) | 2010-08-03 | 2012-02-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for the regulation of rna |
WO2012024478A2 (en) | 2010-08-19 | 2012-02-23 | Opko Curna Llc | Treatment of nicotinamide phosphoribosyltransferase (nampt) related diseases by inhibition of natural antisense transcript to nampt |
WO2012027033A1 (en) | 2010-07-19 | 2012-03-01 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals |
WO2012036433A2 (en) | 2010-09-13 | 2012-03-22 | 서울대학교 산학협력단 | Treatment of neurodegenerative diseases by targeting mirna |
US20120071418A1 (en) | 2010-09-10 | 2012-03-22 | Epizyme, Inc. | Inhibitors of Human EZH2 and Methods of Use Thereof |
US8153602B1 (en) | 1991-11-19 | 2012-04-10 | Isis Pharmaceuticals, Inc. | Composition and methods for the pulmonary delivery of nucleic acids |
US8153365B2 (en) | 1997-09-12 | 2012-04-10 | Exiqon A/S | Oligonucleotide analogues |
WO2012047956A2 (en) | 2010-10-06 | 2012-04-12 | Opko Curna Llc | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
WO2012054723A2 (en) | 2010-10-22 | 2012-04-26 | Opko Curna Llc | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
WO2012058268A2 (en) | 2010-10-27 | 2012-05-03 | Opko Curna Llc | Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1 |
WO2012064806A2 (en) | 2010-11-11 | 2012-05-18 | The University Of North Carolina At Chapel Hill | Methods and compositions for unsilencing imprinted genes |
WO2012065143A1 (en) | 2010-11-12 | 2012-05-18 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
WO2012068340A2 (en) | 2010-11-18 | 2012-05-24 | Opko Curna Llc | Antagonat compositions and methods of use |
WO2012071238A2 (en) | 2010-11-23 | 2012-05-31 | Opko Curna Llc | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
US20120149756A1 (en) | 2009-04-10 | 2012-06-14 | Associatin Institut de Myologie | Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease |
US20120157333A1 (en) | 2002-10-21 | 2012-06-21 | Exiqon A/S | Oligonucleotides useful for detecting and analyzing nucleic acids of interest |
WO2012087983A1 (en) | 2010-12-20 | 2012-06-28 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
WO2012109476A2 (en) | 2011-02-09 | 2012-08-16 | The University Of Rochester | Methods and compositions related to staufen 1 binding sites formed by duplexing alu elements |
US20120252869A1 (en) | 2009-07-24 | 2012-10-04 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
US20120264812A1 (en) | 2009-12-29 | 2012-10-18 | Curna, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
WO2012144220A1 (en) | 2011-04-22 | 2012-10-26 | Oncotherapy Science, Inc. | Ezh2 as target gene for cancer therapy and diagnosis |
US20120277290A1 (en) | 2010-01-11 | 2012-11-01 | Curna, Inc. | Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg |
US20120289581A1 (en) | 2011-05-13 | 2012-11-15 | Chang Howard Y | Diagnostic, prognostic and therapeutic uses of long non-coding rnas for cancer and regenerative medicine |
US20120289583A1 (en) | 2009-12-31 | 2012-11-15 | Curna, Inc. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
US20120295953A1 (en) | 2009-12-29 | 2012-11-22 | Joseph Colalrd | Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63 |
US20120295959A1 (en) | 2010-01-25 | 2012-11-22 | Curna, Inc. | Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 |
US20120309814A1 (en) | 2010-02-22 | 2012-12-06 | Curna, Inc. | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
WO2012170771A1 (en) | 2011-06-09 | 2012-12-13 | Curna, Inc. | Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn |
WO2013006619A1 (en) | 2011-07-05 | 2013-01-10 | The General Hospital Corporation | Rna-yy1 interactions |
US8361980B2 (en) | 2008-03-07 | 2013-01-29 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
US20130035373A1 (en) | 2010-04-09 | 2013-02-07 | Curna, Inc. | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
WO2013036403A1 (en) | 2011-09-06 | 2013-03-14 | Curna, Inc. | TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES |
US20130065947A1 (en) | 2010-05-14 | 2013-03-14 | Cu RNA ,Inc. | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
WO2013040429A1 (en) | 2011-09-14 | 2013-03-21 | Rana Therapeutics Inc. | Multimeric oligonucleotide compounds |
US20130072546A1 (en) | 2010-05-26 | 2013-03-21 | Curna, Inc. | Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra |
US20130079505A1 (en) | 2010-03-24 | 2013-03-28 | Mirrx Therapeutics A/S | Bivalent antisense oligonucleotides |
US8415313B2 (en) | 2004-01-23 | 2013-04-09 | Avi Biopharma, Inc. | Antisense oligomers and methods for inducing immune tolerance and immunosuppression |
EP2591797A1 (en) | 2010-07-09 | 2013-05-15 | Institut Pasteur Of Shanghai, Cas | Regulatory factor of foxp3 and regulatory t cells and use thereof |
WO2013124807A2 (en) | 2012-02-24 | 2013-08-29 | Biogenera Societa' A Responsabilita' Limitata | Oligonucleotides for modulating gene expression and uses thereof |
WO2013138374A2 (en) | 2012-03-15 | 2013-09-19 | Curna, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
WO2013173652A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
WO2013173638A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating smn gene family expression |
WO2013173598A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating atp2a2 expression |
WO2013173635A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
WO2013173637A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
WO2013173601A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating bdnf expression |
WO2013173647A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating apoa1 and abca1 expression |
WO2013173608A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating mecp2 expression |
WO2013173599A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating hemoglobin gene family expression |
WO2013173645A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating utrn expression |
WO2013173605A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating pten expression |
WO2014043544A1 (en) | 2012-09-14 | 2014-03-20 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
WO2014076195A1 (en) | 2012-11-15 | 2014-05-22 | Santaris Pharma A/S | Oligonucleotide conjugates |
US8846639B2 (en) | 2008-04-04 | 2014-09-30 | Isis Pharmaceutical, Inc. | Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity |
WO2014172698A1 (en) | 2013-04-19 | 2014-10-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation nucleic acids through nonsense mediated decay |
US20140356459A1 (en) | 2011-12-15 | 2014-12-04 | Oncostamen S.R.L. | Micrornas and uses thereof |
WO2014197826A1 (en) | 2013-06-07 | 2014-12-11 | Rana Therapeutics, Inc. | Compositions and methods for modulating foxp3 expression |
WO2014203518A1 (en) | 2013-06-16 | 2014-12-24 | National University Corporation Tokyo Medical And Dental University | Double-stranded antisense nucleic acid with exon-skipping effect |
WO2014205551A1 (en) | 2013-06-28 | 2014-12-31 | London Health Sciences Centre Research Inc. | Inhibition of microrna for treatment of sepsis |
WO2015035476A1 (en) | 2013-09-16 | 2015-03-19 | University Of Western Sydney | Modulation of gene expression |
US20150225717A1 (en) | 2012-08-07 | 2015-08-13 | The General Hospital Corporation | Selective Reactivation of Genes on the Inactive X Chromosome |
WO2016077837A1 (en) | 2014-11-14 | 2016-05-19 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of proteins |
US20160201064A1 (en) | 2013-08-16 | 2016-07-14 | Rana Therapeutics, Inc. | Compositions and methods for modulating expression of frataxin |
US20160201063A1 (en) | 2013-08-16 | 2016-07-14 | Rana Therapeutics, Inc. | Epigenetic regulators of frataxin |
US20160222391A1 (en) | 2013-10-04 | 2016-08-04 | Rana Therapeutics, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
US20170037396A1 (en) | 2010-11-12 | 2017-02-09 | The General Hospital Corporation | Polycomb-Associated Non-Coding RNAs |
US20180298384A1 (en) | 2012-05-16 | 2018-10-18 | Translate Bio Ma, Inc. | Compositions and methods for modulating smn gene family expression |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US4476301A (en) | 1982-04-29 | 1984-10-09 | Centre National De La Recherche Scientifique | Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon |
US5550111A (en) | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5188897A (en) | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
US4924624A (en) | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
EP0406309A4 (en) | 1988-03-25 | 1992-08-19 | The University Of Virginia Alumni Patents Foundation | Oligonucleotide n-alkylphosphoramidates |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
US5177196A (en) | 1990-08-16 | 1993-01-05 | Microprobe Corporation | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof |
US5571799A (en) | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
-
2013
- 2013-05-16 CA CA2873779A patent/CA2873779A1/en not_active Abandoned
- 2013-05-16 CN CN201380037614.0A patent/CN104583402A/en active Pending
- 2013-05-16 EA EA201492116A patent/EA201492116A1/en unknown
- 2013-05-16 WO PCT/US2013/041394 patent/WO2013173608A1/en active Application Filing
- 2013-05-16 EP EP13791546.8A patent/EP2850190B1/en active Active
- 2013-05-16 US US14/401,237 patent/US20150152410A1/en not_active Abandoned
- 2013-05-16 JP JP2015512847A patent/JP2015518712A/en active Pending
- 2013-05-16 AU AU2013262709A patent/AU2013262709A1/en not_active Abandoned
-
2017
- 2017-10-19 US US15/787,876 patent/US10655128B2/en active Active
-
2020
- 2020-05-18 US US16/876,271 patent/US11788089B2/en active Active
Patent Citations (432)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5919619A (en) | 1981-10-23 | 1999-07-06 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and methods of making same |
US4725677A (en) | 1983-08-18 | 1988-02-16 | Biosyntech Gmbh | Process for the preparation of oligonucleotides |
WO1989005358A1 (en) | 1987-11-30 | 1989-06-15 | University Of Iowa Research Foundation | Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes |
US6197944B1 (en) | 1987-11-30 | 2001-03-06 | Integrated Dna Technologies, Inc. | DNA molecules stabilized by modifications of the 3′-terminal phosphodiester linkage |
US5491133A (en) | 1987-11-30 | 1996-02-13 | University Of Iowa Research Foundation | Methods for blocking the expression of specifically targeted genes |
US6919439B2 (en) | 1990-01-11 | 2005-07-19 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US6753423B1 (en) | 1990-01-11 | 2004-06-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
US5914396A (en) | 1990-01-11 | 1999-06-22 | Isis Pharmaceuticals, Inc. | 2'-O-modified nucleosides and phosphoramidites |
US6531584B1 (en) | 1990-01-11 | 2003-03-11 | Isis Pharmaceuticals, Inc. | 2'modified oligonucleotides |
US6395492B1 (en) | 1990-01-11 | 2002-05-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
WO1992000386A1 (en) | 1990-06-27 | 1992-01-09 | The Trustees Of Columbia University In The City Of New York | Methods for detecting spinal muscular atrophy type i and types ii/iii and marker therefor |
US5623065A (en) | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
JPH04320700A (en) | 1991-04-17 | 1992-11-11 | Nippon Shoji Kk | Method for testing apolipoprotein e genotype and primer and probe suitable for its testing |
US5965722A (en) | 1991-05-21 | 1999-10-12 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ras gene with chimeric and alternating oligonucleotides |
US5576208A (en) | 1991-06-14 | 1996-11-19 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide inhibition of the RAS gene |
US5661134A (en) | 1991-10-15 | 1997-08-26 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity |
US8153602B1 (en) | 1991-11-19 | 2012-04-10 | Isis Pharmaceuticals, Inc. | Composition and methods for the pulmonary delivery of nucleic acids |
US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
US20040038274A1 (en) | 1991-12-24 | 2004-02-26 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
EP1044987A2 (en) | 1991-12-24 | 2000-10-18 | Isis Pharmaceuticals, Inc. | Gapped 2'-modified oligonucleotides |
US20020160379A1 (en) | 1991-12-24 | 2002-10-31 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
WO1993013121A1 (en) | 1991-12-24 | 1993-07-08 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
EP1695979A2 (en) | 1991-12-24 | 2006-08-30 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US6326199B1 (en) | 1991-12-24 | 2001-12-04 | Isis Pharmaceuticals, Inc. | Gapped 2′ modified oligonucleotides |
US6146829A (en) | 1991-12-24 | 2000-11-14 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US20070032446A1 (en) | 1991-12-24 | 2007-02-08 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US20060270624A1 (en) | 1991-12-24 | 2006-11-30 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US7045609B2 (en) | 1992-07-23 | 2006-05-16 | University Of Massachusetts Worcester | Hybrid oligonucleotide phosphorothioates |
US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
US6346614B1 (en) | 1992-07-23 | 2002-02-12 | Hybridon, Inc. | Hybrid oligonucleotide phosphorothioates |
US6143881A (en) | 1992-07-23 | 2000-11-07 | University Of Massachusetts Worcester | Hybrid oligonucleotide phosphorothioates |
WO1994002499A1 (en) | 1992-07-27 | 1994-02-03 | Hybridon, Inc. | Oligonucleotide alkylphosphonothioates |
US6284458B1 (en) | 1992-09-10 | 2001-09-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
US6831166B2 (en) | 1992-10-23 | 2004-12-14 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
WO1994017093A1 (en) | 1993-01-25 | 1994-08-04 | Hybridon, Inc. | Oligonucleotide alkylphosphonates and alkylphosphonothioates |
US5976879A (en) | 1993-05-11 | 1999-11-02 | The University Of North Carolina At Chapel Hill | Antisense oligonucleotides which combat aberrant splicing and methods of using the same |
WO1995033852A1 (en) | 1994-06-03 | 1995-12-14 | Institut National De La Sante Et De La Recherche Medicale | Method and probes for detecting markers bound to the locus of child spinal muscular atrophies |
US6040142A (en) | 1994-06-03 | 2000-03-21 | Institut National De La Santa Et De La Recherche Medicale | Method and probes for detecting markers linked to the infantile spinal muscular atrophy locus |
US5734039A (en) | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
US7033752B1 (en) | 1994-10-19 | 2006-04-25 | Institut National De La Sante Et De La Recherche Medicale | Spinal muscular atrophy diagnostic methods |
US20070166737A1 (en) | 1994-10-19 | 2007-07-19 | Judith Melki | Survival motor neuron (SMN) gene: a gene for spinal muscular atrophy |
US6080577A (en) | 1994-10-19 | 2000-06-27 | Institut National De La Sante Et De La Recherche Medicale | Survival motor neuron (SMN) gene: a gene for spinal muscular atrophy |
US20060089490A1 (en) | 1994-10-19 | 2006-04-27 | Judith Melki | Survival motor neuron (SMN) gene: a Gene for spinal muscular atrophy |
US6608035B1 (en) | 1994-10-25 | 2003-08-19 | Hybridon, Inc. | Method of down-regulating gene expression |
US6359124B1 (en) | 1995-04-03 | 2002-03-19 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ras gene with chimeric and alternating oligonucleotides |
US5766903A (en) | 1995-08-23 | 1998-06-16 | University Technology Corporation | Circular RNA and uses thereof |
US6451991B1 (en) | 1996-02-14 | 2002-09-17 | Isis Pharmaceuticals, Inc. | Sugar-modified gapped oligonucleotides |
US6015710A (en) | 1996-04-09 | 2000-01-18 | The University Of Texas System | Modulation of mammalian telomerase by peptide nucleic acids |
US6046307A (en) | 1996-04-09 | 2000-04-04 | The University Of Texas System | Modulation of mammalian telomerase by peptide nucleic acids |
US6294650B1 (en) | 1996-04-09 | 2001-09-25 | The Board Of Regents, University Of Texas System | Inhibition of mammalian telomerase by peptide nucleic acids |
US6107094A (en) | 1996-06-06 | 2000-08-22 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides and ribonucleases for cleaving RNA |
US5912332A (en) | 1996-07-26 | 1999-06-15 | Hybridon, Inc. | Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides |
US6063400A (en) | 1997-07-02 | 2000-05-16 | Sdg, Inc. | Targeted liposomal constructs for diagnostic and therapeutic uses |
JPH1133863A (en) | 1997-07-23 | 1999-02-09 | Howa Mach Ltd | Tool replacing device and extruding device for replacing tool |
US8153365B2 (en) | 1997-09-12 | 2012-04-10 | Exiqon A/S | Oligonucleotide analogues |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
US20030235822A1 (en) | 1998-04-03 | 2003-12-25 | Epoch Biosciences, Inc. | Systems and methods for predicting oligonucleotide melting temperature (TmS) |
US20050100923A1 (en) | 1998-09-17 | 2005-05-12 | Trustees Of The University Of Pennsylvania | Compositions, methods, and kits useful for the diagnosis and treatment of spinal muscular atrophy |
WO2000020645A1 (en) | 1998-10-05 | 2000-04-13 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-α (TNF-α) EXPRESSION |
US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
EP0999270A1 (en) | 1998-10-09 | 2000-05-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method of regulating SMN gene expression |
US7041816B2 (en) | 1999-02-04 | 2006-05-09 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligomeric compounds |
JP3420984B2 (en) | 1999-02-12 | 2003-06-30 | 三共株式会社 | New nucleoside and oligonucleotide analogs |
US20040002153A1 (en) | 1999-07-21 | 2004-01-01 | Monia Brett P. | Modulation of PTEN expression via oligomeric compounds |
WO2001007662A1 (en) | 1999-07-22 | 2001-02-01 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the prostaglandin-endoperoxide synthase 2 gene |
US6677445B1 (en) | 1999-08-27 | 2004-01-13 | Chiron Corporation | Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
WO2001036627A2 (en) | 1999-11-16 | 2001-05-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders |
US6602857B1 (en) | 2000-01-18 | 2003-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
US6187545B1 (en) | 2000-01-19 | 2001-02-13 | Isis Pharmaceuticals Inc. | Antisense modulation of pepck-cytosolic expression |
WO2001066129A1 (en) | 2000-03-10 | 2001-09-13 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Substances for the treatment of spinal muscular atrophy |
US7226785B2 (en) | 2000-03-27 | 2007-06-05 | University Of Delaware | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
WO2001072765A1 (en) | 2000-03-28 | 2001-10-04 | Isis Pharmaceuticals, Inc. | ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING |
US20040241651A1 (en) | 2000-04-07 | 2004-12-02 | Alexander Olek | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
US20110191912A1 (en) | 2000-04-26 | 2011-08-04 | Nickolai Alexandrov | Promoter, promoter control elements, and combinations, and uses thereof |
US8067569B2 (en) | 2000-05-04 | 2011-11-29 | Avi Biopharma, Inc. | Splice-region antisense composition and method |
WO2001090341A1 (en) | 2000-05-24 | 2001-11-29 | Isis Pharmaceuticals, Inc. | Antisense modulation of pten expression |
US20100286141A1 (en) | 2000-05-30 | 2010-11-11 | Durden Donald L | Compositions and Methods for Identifying Agents Which Modulate PTEN Function and PI-3 Kinase Pathways |
US6727355B2 (en) | 2000-08-25 | 2004-04-27 | Jcr Pharmaceuticals Co., Ltd. | Pharmaceutical composition for treatment of Duchenne muscular dystrophy |
US6503754B1 (en) | 2000-09-07 | 2003-01-07 | Isis Pharmaceuticals, Inc. | Antisense modulation of BH3 interacting domain death agonist expression |
WO2002022635A1 (en) | 2000-09-11 | 2002-03-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of clusterin expression |
WO2002038738A2 (en) | 2000-11-09 | 2002-05-16 | Cold Spring Harbor Laboratory | Chimeric molecules to modulate gene expression |
US20050054836A1 (en) | 2000-11-09 | 2005-03-10 | Cold Spring Harbor Laboratory | Chimeric molecules to modulate gene expression |
US20110159587A1 (en) | 2000-11-09 | 2011-06-30 | Krainer Adrian R | Chimeric Molecules to Modulate Gene Expression |
JP2008044958A (en) | 2000-11-20 | 2008-02-28 | Board Of Trustees Of The Univ Of Illinois | Membrane scaffold protein |
US20030208061A1 (en) | 2001-03-30 | 2003-11-06 | Muthiah Manoharan | Labeled oligonucleotides, methods for making same, and compounds useful therefor |
EP1967525A2 (en) | 2001-05-08 | 2008-09-10 | Darwin Molecular Corporation | A method for regulating immune function in primates using the foxp3 protein |
US20050176025A1 (en) | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
WO2002103015A2 (en) | 2001-06-14 | 2002-12-27 | Active Pass Pharmaceuticals, Inc. | Abca10 transporter |
US20080242629A1 (en) | 2001-08-01 | 2008-10-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein b expression |
US20050233455A1 (en) | 2001-10-29 | 2005-10-20 | Damha Masad J | Acyclic linker-containing oligonucleotides and uses thereof |
US20030219770A1 (en) | 2001-11-08 | 2003-11-27 | Eshleman James R. | Methods and systems of nucleic acid sequencing |
US20030198983A1 (en) | 2002-02-01 | 2003-10-23 | Affymetrix, Inc. | Methods of genetic analysis of human genes |
US20040096848A1 (en) | 2002-04-05 | 2004-05-20 | Thrue Charlotte Albaek | Oligomeric compounds for the modulation HIF-1alpha expression |
US20030228690A1 (en) | 2002-06-10 | 2003-12-11 | Isis Pharmaceuticals Inc. | Antisense modulation of IL-1 receptor-associated kinase-1 expression |
US20050130924A1 (en) | 2002-06-26 | 2005-06-16 | Monia Brett P. | Antisense inhibition via RNAse H-independent reduction in mRNA |
WO2004011613A2 (en) | 2002-07-29 | 2004-02-05 | Epigenesis Pharmaceuticals, Inc. | Composition & methods for treatment and screening |
US20060135458A1 (en) | 2002-09-13 | 2006-06-22 | Andrew Vaillant | Antiviral oligonucleotides |
US20050003369A1 (en) | 2002-10-10 | 2005-01-06 | Affymetrix, Inc. | Method for depleting specific nucleic acids from a mixture |
US20120157333A1 (en) | 2002-10-21 | 2012-06-21 | Exiqon A/S | Oligonucleotides useful for detecting and analyzing nucleic acids of interest |
US20050026160A1 (en) | 2002-11-05 | 2005-02-03 | Charles Allerson | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
US20060003322A1 (en) | 2002-11-14 | 2006-01-05 | Isaac Bentwich | Bioinformatically detectable group of novel regulatory genes and uses thereof |
US20050246794A1 (en) | 2002-11-14 | 2005-11-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
US7655785B1 (en) | 2002-11-14 | 2010-02-02 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
US20060128646A1 (en) | 2002-11-18 | 2006-06-15 | Santaris Pharma A/S | Antisense design |
US7687617B2 (en) | 2002-11-18 | 2010-03-30 | Santaris Pharma A/S | Oligonucleotides with alternating segments of locked and non-locked nucleotides |
US20090156538A1 (en) | 2002-12-12 | 2009-06-18 | Isis Pharmaceuticals, Inc. | Modulation of endothelial lipase expression |
US20040248840A1 (en) | 2003-02-10 | 2004-12-09 | Santaris Pharma A/S | Oligomeric compounds for the modulation of ras expression |
US20070191294A1 (en) | 2003-03-21 | 2007-08-16 | Santaris Pharma A/S | Short interfering rna (sirna) analogues |
WO2004092356A2 (en) | 2003-04-14 | 2004-10-28 | Aventis Pharma S.A. | Method for obtaining mastocyte lines from porcine tissue and method for production of heparin type molecules |
JP2006522597A (en) | 2003-04-14 | 2006-10-05 | アヴェンティス ファーマ エス.エー. | Method for obtaining mast cell line from porcine tissue and method for producing heparin type molecules |
WO2004099382A2 (en) | 2003-04-30 | 2004-11-18 | Genpathway, Inc. | Methods for global profiling gene regulatory element activity |
US20050226848A1 (en) | 2003-05-29 | 2005-10-13 | Tomoko Kuwabara | Transcriptional regulation of gene expression by small double-stranded modulatory RNA |
US8092992B2 (en) | 2003-05-29 | 2012-01-10 | Salk Institute For Biological Studies | Transcriptional regulation of gene expression by small double-stranded modulatory RNA |
US20110039910A1 (en) | 2003-06-02 | 2011-02-17 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein (a) expression |
WO2004113867A2 (en) | 2003-06-16 | 2004-12-29 | University Of Massachusetts | Exon analysis |
US20110224277A1 (en) | 2003-07-31 | 2011-09-15 | Regulus Therapeutics, Llc. | Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs |
WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US20050261218A1 (en) | 2003-07-31 | 2005-11-24 | Christine Esau | Oligomeric compounds and compositions for use in modulation small non-coding RNAs |
US20070042380A1 (en) | 2003-08-13 | 2007-02-22 | Rosetta Genomics | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
US20050108783A1 (en) | 2003-09-23 | 2005-05-19 | Chihiro Koike | Porcine invariant chain protein, full length cDNA, genomic organization, and regulatory region |
WO2005044981A2 (en) | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
WO2005042018A2 (en) | 2003-10-30 | 2005-05-12 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
US20110150868A1 (en) | 2003-11-05 | 2011-06-23 | Board Of Regents Of The University Of Texas System | Diagnostic and therapeutic methods and compositions involving pten and breast cancer |
US20050203042A1 (en) | 2003-12-23 | 2005-09-15 | Santaris Pharma A/S | Oligomeric compounds for the modulation of Bcl-2 |
WO2005061710A1 (en) | 2003-12-23 | 2005-07-07 | Santaris Pharma A/S | Oligomeric compounds for the modulation of bcl-2 |
US20050244851A1 (en) | 2004-01-13 | 2005-11-03 | Affymetrix, Inc. | Methods of analysis of alternative splicing in human |
US8415313B2 (en) | 2004-01-23 | 2013-04-09 | Avi Biopharma, Inc. | Antisense oligomers and methods for inducing immune tolerance and immunosuppression |
US20050164209A1 (en) | 2004-01-23 | 2005-07-28 | Bennett C. F. | Hepatocyte free uptake assays |
US20080249039A1 (en) | 2004-01-30 | 2008-10-09 | Santaris Pharma A/S | Modified Short Interfering Rna (Modified Sirna) |
WO2005089169A2 (en) | 2004-03-12 | 2005-09-29 | Exelixis, Inc. | Mptens as modifiers of the pten pathway and methods of use |
WO2005094370A2 (en) | 2004-03-29 | 2005-10-13 | The General Hospital Corporation | Oligonucleotide complex compositions and methods of use as gene alteration tools |
US7374927B2 (en) | 2004-05-03 | 2008-05-20 | Affymetrix, Inc. | Methods of analysis of degraded nucleic acid samples |
US20050272080A1 (en) | 2004-05-03 | 2005-12-08 | Affymetrix, Inc. | Methods of analysis of degraded nucleic acid samples |
EP1752536A1 (en) | 2004-05-11 | 2007-02-14 | RNAi Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
US7687616B1 (en) | 2004-05-14 | 2010-03-30 | Rosetta Genomics Ltd | Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof |
US20080318895A1 (en) | 2004-05-17 | 2008-12-25 | Yale University | Intranasal delivery of nucleic acid molecules |
US20070123484A1 (en) | 2004-06-03 | 2007-05-31 | Balkrishen Bhat | Double strand compositions comprising differentially modified strands for use in gene modulation |
US7960541B2 (en) | 2004-06-28 | 2011-06-14 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US8232384B2 (en) | 2004-06-28 | 2012-07-31 | University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US20060046260A1 (en) | 2004-09-01 | 2006-03-02 | Viral Therapeutics, Inc | Amplified Bioassay |
US20080311039A1 (en) | 2004-09-09 | 2008-12-18 | The Regents Of The University Of California | Therapeutic and Prognostic Factor Yy1 in Human Cancer |
US7838657B2 (en) | 2004-12-03 | 2010-11-23 | University Of Massachusetts | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
US8110560B2 (en) | 2004-12-03 | 2012-02-07 | University Of Massachusetts | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
US20070292408A1 (en) | 2004-12-03 | 2007-12-20 | University Of Massachusetts | Spinal Muscular Atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
US20100087511A1 (en) | 2004-12-03 | 2010-04-08 | University Of Massachusetts | Spinal muscular atrophy (sma) treatment via targeting of smn2 splice site inhibitory sequences |
WO2006063356A1 (en) | 2004-12-10 | 2006-06-15 | Isis Phamaceuticals, Inc. | Regulation of epigenetic control of gene expression |
WO2006069584A2 (en) | 2004-12-29 | 2006-07-06 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs |
US7879992B2 (en) | 2005-01-31 | 2011-02-01 | Isis Pharmaceuticals, Inc. | Modification of MyD88 splicing using modified oligonucleotides |
US7888012B2 (en) | 2005-02-09 | 2011-02-15 | Avi Biopharma, Inc. | Antisense composition and method for treating muscle atrophy |
WO2006130201A1 (en) | 2005-03-14 | 2006-12-07 | Board Of Regents, The University Of Texas System | Antigene oligomers inhibit transcription |
US7449297B2 (en) | 2005-04-14 | 2008-11-11 | Euclid Diagnostics Llc | Methods of copying the methylation pattern of DNA during isothermal amplification and microarrays |
US20100210707A1 (en) | 2005-04-15 | 2010-08-19 | Longcheng Li | Small Activating RNA Molecules and Methods of Use |
US20100317606A1 (en) | 2005-04-27 | 2010-12-16 | Pacific Arrow Limited | Novel triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents |
US20100216238A1 (en) | 2005-06-23 | 2010-08-26 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of smn2 splicing |
US8361977B2 (en) | 2005-06-23 | 2013-01-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of SMN2 splicing |
WO2007002390A2 (en) | 2005-06-23 | 2007-01-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of smn2 splicing |
WO2007004977A1 (en) | 2005-07-01 | 2007-01-11 | Index Pharmaceuticals Ab | Immunostimulatory method |
US20080194463A1 (en) | 2005-07-13 | 2008-08-14 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
US20070219244A1 (en) | 2005-11-11 | 2007-09-20 | The Scripps Research Institute | Histone deacetylase inhibitors as therapeutics for neurological diseases |
US20070111963A1 (en) | 2005-11-17 | 2007-05-17 | Board Of Regents, The University Of Texas System | Modulation of gene expression by oligomers targeted to chromosomal DNA |
EP2431467A2 (en) | 2005-11-17 | 2012-03-21 | Board Of Regents, The University Of Texas | Modulation of gene expression by oligomers targeted to chromosomal DNA |
EP1957648A2 (en) | 2005-11-17 | 2008-08-20 | Board of Regents, The University of Texas System | Modulation of gene expression by oligomers targeted to chromosomal dna |
US20110207217A1 (en) | 2005-11-17 | 2011-08-25 | Board Of Regents, The University Of Texas System | Modulation of Gene Expression by Oligomers Targeted to Chromosomal DNA |
WO2007086990A2 (en) | 2005-11-17 | 2007-08-02 | Board Of Regents, The University Of Texas System | Modulation of gene expression by oligomers targeted to chromosomal dna |
US7709456B2 (en) | 2005-11-17 | 2010-05-04 | Board Of Regents, The University Of Texas System | Modulation of gene expression by oligomers targeted to chromosomal DNA |
US20070269815A1 (en) | 2005-11-21 | 2007-11-22 | Rivory Laurent P | Multitargeting interfering RNAs having two active strands and methods for their design and use |
WO2007076328A2 (en) | 2005-12-19 | 2007-07-05 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of hepatitis c virus |
US20090258925A1 (en) | 2005-12-28 | 2009-10-15 | Claes Wahlestedt | Natural antisense and non-coding rna transcripts as drug targets |
US8288354B2 (en) | 2005-12-28 | 2012-10-16 | The Scripps Research Institute | Natural antisense and non-coding RNA transcripts as drug targets |
US20130053428A1 (en) | 2005-12-28 | 2013-02-28 | The Scripps Research Institute | Natural antisense and non-coding rna transcripts as drug targets |
WO2007133812A2 (en) | 2005-12-30 | 2007-11-22 | Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine | Improved carriers for delivery of nucleic acid agents to cells and tissues |
US8129515B2 (en) | 2006-01-27 | 2012-03-06 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
US20090221685A1 (en) | 2006-01-27 | 2009-09-03 | Isis Pharmaceuticals, Inc | Oligomeric compounds and compositions for the use in modulation of micrornas |
US20080293655A1 (en) | 2006-02-08 | 2008-11-27 | Huseyin Aygun | Novel tandem siRNAS |
WO2007112753A2 (en) | 2006-04-03 | 2007-10-11 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
US20120083596A1 (en) | 2006-04-03 | 2012-04-05 | Santaris Pharma A/S | Pharmaceutical Composition |
WO2007112754A2 (en) | 2006-04-03 | 2007-10-11 | Santaris Pharma A/S | Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides |
US20100286234A1 (en) | 2006-04-03 | 2010-11-11 | Joacim Elmen | Pharmaceutical Composition Comprising Anti-Mirna Antisense Oligonucleotides |
WO2007115578A1 (en) | 2006-04-07 | 2007-10-18 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts | Synthetic mecp2 sequence for protein substitution therapy |
EP2023940A2 (en) | 2006-05-05 | 2009-02-18 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of sglt2 |
US20080015162A1 (en) | 2006-05-05 | 2008-01-17 | Sanjay Bhanot | Compounds and methods for modulating gene expression |
JP2009536037A (en) | 2006-05-05 | 2009-10-08 | アイシス ファーマシューティカルズ, インコーポレーテッド | Compounds and methods for modulating gene expression |
EP2021472A2 (en) | 2006-05-05 | 2009-02-11 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating gene expression |
WO2007131237A2 (en) | 2006-05-05 | 2007-11-15 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of ptp1b |
US20100111982A1 (en) | 2006-06-27 | 2010-05-06 | Shanghai Institutes For Biological Sciences | Rheumatoid arthritis t cell vaccine |
WO2008024499A2 (en) | 2006-08-25 | 2008-02-28 | Duke University | Methods for in vivo identification of endogenous mrna targets of micrornas |
WO2008025069A1 (en) | 2006-08-28 | 2008-03-06 | The Walter And Eliza Hall Institute Of Medical Research | Methods of modulating cellular activity and compositions therefor |
WO2008029619A1 (en) | 2006-09-07 | 2008-03-13 | Daiichi Sankyo Company, Limited | Ena antisense oligonucleotide having sequence-specific action |
US20080176793A1 (en) | 2006-09-18 | 2008-07-24 | The Regents Of The University Of California | Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects |
US20080139472A1 (en) | 2006-10-06 | 2008-06-12 | The Regents Of The University Of California | Upregulating bdnf levels to mitigate mental retardation |
US20100197762A1 (en) | 2006-10-18 | 2010-08-05 | Swayze Eric E | Antisense compounds |
JP2010507579A (en) | 2006-10-18 | 2010-03-11 | アイシス ファーマシューティカルズ, インコーポレーテッド | Antisense compound |
US20100021914A1 (en) | 2006-11-23 | 2010-01-28 | Querdenker Aps | Oligonucleotides for modulating target rna activity |
WO2008061537A2 (en) | 2006-11-23 | 2008-05-29 | Querdenker Aps | Oligonucleotides for modulating target rna activity |
US20100143359A1 (en) | 2006-11-27 | 2010-06-10 | Ludwig Institute For Cancer Research Ltd. | Expression of foxp3 by cancer cells |
JP2010516256A (en) | 2007-01-19 | 2010-05-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ADRB2 cancer marker |
US20090324549A1 (en) | 2007-01-29 | 2009-12-31 | Fondazione I.R.C.C.S. Istituto Neurologico "Carlo Besta" | Proteins and/or peptides for the prevention and/or treatment of neurodegenerative diseases |
WO2008103761A2 (en) | 2007-02-20 | 2008-08-28 | Sequenom, Inc. | Methods and compositions for cancer diagnosis and treatment based on nucleic acid methylation |
WO2008103763A2 (en) | 2007-02-20 | 2008-08-28 | Sequenom, Inc. | Methods and compositions for cancer diagnosis and treatment based on nucleic acid methylation |
US7858592B2 (en) | 2007-02-26 | 2010-12-28 | The Board Of Regents Of The University Of Texas System | Interfering RNAs against the promoter region of P53 |
US20090099109A1 (en) | 2007-02-26 | 2009-04-16 | Shames David S | Interfering rnas against the promoter region of p53 |
WO2008113832A2 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
US20100210712A1 (en) | 2007-03-22 | 2010-08-19 | Santaris Pharma A/S | Short RNA Antagonist Compounds for the Modulation of Target mRNA |
WO2008132234A2 (en) | 2007-05-01 | 2008-11-06 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of beta-catenin |
WO2008138904A2 (en) | 2007-05-11 | 2008-11-20 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of her3 |
WO2008141282A2 (en) | 2007-05-11 | 2008-11-20 | The Regents Of The University Of Michigan | Materials and methods for foxp3 tumor suppression |
US20090325868A1 (en) | 2007-05-11 | 2009-12-31 | The Regents Of The University Of Michigan | Materials And Methods For FOXP3 Tumor Suppression |
US20100256223A1 (en) | 2007-06-14 | 2010-10-07 | Querdenker Aps | Oligonucleotides for modulating target rna activity |
US20090082297A1 (en) | 2007-06-25 | 2009-03-26 | Lioy Daniel T | Compositions and Methods for Regulating Gene Expression |
US20090099066A1 (en) | 2007-06-29 | 2009-04-16 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
US20090123467A1 (en) | 2007-07-31 | 2009-05-14 | The Johns Hopkins University | Polypeptide-Nucleic Acid Conjugate for Immunoprophylaxis or Immunotherapy for Neoplastic or Infectious Disorders |
US20100247543A1 (en) | 2007-08-24 | 2010-09-30 | Oryzon Genomics, S.A. | Treatment and prevention of neurodegenerative diseases |
US20120288869A1 (en) | 2007-10-04 | 2012-11-15 | Schwartz Jacob C | Modulating Gene Expression With agRNA and Gapmers Targeting Antisense Transcripts |
WO2009046397A2 (en) | 2007-10-04 | 2009-04-09 | Board Of Regents, The University Of Texas System | Modulating gene expression with agrna and gapmers targeting antisense transcripts |
WO2009043353A2 (en) | 2007-10-04 | 2009-04-09 | Santaris Pharma A/S | Micromirs |
US20090143326A1 (en) | 2007-10-04 | 2009-06-04 | Santaris Pharma A/S | MICROMIRs |
US20090092988A1 (en) | 2007-10-04 | 2009-04-09 | Schwartz Jacob C | Modulating Gene Expression with agRNA and Gapmers Targeting Antisense Transcripts |
US8288356B2 (en) | 2007-10-04 | 2012-10-16 | Santaris Pharma A/S | MicroRNAs |
US20100298410A1 (en) | 2007-10-04 | 2010-11-25 | Santaris Pharma A/S | MICROMIRs |
WO2009044383A1 (en) | 2007-10-05 | 2009-04-09 | Consiglio Nazionale Delle Ricerche | Nucleic acid codifying for a utrophin transcription specific regulating protein, protein codified thereby and uses thereof |
WO2009061851A2 (en) | 2007-11-09 | 2009-05-14 | Isis Pharmaceuticals, Inc. | Modulation of factor 7 expression |
WO2009064920A2 (en) | 2007-11-13 | 2009-05-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating protein expression |
US20090155910A1 (en) | 2007-12-18 | 2009-06-18 | E.I.Du Pont De Nemours And Company | Down-regulation of gene expression using artificial micrornas |
WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
US20100004314A1 (en) | 2008-03-07 | 2010-01-07 | Senesco Technologies, Inc. | Use of sirna to achieve down regulation of an endogenous gene in combination with the use of a sense construct to achieve expression of a polynucleotide |
US8404659B2 (en) | 2008-03-07 | 2013-03-26 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of MicroRNA related diseases |
US8361980B2 (en) | 2008-03-07 | 2013-01-29 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
US8846639B2 (en) | 2008-04-04 | 2014-09-30 | Isis Pharmaceutical, Inc. | Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity |
US20110263687A1 (en) | 2008-04-07 | 2011-10-27 | Riken | Rna molecules and uses thereof |
WO2009124341A1 (en) | 2008-04-07 | 2009-10-15 | The University Of Queensland | Rna molecules and uses thereof |
WO2009127680A1 (en) | 2008-04-16 | 2009-10-22 | Santaris Pharma A/S | Pharmaceutical composition comprising anti pcsk9 oligomers |
WO2009134710A2 (en) | 2008-04-28 | 2009-11-05 | The Trustees Of The University Of Pennsylvania | Methods for enhancing utrophin production via inhibition of microrna |
US20110086833A1 (en) | 2008-05-27 | 2011-04-14 | Paushkin Sergey V | Methods for treating spinal muscular atrophy |
WO2009151546A2 (en) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
WO2009149182A1 (en) | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
US20090326051A1 (en) | 2008-06-04 | 2009-12-31 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small RNA targeting of gene promoters |
US8222221B2 (en) | 2008-06-04 | 2012-07-17 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small RNA targeting of gene promoters |
US20110077286A1 (en) | 2008-06-05 | 2011-03-31 | Damha Masad J | Oligonucleotide duplexes comprising dna-like and rna-like nucleotides and uses thereof |
WO2010000665A1 (en) | 2008-06-30 | 2010-01-07 | Santaris Pharma A/S | Antidote oligomers |
US20110172292A1 (en) | 2008-06-30 | 2011-07-14 | Hansen Jens Bo Rode | Antidote oligomers |
WO2010007522A1 (en) | 2008-07-15 | 2010-01-21 | Santaris Pharma A/S | Rna antagonists targeting gli2 |
WO2010014592A1 (en) | 2008-07-29 | 2010-02-04 | The Board Of Regents Of The University Of Texas Sytem | Selective inhibition of polyglutamine protein expression |
US20110237606A1 (en) | 2008-09-26 | 2011-09-29 | Agency Of Science, Technology And Research | 3-Deazaneplanocin Derivatives |
WO2010040112A2 (en) | 2008-10-03 | 2010-04-08 | Curna, Inc. | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1 |
US20100105760A1 (en) | 2008-10-03 | 2010-04-29 | Curna, Inc. | Treatment of Apolipoprotein-A1 Related Diseases by Inhibition of Natural Antisense Transcript to Apolipoprotein-A1 |
US8153606B2 (en) | 2008-10-03 | 2012-04-10 | Opko Curna, Llc | Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1 |
US20100112042A1 (en) | 2008-10-16 | 2010-05-06 | Mdrna, Inc. | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics |
US20100124547A1 (en) | 2008-11-17 | 2010-05-20 | Birgit Bramlage | Compositions and methods for inhibiting expression of factor vii genes |
US20110319283A1 (en) | 2008-11-24 | 2011-12-29 | Trillion Genomics Limited | Oligonucleotides capable of discriminating between nucleic acid sequences that comprise a conserved sequence |
WO2010065787A2 (en) | 2008-12-04 | 2010-06-10 | Curna, Inc. | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
US20110237649A1 (en) | 2008-12-04 | 2011-09-29 | Opko Curna, Llc | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1 |
US20110237651A1 (en) | 2008-12-04 | 2011-09-29 | Opko Curna, Llc | Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo |
US20110237650A1 (en) | 2008-12-04 | 2011-09-29 | Opko Curna, Llc | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
US20110294870A1 (en) | 2008-12-04 | 2011-12-01 | Opko Curna, Llc | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
WO2010065671A2 (en) | 2008-12-04 | 2010-06-10 | Curna, Inc. | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
WO2010076248A1 (en) | 2008-12-31 | 2010-07-08 | Santaris Pharma A/S | Use of lna apob antisense oligomers for the treatment of acute coronary syndromes |
WO2010083615A1 (en) | 2009-01-26 | 2010-07-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein c-iii expression |
US20110319476A1 (en) | 2009-02-12 | 2011-12-29 | Opko Curna, Llc | Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf |
US20130137751A1 (en) | 2009-02-12 | 2013-05-30 | Curna, Inc. | Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf |
US20110319475A1 (en) | 2009-02-12 | 2011-12-29 | Opko Curna, Llc | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
WO2010093904A2 (en) | 2009-02-12 | 2010-08-19 | Curna, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
WO2010093860A2 (en) | 2009-02-13 | 2010-08-19 | The General Hospital Corporation | Isolation of factors that associate directly or indirectly with chromatin |
US20110319317A1 (en) | 2009-03-04 | 2011-12-29 | Opko Curna, Llc | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1 |
WO2010102058A2 (en) | 2009-03-04 | 2010-09-10 | Curna, Inc. | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1 |
WO2010107733A2 (en) | 2009-03-16 | 2010-09-23 | Curna, Inc. | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
US20120004184A1 (en) | 2009-03-16 | 2012-01-05 | Joseph Collard | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
US20120010156A1 (en) | 2009-03-17 | 2012-01-12 | OPKP CuRNA, LLC | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
US20120149756A1 (en) | 2009-04-10 | 2012-06-14 | Associatin Institut de Myologie | Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease |
WO2010124231A2 (en) | 2009-04-24 | 2010-10-28 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions |
WO2010122538A1 (en) | 2009-04-24 | 2010-10-28 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon |
US8318690B2 (en) | 2009-05-01 | 2012-11-27 | Curna, Inc. | Treatment of hemoglobin (HBF/HBG) related diseases by inhibition of natural antisense transcript to HBF/HBG |
US20100280100A1 (en) | 2009-05-01 | 2010-11-04 | Curna, Inc. | Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg |
WO2010129746A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
US20120046344A1 (en) | 2009-05-06 | 2012-02-23 | Joseph Collard | Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene |
US20120046236A1 (en) | 2009-05-06 | 2012-02-23 | Opko Curna Llc | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
WO2010129799A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene |
WO2010129861A2 (en) | 2009-05-08 | 2010-11-11 | Curna, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
US20120046345A1 (en) | 2009-05-08 | 2012-02-23 | Opko Curna, Llc | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
WO2010135329A2 (en) | 2009-05-18 | 2010-11-25 | Curna, Inc. | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
US20120064048A1 (en) | 2009-05-18 | 2012-03-15 | Opko Curna, Llc | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
US20120095079A1 (en) | 2009-05-22 | 2012-04-19 | Opko Curna, Llc | Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3 |
WO2010135695A2 (en) | 2009-05-22 | 2010-11-25 | Curna, Inc. | TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 |
WO2010138806A2 (en) | 2009-05-28 | 2010-12-02 | Curna, Inc. | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
US20120088817A1 (en) | 2009-05-28 | 2012-04-12 | Opko Curna, Llc | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
WO2010148065A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1 |
WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
US20120095081A1 (en) | 2009-06-16 | 2012-04-19 | Joseph Collard | Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1 |
US20120171170A1 (en) | 2009-06-16 | 2012-07-05 | Opko Curna, Llc | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
US20120094934A1 (en) | 2009-06-24 | 2012-04-19 | Opko Curna, Llc | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
WO2010151671A2 (en) | 2009-06-24 | 2010-12-29 | Curna, Inc. | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
US20120142758A1 (en) | 2009-06-26 | 2012-06-07 | OPKO CuRNA,, LLC | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
WO2010151674A2 (en) | 2009-06-26 | 2010-12-29 | Curna, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
WO2011005786A2 (en) | 2009-07-06 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for enhancing production of a biological product |
WO2011009624A1 (en) | 2009-07-22 | 2011-01-27 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
WO2011010706A1 (en) | 2009-07-23 | 2011-01-27 | 武田薬品工業株式会社 | Fgf21 cis-element binding substance |
US20120252869A1 (en) | 2009-07-24 | 2012-10-04 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
US20120149759A1 (en) | 2009-08-05 | 2012-06-14 | Opko Curna, Llc | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
WO2011017516A2 (en) | 2009-08-05 | 2011-02-10 | Curna, Inc. | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
WO2011019815A2 (en) | 2009-08-11 | 2011-02-17 | Curna, Inc. | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
US20120129917A1 (en) | 2009-08-11 | 2012-05-24 | Opko Curna, Llc | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
WO2011022606A2 (en) | 2009-08-21 | 2011-02-24 | Curna, Inc. | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
US20120135941A1 (en) | 2009-08-21 | 2012-05-31 | Joseph Collard | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
WO2011031482A2 (en) | 2009-08-25 | 2011-03-17 | Curna, Inc. | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
US20120142610A1 (en) | 2009-08-25 | 2012-06-07 | Opko Curna, Llc | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
WO2011025862A2 (en) | 2009-08-28 | 2011-03-03 | Curna, Inc. | Treatment of atp-binding cassette sub-family b member 1 (abcb1) related diseases by inhibition of natural antisense transcript to abcb1 |
WO2011032109A1 (en) | 2009-09-11 | 2011-03-17 | Sma Foundation | Biomarkers for spinal muscular atrophy |
WO2011038205A2 (en) | 2009-09-25 | 2011-03-31 | Curna, Inc. | Treatment of growth hormone (gh) related diseases by inhibition of natural antisense transcript to gh |
US20120295952A1 (en) | 2009-09-25 | 2012-11-22 | Curna, Inc. | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
WO2011038210A2 (en) | 2009-09-25 | 2011-03-31 | Curna, Inc. | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
WO2011048125A1 (en) | 2009-10-20 | 2011-04-28 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
US20120322851A1 (en) | 2009-10-20 | 2012-12-20 | Gregroy Hardee | Oral delivery of therapeutically effective lna oligonucleotides |
KR20110050134A (en) | 2009-11-06 | 2011-05-13 | 성균관대학교산학협력단 | Novel peptides upregulating bdnf expression and pharmaceutical composition for protection and therapy against alzheimer's disease and parkinson's disease comprising the same |
US20130116300A1 (en) | 2009-12-16 | 2013-05-09 | Curna, Inc. | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
WO2011084455A2 (en) | 2009-12-16 | 2011-07-14 | Opko Curna, Llc. | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
US20120329727A1 (en) | 2009-12-23 | 2012-12-27 | Curna, Inc. | Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2 |
US20130184325A9 (en) | 2009-12-23 | 2013-07-18 | CuRNA ,Inc. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
WO2011079263A2 (en) | 2009-12-23 | 2011-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2 |
US20120329855A1 (en) | 2009-12-23 | 2012-12-27 | CuRNA ,Inc. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
WO2011079261A2 (en) | 2009-12-23 | 2011-06-30 | Curna, Inc. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
US20120295953A1 (en) | 2009-12-29 | 2012-11-22 | Joseph Colalrd | Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63 |
US20120264812A1 (en) | 2009-12-29 | 2012-10-18 | Curna, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
US20120289583A1 (en) | 2009-12-31 | 2012-11-15 | Curna, Inc. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
US20120295954A1 (en) | 2010-01-04 | 2012-11-22 | Joseph Collard | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
WO2011082409A2 (en) | 2010-01-04 | 2011-07-07 | Curna, Inc. | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
US20120322853A1 (en) | 2010-01-06 | 2012-12-20 | Curna, Inc. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene |
WO2011085066A2 (en) | 2010-01-06 | 2011-07-14 | Curna, Inc. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene |
US20120277290A1 (en) | 2010-01-11 | 2012-11-01 | Curna, Inc. | Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg |
US20120295959A1 (en) | 2010-01-25 | 2012-11-22 | Curna, Inc. | Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 |
WO2011097388A1 (en) | 2010-02-03 | 2011-08-11 | Alnylam Pharmaceuticals, Inc. | Selective inhibition of polyglutamine protein expression |
WO2011097582A2 (en) | 2010-02-08 | 2011-08-11 | Opko Curna Llc | Treatment of arachidonate 12-lipoxygenase, 12r type (alox12b) related diseases by inhibition of natural antisense transcript to alox12b |
WO2011097641A1 (en) | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Methods and compositions useful in treatment of diseases or conditions related to repeat expansion |
US20120309814A1 (en) | 2010-02-22 | 2012-12-06 | Curna, Inc. | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
US20130079505A1 (en) | 2010-03-24 | 2013-03-28 | Mirrx Therapeutics A/S | Bivalent antisense oligonucleotides |
WO2011123745A2 (en) | 2010-04-02 | 2011-10-06 | Opko Curna Llc | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
US20130035372A1 (en) | 2010-04-02 | 2013-02-07 | Curna, Inc. | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
US20130035373A1 (en) | 2010-04-09 | 2013-02-07 | Curna, Inc. | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
US20110251261A1 (en) | 2010-04-13 | 2011-10-13 | Life Technologies Corporation | Compositions and methods for inhibition of nucleic acids function |
WO2011139917A1 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Modulation of transthyretin expression |
WO2011139387A1 (en) | 2010-05-03 | 2011-11-10 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
US20130072421A1 (en) | 2010-05-03 | 2013-03-21 | Curna, Inc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
US20130065947A1 (en) | 2010-05-14 | 2013-03-14 | Cu RNA ,Inc. | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
WO2011146674A2 (en) | 2010-05-19 | 2011-11-24 | Opko Curna Llc | Treatment of bcl2-like 11 (bcl2l11) related diseases by inhibition of natural antisense transcript to bcl2l11 |
WO2011146675A2 (en) | 2010-05-19 | 2011-11-24 | Opko Curna Llc | Treatment of lim homeobox 2 (lhx2) related diseases by inhibition of natural antisense transcript to lhx2 |
WO2011150005A2 (en) | 2010-05-26 | 2011-12-01 | Opko Curna Llc | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
US20130085112A1 (en) | 2010-05-26 | 2013-04-04 | Curna, Inc. | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
US20130072546A1 (en) | 2010-05-26 | 2013-03-21 | Curna, Inc. | Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra |
WO2011159836A2 (en) | 2010-06-15 | 2011-12-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating interaction between proteins and target nucleic acids |
US20130289092A1 (en) | 2010-06-15 | 2013-10-31 | Cold Spring Harbor Laboratory | Compounds and methods for modulating interaction between proteins and target nucleic acids |
US20120004278A1 (en) | 2010-06-18 | 2012-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Linc rnas in cancer diagnosis and treatment |
US20130164846A1 (en) | 2010-06-23 | 2013-06-27 | Mina Therapeutics Limited | Rna molecules and uses thereof |
WO2011163499A2 (en) | 2010-06-23 | 2011-12-29 | Opko Curna, Llc | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
WO2011161460A2 (en) | 2010-06-23 | 2011-12-29 | Mina Therapeutics Limited | Rna molecules and uses thereof |
US20130096183A1 (en) | 2010-06-23 | 2013-04-18 | Curna, Inc. | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
EP2591797A1 (en) | 2010-07-09 | 2013-05-15 | Institut Pasteur Of Shanghai, Cas | Regulatory factor of foxp3 and regulatory t cells and use thereof |
WO2012009347A2 (en) | 2010-07-12 | 2012-01-19 | Opko Curna Llc | Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3 |
WO2012009402A2 (en) | 2010-07-14 | 2012-01-19 | Opko Curna Llc | Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg |
US20130143946A1 (en) | 2010-07-14 | 2013-06-06 | Curna Inc. | Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg |
WO2012012467A2 (en) | 2010-07-19 | 2012-01-26 | Isis Pharmaceuticals, Inc. | Modulation of nuclear-retained rna |
CA2805791A1 (en) | 2010-07-19 | 2012-01-26 | Isis Pharmaceuticals, Inc. | Modulation of nuclear-retained rna |
WO2012027033A1 (en) | 2010-07-19 | 2012-03-01 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals |
WO2012018881A2 (en) | 2010-08-03 | 2012-02-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for the regulation of rna |
WO2012024478A2 (en) | 2010-08-19 | 2012-02-23 | Opko Curna Llc | Treatment of nicotinamide phosphoribosyltransferase (nampt) related diseases by inhibition of natural antisense transcript to nampt |
US20120071418A1 (en) | 2010-09-10 | 2012-03-22 | Epizyme, Inc. | Inhibitors of Human EZH2 and Methods of Use Thereof |
WO2012036433A2 (en) | 2010-09-13 | 2012-03-22 | 서울대학교 산학협력단 | Treatment of neurodegenerative diseases by targeting mirna |
US20130245095A1 (en) | 2010-10-06 | 2013-09-19 | Joseph Collard | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
WO2012047956A2 (en) | 2010-10-06 | 2012-04-12 | Opko Curna Llc | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
WO2012054723A2 (en) | 2010-10-22 | 2012-04-26 | Opko Curna Llc | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
US20130253036A1 (en) | 2010-10-22 | 2013-09-26 | Curna, Inc. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
WO2012058268A2 (en) | 2010-10-27 | 2012-05-03 | Opko Curna Llc | Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1 |
US20130210893A1 (en) | 2010-10-27 | 2013-08-15 | Curna, Inc. | Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1 |
WO2012064806A2 (en) | 2010-11-11 | 2012-05-18 | The University Of North Carolina At Chapel Hill | Methods and compositions for unsilencing imprinted genes |
US9328346B2 (en) | 2010-11-12 | 2016-05-03 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
US20140142160A1 (en) | 2010-11-12 | 2014-05-22 | The General Hospital Corporation | Polycomb-associated Non-Coding RNAs |
WO2012065143A1 (en) | 2010-11-12 | 2012-05-18 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
US20170037396A1 (en) | 2010-11-12 | 2017-02-09 | The General Hospital Corporation | Polycomb-Associated Non-Coding RNAs |
US20130245099A1 (en) | 2010-11-18 | 2013-09-19 | Curna, Inc. | Antagonat compositions and methods of use |
WO2012068340A2 (en) | 2010-11-18 | 2012-05-24 | Opko Curna Llc | Antagonat compositions and methods of use |
WO2012071238A2 (en) | 2010-11-23 | 2012-05-31 | Opko Curna Llc | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
US20130261065A1 (en) | 2010-11-23 | 2013-10-03 | Joseph Collard | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
WO2012087983A1 (en) | 2010-12-20 | 2012-06-28 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
WO2012109476A2 (en) | 2011-02-09 | 2012-08-16 | The University Of Rochester | Methods and compositions related to staufen 1 binding sites formed by duplexing alu elements |
WO2012144220A1 (en) | 2011-04-22 | 2012-10-26 | Oncotherapy Science, Inc. | Ezh2 as target gene for cancer therapy and diagnosis |
US20120289581A1 (en) | 2011-05-13 | 2012-11-15 | Chang Howard Y | Diagnostic, prognostic and therapeutic uses of long non-coding rnas for cancer and regenerative medicine |
US20140187606A1 (en) | 2011-06-09 | 2014-07-03 | Curna, Inc. | Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn |
WO2012170771A1 (en) | 2011-06-09 | 2012-12-13 | Curna, Inc. | Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn |
US9593330B2 (en) | 2011-06-09 | 2017-03-14 | Curna, Inc. | Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN |
WO2013006619A1 (en) | 2011-07-05 | 2013-01-10 | The General Hospital Corporation | Rna-yy1 interactions |
WO2013036403A1 (en) | 2011-09-06 | 2013-03-14 | Curna, Inc. | TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES |
US9580708B2 (en) | 2011-09-14 | 2017-02-28 | Rana Therapeutics, Inc. | Multimeric oligonucleotides compounds |
WO2013040429A1 (en) | 2011-09-14 | 2013-03-21 | Rana Therapeutics Inc. | Multimeric oligonucleotide compounds |
US20140356459A1 (en) | 2011-12-15 | 2014-12-04 | Oncostamen S.R.L. | Micrornas and uses thereof |
WO2013124807A2 (en) | 2012-02-24 | 2013-08-29 | Biogenera Societa' A Responsabilita' Limitata | Oligonucleotides for modulating gene expression and uses thereof |
WO2013138374A2 (en) | 2012-03-15 | 2013-09-19 | Curna, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
WO2013173601A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating bdnf expression |
WO2013173638A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating smn gene family expression |
WO2013173605A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating pten expression |
WO2013173635A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
WO2013173599A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating hemoglobin gene family expression |
US20150252364A1 (en) | 2012-05-16 | 2015-09-10 | Rana Therapeutics, Inc. | Compositions and methods for modulating smn gene family expression |
WO2013173608A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating mecp2 expression |
WO2013173647A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating apoa1 and abca1 expression |
US20150218560A1 (en) | 2012-05-16 | 2015-08-06 | Rana Therapeutics, Inc. | Compositions for modulating gene expression |
WO2013173637A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
WO2013173645A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating utrn expression |
US20180298384A1 (en) | 2012-05-16 | 2018-10-18 | Translate Bio Ma, Inc. | Compositions and methods for modulating smn gene family expression |
WO2013173652A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
WO2013173598A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating atp2a2 expression |
US20150099791A1 (en) | 2012-05-16 | 2015-04-09 | Rana Therapeutics, Inc. | Compositions and methods for modulating utrn expression |
US20150133529A1 (en) | 2012-05-16 | 2015-05-14 | Rana Therapeutics, Inc. | Compositions and methods for modulating bdnf expression |
US20150133528A1 (en) | 2012-05-16 | 2015-05-14 | Rana Therapeutics, Inc. | Compositions and methods for modulating hemoglobin gene family expression |
US20150133362A1 (en) | 2012-05-16 | 2015-05-14 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
US20150141320A1 (en) | 2012-05-16 | 2015-05-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
US20150159161A1 (en) | 2012-05-16 | 2015-06-11 | Rana Therapeutics, Inc. | Compositions and methods for modulating pten expression |
US20150159160A1 (en) | 2012-05-16 | 2015-06-11 | Rana Therapeutics, Inc. | Compositions and methods for modulating atp2a2 expression |
JP2015518714A (en) | 2012-05-16 | 2015-07-06 | ラナ セラピューティクス インコーポレイテッド | Compositions and methods for regulating gene expression |
US20150191722A1 (en) | 2012-05-16 | 2015-07-09 | Rana Therapeutics, Inc. | Compositions and methods for modulating apoa1 and abca1 expression |
US20150225717A1 (en) | 2012-08-07 | 2015-08-13 | The General Hospital Corporation | Selective Reactivation of Genes on the Inactive X Chromosome |
US9567581B2 (en) | 2012-08-07 | 2017-02-14 | The General Hospital Corporation | Selective reactivation of genes on the inactive X chromosome |
WO2014043544A1 (en) | 2012-09-14 | 2014-03-20 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
WO2014076195A1 (en) | 2012-11-15 | 2014-05-22 | Santaris Pharma A/S | Oligonucleotide conjugates |
WO2014172698A1 (en) | 2013-04-19 | 2014-10-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation nucleic acids through nonsense mediated decay |
WO2014197826A1 (en) | 2013-06-07 | 2014-12-11 | Rana Therapeutics, Inc. | Compositions and methods for modulating foxp3 expression |
US20160122760A1 (en) | 2013-06-07 | 2016-05-05 | Rana Therapeutics, Inc. | Compositions and methods for modulating foxp3 expression |
WO2014203518A1 (en) | 2013-06-16 | 2014-12-24 | National University Corporation Tokyo Medical And Dental University | Double-stranded antisense nucleic acid with exon-skipping effect |
WO2014205551A1 (en) | 2013-06-28 | 2014-12-31 | London Health Sciences Centre Research Inc. | Inhibition of microrna for treatment of sepsis |
US20160201064A1 (en) | 2013-08-16 | 2016-07-14 | Rana Therapeutics, Inc. | Compositions and methods for modulating expression of frataxin |
US20160201063A1 (en) | 2013-08-16 | 2016-07-14 | Rana Therapeutics, Inc. | Epigenetic regulators of frataxin |
WO2015035476A1 (en) | 2013-09-16 | 2015-03-19 | University Of Western Sydney | Modulation of gene expression |
US20160222391A1 (en) | 2013-10-04 | 2016-08-04 | Rana Therapeutics, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
WO2016077837A1 (en) | 2014-11-14 | 2016-05-19 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of proteins |
Non-Patent Citations (314)
Title |
---|
[No Author Listed] Catalogue of Parent of Origin Effects, Imprinted Genes and Related Effects, Parental Origins of de novo Mutations, downloaded at http://igc.otago.ac.nz/home.html on May 22, 2015, 2 pages. |
[No Author Listed] Designing Antisense Oligonucleotides. Integrated DNA Technologies. 2011. 1-16. |
[No Author Listed] Locked Nucleic Acid. Exiqon. 2009. Retrieved from http://www.exiqon.com/Is/documents/scientific/lna_folder.pdf on Jun. 6, 2016. |
[No Author Listed] ncRNA. 2011;29(11):1716-1721. |
[No Author Listed] UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19) Assembly. Retrieved from http://genome.ucsc.edu/cgi-bin/hgTracks?db=hgl9&position=chr5%3A70211956-70271955&hgsid=452570083sxavccFldzrwhzM3tcNOyMcxbye7 on Nov. 9, 2015. |
[No Author Listed], Geneimprint. 2012. http://www.geneimprint.com/site/about-this-site [last accessed May 22, 2015]. 1 page. |
[No Author Listed], Imprinted gene. Mosby's Dictionary of Medicine, Nursing and Health Professions. 8th ed. 2009;949. |
[No Author Listed], New England BioLabs 1998/99 Catalog. 121, 284. |
Aartsma-Rus et al., Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet. Jan. 2004;74(1):83-92. |
Ahn et al., Retinoic acid accelerates downregulation of the Xist repressor, Oct4, and increases the likelihood of Xist activation when Tsix is deficient. BMC Develop Biol. 201 O; 10:90. 14 pages. |
Alvarez-Salas, Nucleic acids as therapeutic agents. Curr Top Med Chem. 2008;8(15): 1379-404. |
Anderson et al., Post-transcriptional regulons coordinate the initiation and resolution of inflammation. Nat Rev Immunol. Jan. 2010;10(1):24-35. doi: 10.1038/nri2685. |
Arvey et al., Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 inregulatoiy T cells. Nat Immunol. Jun. 2014;15(6):580-587, doi: 10.1038/ni.2868. Epub Apr. 13, 2014. |
Astuti et al., Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour. Br J Cancer. Apr. 25, 2005;92(8): 1574-80. |
Axelson, The Notch signaling cascade in neuroblastoma: role of the basic helix-loop-helix proteins HASH-1 and HES-1. Cancer Lett. Feb. 20, 2004;204(2): 171-8. |
Bauer et al., The quest for mammalian Polycomb response elements: are we there yet? Chromosoma. Jun. 2016;125(3):471-96. doi:10.1007/s00412-015-0539-4. |
Behlke et al., Designing antisense oligonucleotides. Integrated DNA Technologies. 2005. 1-17. |
Beletskii et al., PNA interference mapping demonstrates functional domains in the noncoding RNA Xist. Proc Natl Acad Sci US A Jul. 31, 2001;98(16):9215-20. |
Beltran et al., The interaction of PRC2 with RN A or chromatin is mutually antagonistic. Genome Res. Jul. 2016;26(7):896-907. doi: 10.1101/gr.197632.115. Epub May 9, 2016. |
Bernardi et al., Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol. Dec. 2007;8(12):1006-16. Review. |
Bernstein et al., Mouse polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin. Mol Cell Biol. Apr. 2006;26(7):2560-9. |
Bernstein et al., RNA meets chromatin. Genes Dev. Jul. 15, 2005;19(14):1635-55. Review. |
Blauw et al., SMN1 gene duplications are associated with sporadic ALS. Neurology. Mar. 13, 2012;78(11):776-80. doi: 10.1212/WNL.0b013e318249f697. Epub Feb. 8, 2012. |
Boyer et al., Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. May 18, 2006;441(7091):349-53. Epub Apr. 19, 2006. |
Braasch et al., Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA Chem Biol. Jan. 2001;S(1):1-7. |
Bracken et al., "Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions," Genes & Development, 2006, 20:1123-1136. |
Brockdorff et al., The product of the mouse Xist gene is a 15 kb inactive X-specific transcript containing no conserved ORF and located in the nucleus. Cell. Oct. 30, 1992;71(3):515-26. |
Broderick et al., Micro RNA therapeutics. Gene Ther. Dec. 2011; 18(12): 1104-10. doi: 10.1038/gt.2011.50. Epub Apr. 28, 2011. |
Brown et al., A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nature. Jan. 3, 1991;349:38-44. |
Brown et al., The Human XIST Gene: Analysis of a 17 kb Inactive X-Specific RNA That Contains Conserved Repeats and Is Highly Localized within the Nucleus. Cell. Oct. 30, 1992;71:527-42. |
Buck et al., Design strategies and performance of custom DNA sequencing primers. Biotechniques. Sep. 1999;27(3):528-36. |
Burghes et al., Antisense oligonucleotides and spinal muscular atrophy: skipping along. Genes Dev. Aug. 1, 2010;24(15):1574-9. doi:10.1101/gad.1961710. |
Burglen et al., Structure and organization of the human survival motor neuron (SMN) gene. Genomics. Mar. 15, 1996;32(3):479-82. |
Cantafora et al., Evaluation of RNA messengers involved in lipid trafficking of human intestinal cells by reverse-transcription polymerase chain reaction with competimer technology and microchip electrophoresis. Electrophoresis. Nov. 2003;24(21):3748-54. |
Carninci et al., The transcriptional landscape of the mammalian genome. Science. Sep. 2, 2005;309(5740): 1559-63. |
Chahrour et al., MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. May 30, 2008;320(5880):1224-9. |
Chen et al., Decoding the function of nuclear long non-coding RN As. Curr Opin Cell Biol. Jun. 2010;22(3):357-64. doi: 10.1016/j.ceb.2010.03.003. Epub Mar. 29, 2010. Review. |
Chow et al., Inducible XIST-dependent X-chromosome inactivation in human somatic cells is reversible. Proc Natl Acad Sci USA. Jun. 12, 2007;104(24):10104-9. Epub May 30, 2007. |
Clark et al., The Reality of Pervasive Transcription. PLOS Bio. Jul. 2011;9(7):e1000625. 6 pages. |
Clemson et al., XIST RNA paints the inactive X chromosome at interphase: evidence for a novel RNA involved in nuclear/chromosome structure. J Cell Biol. Feb. 1996;132(3):259-75. |
Cloonan et al., Stem cell transcriptome profiling via massive-scale mRNA sequencing. Nat Methods. Jul. 2008;5(7):613-9. |
Cohen et al., X-chromosome inactivation and the search for chromosome-wide silencers. Curr Opin Genet Dev. 2002;12:219-24. |
Coombes et al., Epigenetic properties and identification of an imprint mark in the Nesp-Gnasxl domain of the mouse Gnas imprinted locus. Mol Cell Biol. Aug. 2003;23(16):5475-88. |
Corcia et al., Homozygous SMN2 deletion is a protective factor in the Swedish ALS population. Eur J Hum Genet. May 2012;20(5):588-91. doi: 10.1038/ejhg.2011.255. Epub Jan. 25, 2012. |
Corcia et al., The importance of the SMN genes in the genetics of sporadic ALS. Amyotroph Lateral Scler. Oct.-Dec. 2009;10(5-6):436-40. doi: 10.3109/17482960902759162. |
Core et al., Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science. Dec. 19, 2008;322(5909): 1845-8. doi: 10.1126/science.1162228. Epub Dec. 4, 2008. |
Costa, Non-coding RNAs: new players in eukaryotic biology. Gene. Sep. 12, 2005;357(2):83-94. Review. |
Crea et al., Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer. Apr. 18, 2011;10:40. doi: 10.1186/1476-4598-10-40. |
Crooke et al., Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. Biochem J. Dec. 1, 1995;312 ( Pt 2):599-608. |
Cuddapa h et al., A novel human polycomb binding site acts as a functional polycomb response element in Drosophila. PLoS One. 2012;7(5):e36365. doi: 10.1371/journal.pone.0036365. Epub May 3, 2012. |
Cushman et al., Synthesis of the covalent hydrate of the incorrectly assumed structure of aurintricarboxylic acid (ATA). Tetrahedron. 1990;46(5):1491-1498. |
Daughters et al., RNA gain-of-function in spinocerebellar ataxia type 8. PLoS Genet. Aug. 2009;5(8):e1000600. doi: 10.1371/journal.pgen.1000600. Epub Aug. 14, 2009. |
Davidovich et al., The recruitment of chromatin modifiers by long noncoding RN As: lessons from PRC2. RNA Dec. 2015;21(12):2007-22. doi: 10.1261/rna.053918.115. |
Davidovich et al., Toward a consensus on the binding specificity and promiscuity of PRC2 for RNA. Mol Cell. Feb. 5, 2015;57(3):552-8. doi: 10.1016/j.molcel.2014.12.017. Epub Jan. 15, 2015. |
Davidson et al., Singles engage the RNA interference pathway. Cell. Aug. 31, 2012;150(5):873-5. doi: 10.1016/j.cell.2012.08.008. |
Denisenko et al., Point mutations in the WD40 domain of Eed block its interaction with Ezh2. Mol Cell Biol. Oct. 1998;18(10):5634-42. |
Dheda et al., Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques. Jul. 2004;37(1):112-4, 116, 118-9. |
Di Certo et al., The artificial gene Jazz, a transcriptional regulator of utrophin, corrects the dystrophic pathology in mdx mice. Hum Mol Genet. Mar. 1, 2010;19(5):752-60. doi: 10.1093/hmg/ddp539. Epub Dec. 4, 2009. |
Dias et al., Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther. Mar. 2002;1(5):347-55. |
Dinger et al., NRED: a database of long noncoding RNA expression. Nucleic Acids Res. Jan. 2009;37(Database issue):D122-6. doi: 10.1093/nar/gkn617. Epub Oct. 1, 2008. |
Dominski et al., Identification and characterization by antisense oligonucleotides of exon and intron sequences required for splicing. Mol Cell Biol. Nov. 1994; 14(11): 7445-7454. |
Dominski et al., Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci USA Sep. 15, 1993;90(18):8673-7. |
Du et al., Progress toward therapy with antisense-mediated splicing modulation. Curr Opin Mol Ther. Apr. 2009;11(2):116-23. |
Duthie et al., Xist RNA exhibits a banded localization on the inactive X chromosome and is excluded from autosomal material in cis. Hum Mol Genet. Feb. 1999;8(2):195-204. |
Ebralidze et al., PU.1 expression is modulated by the balance of functional sense and antisense RNAs regulated by a shared cis-regulatory element. Genes Dev. Aug. 1, 2008;22(15):2085-92. doi: 10.1101/ gad.1654808. Supplemental Data. |
Eddy, Non-coding RNA genes and the modern RNA world. Nat Rev Genet. Dec. 2001;2(12):919-29. |
Edwards et al., Mechanisms regulating imprinted genes in clusters. Curr Opin Cell Biol. Jun. 2007;19(3):281-9. Review. |
Edwards et al., The evolution of the DLK1-DIO3 imprinted domain in mammals. PLoS Biol. Jun. 3, 2008;6(6):e135. doi: 10.1371/journal.pbio.0060135. |
Efthymiou, T. et al., Chemical architecture and applications of nucleic acid derivatives containing 1, 2, 3-triazole functionalities synthesized via click chemistry, Molecules, 2012, vol. 17, No. 11, pp. 12665-12703. |
ENCODE Project Consortium. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol. Apr. 2011;9(4):e1001046. doi: 10.1371/journal.pbio.1001046. Epub Apr. 19, 2011. |
Engstrom et al., Complex Loci in human and mouse genomes. PLoS Genet. Apr. 2006;2(4):e47. Epub Apr. 28, 2006. |
Extended European Search Report in European Appln. No. 13791546.8, dated Jan. 11, 2016, 10 pages. |
Faghihi et al., Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of [beta]-secretase. Nat Med. Jul. 2008;14(7):723-30. doi:10.1038/nml 784. Epub Feb. 23, 2010, 19 pages. |
Feldkotter et al., Quantitative analyses of SMN1 and SMN2 based on real-time light Cycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. Feb. 2002;70(2):358-68. Epub Dec. 21, 2001. |
Fish et al., Hypoxia-inducible expression of a natural cis-antisense transcript inhibits endothelial nitric-oxide synthase. J Biol Chem. May 25, 2007;282(21):15652-66. Epub Apr. 2, 2007. |
Francis et al., Reconstitution of a functional core polycomb repressive complex. Mol Cell. Sep. 2001;8(3):545-56. |
Frieden et al., Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. Nucleic Acids Res. Nov. 1, 2003;31(21):6365-72. |
Froberg et al., Guided by RN As: X-inactivation as a model for IncRNA function. J Mol Biol. Oct. 9, 2013;425(19):3698-706. doi: 10.1016/j.jmb.2013.06.031. Epub Jun. 28, 2013. Review. 15 pages. |
Fu et al., Mir-144 selectively regulates embryonic alpha-hemoglobin synthesis during primitive erythropoiesis. Blood. Feb. 5, 2009;113(6):1340-9. |
Gadalla et al., "MeCP2 and Rett syndrome: reversibility and potential avenues for therapy," Biochem. J., 2011, 439(1):1-14. |
Gajera et al., Molecular and biochemical characterization of Trichoderma isolates inhibiting a phytopathogenic fungi Aspergillus niger Van Tieghem. Phys Mol Plant Path. 2010;74:274-282. |
Ganguli et al., Antagomirbase—a putative antagomir database. Bioinformation. 2011;7(1):41-3. |
Genbank Submission; Accession No. AM750048. Gupta et al. Jul. 12, 2007. |
Genbank Submission; NCBI, Accession No. AM773775. Radha et al., Jul. 13, 2007. |
Genbank Submission; NCBI, Accession No. AM911724.1; Talwar et al. Nov. 26, 2007. |
Genbank Submission; NCBI, Accession No. NG 008691.1 Mar. 2011. 11 pages. |
Genbank Submission; NCBI, Accession No. NG 009361.1; Salomons et al.; Jun. 27, 2016. |
Genbank Submission; NCBI, Accession No. NM 007294.3; Orban et al.; May 25, 2016. |
Genbank Submission; NCBI, Accession No. NM 022876.2. Apr. 2010. 5 pages. |
Genbank Submission; NCBI, Accession No. NM 199461.3; Miles et al.; Jun. 4, 2016. |
Genbank Submission; NIH/NCBI, Accession No. AA106140. Marra et al., Feb. 4, 1997. 1 page. |
Genbank Submission; NIH/NCBI, Accession No. ABZ86223. Nyce et al. Oct. 17, 2003. |
Genbank Submission; NIH/NCBI, Accession No. AL137002. Holt, Dec. 13, 2012. 29 pages. |
Genbank Submission; NIH/NCBI, Accession No. BX383579. Li et al., Dec. 23, 2010. 1 page. |
Genbank Submission; NIH/NCBI, Accession No. NM_001079668. Young et al., Jan. 18, 2014. 4 pages. |
Genbank Submission; NIH/NCBI, Accession No. NM_003317. Young et al., Jan. 18, 2014. 4 pages. |
Genbank Submission; NIH/NCBI, Accession No. NM_022876.2. Singh et al. Mar. 13, 2011. 11 pages. |
Genbank Submission; NIH/NCBI, Accession No. NM_028475. Diez-Roux et al., Feb. 3, 2014. 6 pages. |
Gerbino et al., Mislocalised FUS mutants stall spliceosomal snRNPs in the cytoplasm. Neurobiol Dis. Jul. 2013;55:120-8. doi:10.1016/j.nbd.2013.03.003. Epub Mar. 21, 2013. |
Golding et al., Depletion of Kcnq1ot1 non-coding RNA does not affect imprinting maintenance in stem cells. Development. 2011;138:3667-8. doi: 10.1242/dev.057778. |
Gontan et al., Long Noncoding RNAs and X Chromosome Inactivation. Prog Mol Subcell Biol. 2011;51:43-64. doi: 10.1007/978-3-642-16502-3_3. |
Gooding, M. et al., Oligonucleotide conjugates—Candidates for gene silencing therapeutics. European Journal of Pharmaceutics and Biopharmaceutics, 2016, vol. 107, pp. 321-340, [Epub.] Aug. 10, 2016. |
Guo et al., High resolution genome wide binding event finding and motif discovery reveals transcription factor spatial binding constraints. PLoS Comput Biol. 2012;8(8):e1002638. doi: 10.1371/journal.pcbi.1002638. Epub Aug. 9, 2012. |
Gupta et al., Long non-coding RNA Hot Air reprograms chromatin state to promote cancer metastasis. Nature. Apr. 15, 2010;464(7291):1071-6. doi: 10.1038/nature08975. E-pub version. |
Guttman et al., Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. Mar. 12, 2009;458(7235):223-7. doi: 10.1038/nature07672. Epub Sep. 30, 2009. 13 pages. |
Guttman et al., Modular regulatory principles of large non-coding RN As. Nature. Feb. 15, 2012;482(7385):339-4. Review. |
Halley et al., Natural antisense transcripts as therapeutic targets. Drug Discov Today Ther Strateg. 2013 Fall;10(3):e1 19-e125. |
He et al., Polycomb repressive complex 2 regulates normal development of the mouse heart. Circ Res. Feb. 3, 2012;110(3):406-15. doi: 10.1161/CIRCRESAHA.111.252205. Epub Dec. 8, 2011. |
He, K. et al., Conjugation and Evaluation of Triazole-Linked Single Guide RNA for CRISPR-Cas9 Gene Editing, ChemBioChem, 2016, vol. 17, pp. 1809-1812. |
Hendrich et al., Evolutionary conservation of possible functional domains of the human and murine XIST genes. Human Malec Gen. 1993;2(6):663-72. |
Hernandez et al., Degradation of nuclease-stabilized RNA oligonucleotides in Mycoplasma contaminated cell culture media. Nucleic Acid Ther. Feb. 2012;22(1):58-68. doi: 10.1089/nat.2011.0316. Epub Jan. 9, 2012. |
Horike et al., Targeted disruption of the human LIT1 locus defines a putative imprinting control element playing an essential role in Beckwith-Wiedemann syndrome. Hum Mol Genet. Sep. 1, 2000;9(14):2075-83. |
Huang et al., Non-encoding RNA and development of animals, Science China Life Science, Dec. 31, 2009; pp. 21-30 (with English abstract). |
Inesi et al., Studies of Ca2+ ATPase (SERCA) inhibition. J Bioenerg Biomembr. Dec. 2005;37(6):365-8. Review. |
Inoue et al., Synthesis and hybridization studies on two complementary nona(2′-O-methyl)ribonucleotides. Nucleic Acids Res. Aug. 11, 1987;15(15):6131-48. |
Inouye, Antisense RNA: its functions and applications in gene regulation—a review. Gene. Dec. 10, 1988;72(1-2):25-34. |
International Preliminary Report on Patentability for Application No. PCT/US2013/041461 dated Nov. 27, 2014. |
International Search Report and Written Opinion for Application No. PCT/US2013/041461 dated Aug. 21, 2013, 13 pages. |
Jackson et al., Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol. Jun. 2003;21(6):635-7. Epub May 18, 2003. |
Jayaprakash, K. N. et al., Non-nucleoside building blocks for copper-assisted and copper-free click chemistry for the efficient synthesis of RNA conjugates. Organic Letters, 2010, vol. 12, No. 23,pp. 5410-5413. |
Jensen et al., Chapter 6: CLIP—Crosslinking and ImmunoPrecipitation of In Vivo RNA Targets of RNA-Binding Proteins. Methods in Molecular Biology. 2008;488:85-98. |
Jeon et al., YY1 tethers Xist RNA to the inactive X nucleation center. Cell. Jul. 8, 2011;146(1):119-33. doi: 10.1016/j.cell.2011.06.026. |
Jepsen et al., Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology. Oligonucleotides. 2004; 14(2): 130-46. Review. |
Jia et al., Genome-wide computational identification and manual annotation of human long noncoding RNA genes. RNA Aug. 2010;16(8): 1478-87. doi: 10.1261/rna.1951310. Epub Jun. 29, 2010. |
Johansson et al., Target-specific arrest of mRNAtranslation by antisense 2′-0-alkyloligoribonucleotides. Nucleic Acids Res. Nov. 11, 1994;22(22):4591-8. |
Johnson, Long non-coding RNAs in Huntington's disease neurodegeneration. Neurobiol Dis. 2012;46:245-54. |
Kanduri et al., The length of the transcript encoded from the Kcnq1ot1 antisense promoter determines the degree of silencing. EMBO J. 2006;25:2096-106. |
Kanhere et al., Short RN As are transcribed from repressed polycomb target genes and interact with polycomb repressive complex-2. Mol Cell. Jun. 11, 2010;38(5):675-88. doi: 10.1016/j.molcel.2010.03.019. |
Kao et al., Tumor necrosis factor-alpha decreases sarcoplasmic reticulum Ca2+-ATPase expressions via the promoter methylation in cardiomyocytes. Crit Care Med. Jan. 2010;38(1):217-22. doi: 10.1097/CCM.0b013e3181b4a854. |
Kapranov et al., Genome-wide transcription and the implications for genomic organization. Nat Rev Genet. Jun. 2007;8(6):413-23. |
Kapranov et al., RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science. Jun. 8, 2007;316(5830):1484-8. |
Kariya et al., Mutant superoxide dismutase 1 (SOD1), a cause of amyotrophic lateral sclerosis, disrupts the recruitment of SMN, the spinal muscular atrophy protein to nuclear Cajal bodies. Hum Mol Genet. Aug. 1, 2012;21(15):3421-34. doi: 10.1093/hmg/ddsl 74. Epub May 11, 2012. |
Keil et al., A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy. Mol Ther Nucleic Acids. Jul. 8, 2014;3:el 74. doi: 10.1038/mtna.2014.23. |
Khalil et al., Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA Jul. 14, 2009; 106(28): 11667-72. |
Kierzek et al., The influence of locked nucleic acid residues on the thermodynamic properties of 2′-O-methyl RNA/RNA heteroduplexes. Nucleic Acids Res. Sep. 9, 2005;33(16):5082-93. Print 2005. |
Kim et al., Identification of clustered YY1 binding sites in imprinting control regions. Genome Res. Jul. 2006; 16(7):901-11. Epub Jun. 7, 2006. |
Kim et al., Widespread transcription at neuronal activity-regulated enhancers. Nature. 2010; 465(7295):182-7. Epub Jan. 12, 2011. 15 pages. |
Kiss, Small nucleolar RNA-guided post-transcriptional modification of cellular RNAs. EMBO J. Jul. 16, 2001;20(14):3617-22. |
Klein et al., Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat Neurosci. Dec. 2007;10(12):1513-4. |
Krutzfeldt et al., Silencing of microRNAs in vivo with ‘antagomirs’. Nature. Dec. 1, 2005;438(7068):685-9. Epub Oct. 30, 2005. |
Ku et al., Genomewide analysis of PR C1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet. Oct. 2008;4(10):e1000242. doi: 10.1371/journal.pgen.1000242. Epub Oct. 31, 2008. 14 pages. |
Kutyavin et al., Reduced aggregation and improved specificity of G-rich oligodeoxyribonucleotides containing pyrazolo[3,4-d]pyrimidine guanine bases. Nucleic Acids Res. Nov. 15, 2002;30(22):4952-9. |
Lapointe et al., Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci US A Jan. 20, 2004;101(3):811-6. Epub Jan. 7, 2004. |
Latorra et al., Design considerations and effects of LNA in PCR primers. Mol Cell Probes. Oct. 2003;1 7(5):253-9. |
Lebedeva et al., Phosphorothioate Oligodeoxynucleotides as inhibitors of gene expression: antisense and non-antisense effects. 1991. 99-118. |
Lee et al., A 450 kb Transgene Displays Properties of the Mammalian X-Inactivation Center. Cell. Jul. 12, 1996;86:83-94. |
Lee et al., Control of developmental regulators by Polycomb in human embryonic stem cells. Cell. Apr. 21, 2006;125(2):301-13. |
Lee et al., Genetic analysis of the mouse X inactivation center defines an 80-kb multifunction domain. Proc Natl Acad Sci USA. Mar. 30, 1999;96(7):3836-41. |
Lee et al., Homozygous SMN2 Deletion is a Major Risk Factor among Twenty-Five Korean Sporadic Amyotrophic Lateral Sclerosis Patients. Yonsei Med J. Jan. 2012;53(1):53-57. |
Lee et al., Targeted Mutagenesis of Tsix Leads to Nomandom X Inactivation. Cell. Oct. 1, 1999;99:47-57. |
Lee et al., Tsix, a gene antisense to Xist at the X-inactivation centre. Nat Genet. Apr. 1999;21:400-4. |
Lee et al., Yin Yang 1 positively regulates BRCA1 and inhibits mammary cancer formation. Oncogene. 2012;31:116-27. |
Lee, Disruption of Imprinted X Inactivation by Parent-of-Origin Effects at Tsix. Cell. Sep. 29, 2000; 103:17-27. |
Lee, Epigenetic regulation by long noncoding RNAs. Science. Dec. 14, 2012;338(6113):1435-9. Review. |
Lee, Homozygous Tsix mutant mice reveal a sex-ratio distortion and revert to random X inactivation. Nat Genet. Sep. 2002;32: 195-200. |
Lee, Lessons from X-chromosome inactivation: long ncRNA as guides and tethers to the epigenome. Genes Dev. Aug. 15, 2009;23(16):1831-42. doi: 10.1101/gad.1811209. |
Lee, The X as a Model for RN A's Niche in Epigenomic Regulation. Cold Spring Harb Perspect Biol. 2010;2:A003749. 12 pages. |
Lennox et al., Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier. Mol Ther Nucleic Acids. Aug. 27, 2013;2:e1 17. doi: 10.1038/mtna.2013.46. |
Li et al., CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex 2 intrachromosomal loop. Mol Cell Biol. Oct. 2008;28(20):6473-82. doi: 10.1128/MCB.00204-08. Epub Jul. 28, 2008. |
Li et al., Jarid2 and PRC2, partners in regulating gene expression. Genes Dev. Feb. 15, 2010;24(4):368-80. doi: 10.1101/gad.1886410. Epub Feb. 1, 2010. |
Liang et al., B1-induced caspase-independent apoptosis in MCF-7 cells is mediated by downregulation of Bcl-2 via p53 binding to P2 promoter TATA box. Toxicol Appl Pharmacol. Oct. 1, 2011;256(1):52-61. doi: 10.1016/j.taap.2011.07.010. Epub Jul. 23, 2011. |
Lim et al., Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3′ splice site pairing. J Biol Chem. Nov. 30, 2001;276(48):45476-83. Epub Oct. 2, 2001. |
Lima et al., Single-stranded siRNAs activate RNAi in animals. Cell. Aug. 31, 2012;150(5):883-94. doi: 10.1016/j.cell.2012.08.014. |
Lin et al., An in-depth map of polyadenylation sites in cancer. Nucleic Acids Res. Sep. 1, 2012;40(17):8460-71. Epub Jun. 29, 2012. |
Lin et al., Asymmetric regulation of imprinting on the maternal and paternal chromosomes at the Dlk1-Gtl2 imprinted cluster on mouse chromosome 12. Nat Genet. Sep. 2003;35(1):97-102. Epub Aug. 24, 2003. |
Lipovich et al., MacroRNA underdogs in a microRNA world: evolutionary, regulatory, and biomedical significance of mammalian long non-protein-coding RNA. Biochim Biophys Acta. Sep. 2010;1 799(9):597-615. Review. |
Margueron et al., The Polycomb complex PRC2 and its mark in life. Nature. Jan. 20, 2011;469(7330):343-9. Review. |
Matsuda, S. et al., siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes., ACS Chemical Biology, 2015, vol. 10, pp. 1181-1187. |
Mencia et al., Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss. Nat Genet. May 2009;41(5):609-13. doi: 10.1038/ng.355. Epub Apr. 12, 2009. |
Mendenhall et al., GC-rich sequence elements recruit PRC2 in mammalian ES cells. PLoS Genet. Dec. 9, 2010;6(12):e1001244. doi: 10.1371/journal.ogen.1001244. |
Mercer et al., Long non-coding RNAs: insights into functions. Nat Rev Genet. Mar. 2009;10(3):155-9. Review. |
Mercer et al., Structure and function of long noncoding RNAs in epigenetic regulation. Mar. 5, 2013;20:300-7. |
Merienne et al., SCA8 CAG/CTG expansions, a tale of two TOXICities: a unique or common case? PLoS Genet. Aug. 2009;5(8):e1000593. doi: 10.1371/journal.pgen.1000593. Epub Aug. 14, 2009. |
Mikkelsen et al., Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature. Aug. 2, 2007;448(7153):553-60. doi:10.1038/nature06008. Epub Aug. 13, 2010. |
Miremadi et al., Cancer genetics of epigenetic genes. Hum Mol Genet. Apr. 15, 2007; 16 Spec No. 1:R28-49. Review. |
Mirguet et al., From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151. Bioorg Med Chem Lett. Apr. 15, 2012;22(8):2963-7. doi:10.1016/j.bmcl.2012.01.125. Epub Feb. 8, 2012. |
Miura et al., Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we? Trends Mol Med. Mar. 2006;12(3):122-9. Epub Jan. 27, 2006. |
Miyajima et al., Identification of a cis-acting element for the regulation of SMN exon 7 splicing. J Biol Chem. Jun. 28, 2002;277(26):23271-7. Epub Apr. 15, 2002. |
Modarresi et al., Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat Biotechnol. Mar. 25, 2012;30(5):453-9. doi: 10.1038/nbt.2158. 21 pages. |
Modarresi et al., Natural Antisense Inhibition Results in Transcriptional De-Repression and Gene Upregulation. Nat Biotechnol. Mar. 25, 2012;30(5):453-9. doi: 10.1038/nbt.2158. 21 pages. |
Montgomery et al., The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation. Curr Biol. May 24, 2005;15(10):942-7. |
Morris et al., Small interfering RNA-induced transcriptional gene silencing in human cells. Science. Aug. 27, 2004;305(5688):1289-92. Epub Aug. 5, 2004. |
Morris, RNA-mediated transcriptional gene silencing in human cells. Curr Top Microbial Immunol. 2008;320:211-24. Review. |
Morse et al., Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function. Cancer Gene Ther. Jan. 2012;19(1):30-7. doi: 10.1038/cgt.2011.63. |
Mortazavi et al., Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. Jul. 2008;5(7):621-8. |
Munroe, Antisense RNA inhibits splicing of pre-mRNA in vitro. EMBO J. Aug. 1988; 7(8):2523-32. |
Nagano et al., The Air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Science. Dec. 12, 2008;322(5908): 1717-20. |
Nair, J. K. et al., Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing, Journal of the American Chemical Society, 2014, vol. 136, pp. 16958-16961. |
Nakao, Gene Cluster control through epigenetic mechanisms and cytopathology. Uehara memorial life science foundation research report collection. 23;2009: 1-4. |
Nie et al., Long non-coding RN As: versatile master regulators of gene expression and crucial players in cancer. Am J Transl Res. 2012;4(2):127-50. Epub Apr. 8, 2012. |
Nishida et al., Synthesis, RNA selective hybridization and high nuclease resistance of an oligonucleotide containing novel bridged nucleic acid with cyclic urea structure. Chem Commun (Camb). Aug. 7, 2010;46(29):5283-5. doi: 10.1039/c0cc00154f. Epub Jun. 22, 2010. |
Niwano et al., Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats. Mol Ther. Jun. 2008; 16(6): 1026-32. doi: 10.1038/rnt.2008.61. Epub Mar. 25, 2008. |
Numata et al., Comparative analysis of cis-encoded antisense RNAs in eukaryotes. Gene. May 1, 2007;392(1-2):134-41. |
Numata et al., Identification of novel endogenous antisense transcripts by DNA microarray analysis targeting complementary strand of annotated genes. BMC Genomics. Aug. 22, 2009;10:392. doi: 10.1186/1471-2164-10-392. |
Office Action in Chinese Appln. No. 201380037614.0, dated Dec. 14, 2016, 14 pages. |
Office Action in Chinese Appln. No. 201380037614.0, dated Jan. 26, 2016, 17 pages. |
Office Action in European Appln. No. 13791546.8, dated Jun. 19, 2017, 11 pages. |
Office Action in European Appln. No. 13791546.8, dated Nov. 9, 2018, 7 pages. |
Office Action in Japanese Appln. No. 2015-512847, dated Jun. 1, 2017, 14 pages. |
Okada et al., Comparative expression analysis uncovers novel features of endogenous antisense transcription. Hum Mol Genet. Jun. 1, 2008;17(11):1631-40. doi: 10.1093/hmg/ddn051. Epub Feb. 18, 2008. |
Orom et al., LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene. May 10, 2006;372:137-41. Epub Feb. 24, 2006. |
Ozsolak et al., Comprehensive polyadenylation site maps in yeast and human reveal pervasive alternative polyadenylation. Cell. Dec. 10, 2010;143(6): 1018-29. doi: 10.1016/j.cell.2010.11.020. |
Pandey et al., Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. Mol Cell. Oct. 24, 2008;32(2):232-46. doi: 10.1016/j.molcel.2008.08.022. |
Paro et al., Extending the frontiers of epigenetic regulation. Curr Opin Genet Dev. Apr. 2010;20(2):107-9. doi: 10.1016/j.gde.2010.03.011. |
Pasini et al., Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J. Oct. 13, 2004;23(20):4061-71. Epub Sep. 23, 2004. |
Pedersen et al., Identification and classification of conserved RNA secondary structures in the human genome. PLoS Comput Biol. Apr. 2006;2(4):e33. Epub Apr. 21, 2006. |
Peng et al., Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell. Dec. 24, 2009;139(7):1290-302. doi: 10.1016/j.cell.2009.12.002. Epub Jul. 29, 2010. 24 pages. |
Penny et al., Requirement for Xist in X chromosome inactivation. Nature. Jan. 11, 1996 ;379(6561): 131-7. |
Pereira et al., Ezh2, the histone methyltransferase of PRC2, regulates the balance between self renewal and differentiation in the cerebral cortex. Proc Natl Acad Sci U S A Sep. 7, 2010;107(36):15957-62. doi: 10.1073/pnas.1002530107. Epub Aug. 23, 2010. |
Petersen et al., LNA: a versatile tool for therapeutics and genomics. Trends Biotech. Feb. 2003;21(2):74-81. Review. |
Pietersen et al., Stem cell regulation by polycomb repressors: postponing commitment. Curr Opin Cell Biol. Apr. 2008;20(2):201-7. doi: 10.1016/j.ceb.2008.01.004. Epub Mar. 4, 2008. Review. |
Plath et al., Role of Histone H3 Lysine 27 Methylation in X Inactivation. Science. Apr. 4, 2003;300:131-5. doi: 10.1126/science.1084274. |
Ponting et al., Evolution and functions of long noncoding RNAs. Cell. Feb. 20, 2009;136(4):629-41. doi: 10.1016/j.cell.2009.02.006. Review. |
Prensner et al., Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. Jul. 31, 2011 ;29(8):742-9. doi: 10.1038/nbt.1914. |
Qi et al., Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. Feb. 28, 2013;152(5):1173-83. doi: 10.1016/j.cell.2013.02.022. |
Rader, Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. Dec. 2006;1 16(12):3090-100. |
Rajasekhar et al., Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. Stem Cells. Oct. 2007;25(10):2498-510. Epub Jun. 28, 2007. Review. |
Redrup et al., The long noncoding RNA Kcnq1ot1 organises a lineage-specific nuclear domain for epigenetic gene silencing. Development. Feb. 2009; 136( 4 ):525-30. doi: 10.1242/dev.031328. Epub Jan. 14, 2009. 14 pages. |
Reyon et al., FLASH assembly of TALEN s for high-throughput genome editing. Nat Biotechnol. May 2012;30(5):460-5. doi: 10.1038/nbt.2170. |
Ringrose et al., Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet. 2004;38:413-43. Review. |
Rinn et al., Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. Jun. 29, 2007;129(7):1311-23. |
Rinn et al., Genome Regulation by Long Noncoding RN As. Annu Rev Biochem. 2012;81:145-66. |
Rosok et al., Systematic identification of sense-antisense transcripts in mammalian cells. Nat Biotechnol. Jan. 2004;22(1):104-8. Epub Dec. 14, 2003. |
Rozen et al., Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000;132:365-86. |
Sankaran et al., MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. Proc Natl Acad Sci USA Jan. 25, 2011;108(4):1519-24. |
Sankaran, Targeted therapeutic strategies for fetal hemoglobin induction. Hematol Am Soc Hematol Educ Program. 2011;2011:459-65. |
Sarma et al., Locked nucleic acids (LNAs) reveal sequence requirements and kinetics of Xist RNA localization to the X chromosome. Proc Natl Acad Sci USA. Dec. 21, 2010;107(51):22196-201. doi: 10.1073/pnas.1009785107. Epub Dec. 6, 2010. |
Saxena et al., Long non-coding RNA modifies chromatin. Bioessays. 2011 ;33:830-9. Review. |
Schadt et al., An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet. Jul. 2005;37(7):710-7. Epub Jun. 19, 2005. |
Schlesinger et al., Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet. Feb. 2007;39(2):232-6. Epub Dec. 31, 2006. |
Schoeftner et al., Recruitment of PRC1 function at the initiation of X inactivation independent of PRC2 and silencing. EMBO J. Jul. 12, 2006;25(13):3110-22, Epub Jun. 8, 2006. |
Schuettengruber et al., Genome regulation by polycomb and trithorax proteins. Cell. Feb. 23, 2007;128(4):735-45. |
Schultz et al., Enhancers compete with a long non-coding RNA for regulation of the Kcnq1 domain, Nucl Acids Res. 2015;43(2):745-59. |
Schwartz et al., Genome-wide analysis of Polycomb targets in Drosophila melanogaster. Nat Genet. Jun. 2006;38(6):700-5. |
Schwartz et al., Polycomb complexes and epigenetic states. Curr Opin Cell Biol. 2008;20:266-73. doi: 10.1016/j.ceb.2008.03.002. |
Schwartz et al., Polycomb silencing mechanisms and the management of genomic programmes. Nat Rev Genet. Jan. 2007;8(1):9-22. |
Sciabola et al., Improved nucleic acid descriptors for siRNA efficacy prediction. Nucleic Acids Res. Feb. 1, 2013;41(3):1383-94. doi: 10.1093/nar/gks1191. Epub Dec. 14, 2012. |
Seila et al., Divergent transcription from active promoters. Science. Dec. 19, 2008;322(5909):1849-51. doi: 10.1126/science.1162253. Epub Dec. 4, 2008. |
Seong et al., Huntingtin facilitates polycomb repressive complex 2. Hum Mol Genet. Feb. 15, 2010;19(4):573-83. doi: 10.1093/hmg/ddp524. Epub Nov. 23, 2009. |
Shaver et al., Origin of the polycomb repressive complex 2 and gene silencing by an E(z) homolog in the unicellular alga Chlamydomonas. Epigenetics. May 16, 2010;5(4):301-12. Epub May 24, 2010. |
Shen et al,. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell. Nov. 21, 2008;32(4):491-502. doi: 10.1016/j.molcel.2008.10.016. |
Shen et al., Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells. Cell. Dec. 24, 2009;139(7):1303-14. doi: 10.1016/j.cell.2009.12.003. Epub Jun. 24, 2010. 26 pages. |
Shiraki et al., Cap analysis gene expression for high-throughput analysis of transcriptional starting point and identification of promoter usage. Proc Natl Acad Sci U S A Dec. 23, 2003; 100(26):15776-81. Epub Dec. 8, 2003. |
Shore et al., Pregnancy-induced noncoding RNA (PINC) associates with polycomb repressive complex 2 and regulates mammary epithelial differentiation. PLoS Genet. 2012;8(7):e1002840. doi: 10.1371/journal.ogen.1002840. Epub Jul. 26, 2012. |
Simon et al., High-resolution Xist binding maps reveal two-step spreading during X-chromosome inactivation. Nature. Dec. 19, 2013;504(7480):465-9. doi: 10.1038/nature12719. Epub Oct. 27, 2013. |
Simon et al., Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. Dec. 1, 2008;647(1-2):21-9. Review. |
Sing et al., A vertebrate Polycomb response element governs segmentation of the posterior hindbrain. Cell. Sep. 4, 2009;138(5):885-97. doi: 10.1016/j.cell.2009.08.020. |
Singh et al., A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy. RNA Biol. Jul.-Aug. 2009;6(3):341-50. Epub Jul. 14, 2009. |
Singh et al., Splicing of a Critical Exon of Human Survival Motor Neuron is Regulated by a Unique Silencer Element Located in the Last Intron. Mol Cell Biol. Feb. 2006;26(4):1333-46. doi: 10.1128/MCB.26.4.1333-1346.2006. |
Sirchia et al., Misbehaviour of XIST RNA in breast cancer cells. PLoS One. 2009;4(5):e5559. doi: 10,1371/journal.pone.0005559. Epub May 15, 2009. |
Skordis et al., antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci U S A Apr. 1, 2003; 100(7):4114-9. Epub Mar. 17, 2003. |
Sparmann et al., Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. Nov. 2006;6(11):846-56. Review. |
Submission. EBI Accession No. ADH50651. Baker et al. Mar. 25, 2004. |
Submission. EBI Accession No. EMBL:GC092872. Palma et al. Aug. 31, 2008. |
Summerton, Morpholino antisense oligomers: the case for an Rnase H-independent structural type. Biochim Biophys Acta. Dec. 10, 1999;1489(1):141-58. |
Summons to Attend Oral Proceedings in European Appln. No. 13791546.8, dated Apr. 18, 2018, 9 pages. |
Sun et al., Evidence for a preferential targeting of 3′-UTRs by cis-encoded natural antisense transcripts. Nucleic Acids Res. Oct. 4, 2005;33(17):5533-43. Print 2005. |
Sun et al., SNPs in human miRNA genes affect biogenesis and function. RNA. Sep. 2009;15(9): 1640-51. doi: 10.1261/rna.1560209. Epub Jul. 17, 2009. |
Tae et al., Bromodomain protein 7 interacts with PRMT5 and PRC2, and is involved in transcriptional repression of their target genes. Nucleic Acids Res. Jul. 2011;39(13):5424-38. doi: 10.1093/nar/gkr170. |
Taft et al., Non-coding RN As: regulators of disease. J Pathol. Jan. 2010;220(2): 126-39. doi: 10.1002/path.2638. Review. |
Taft et al., Tiny RN As associated with transcription start sites in animals. Nat Genet. May 2009;41(5):572-8. doi: 10.1038/ng.312. Epub Apr. 19, 2009. Erratum in: Nat Genet. Jul. 2009;41(7):859. |
Takagi et al., Role of Sp 1 in transcription of human ATP2A2 gene in keratinocytes. J Invest Dermatol. Jan. 2008;128(1):96-103. Epub Jun. 28, 2007. |
Takahashi et al., Deletion of Gtl2, imprinted non-coding RNA, with its differentially methylated region induces lethal parent-origin-dependent defects in mice. Hum Mol Genet. May 15, 2009;18(10):1879-88. doi: 10.1093/hmg/ddp108. Epub Mar. 4, 2009. |
Tano et al., MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEES Lett. Nov. 19, 2010;584(22):4575-80. doi: 10.1016/j.febslet.2010.10.008. Epub Oct. 13, 2010. |
Taylor et al. Drug Discovery Today 1999, vol. 4, pp. 562-567. |
Thomas et al., Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia. Curr Atheroscler Rep. Jan. 2010;12(1):58-65. doi: 10.1007 /s1 1883-009-0078-7. |
Thorvaldsen et al., A YY1 bridge for X inactivation. Cell. Jul. 8, 2011;146(1): 11-3. doi: 10.1016/j.cell.2011.06.029. |
Thorvaldsen et al., SnapShot: imprinted gene clusters. Cell. Sep. 7, 2007;130(5):958. |
Tian et al., The long noncoding RNA, Jpx, is a molecular switch for X chromosome inactivation. Cell. Oct. 29, 2010;143(3):390-403. doi: 10.1016/j.cell.2010.09.049. 21 pages. |
Torarinsson et al., Thousands of corresponding human and mouse genomic regions unalignable in primary sequence contain common RNA structure. Genome Res. Jul. 2006;16(7):885-9. Epub Jun. 2, 2006. Erratum in: Genome Res. Nov. 2006;16(11): 1439. |
Tsai et al., Higher order chromatin structure at the X-inactivation center via looping DNA Dev Biol. Jul. 15, 2008;319(2):416-25. doi: 10.1016/j.ydbio.2008.04.010. Epub Apr. 18, 2008. 22 pages. |
Tsai et al., Long noncoding RNA as modular scaffold of histone modification complexes. Science. Aug. 6, 2010;329(5992):689-93. doi: 10.1126/science.1192002. Epub Nov. 2, 2010. 9 pages. |
Tsuiji et al., Spliceosome integrity is defective in the motor neuron diseases ALS and SMA. EMBO Mol Med. Feb. 2013;5(2):221-34. doi: 10.1002/emmm.201202303. Epub Jan. 25, 2013. |
Turner et al., Survival motor neuron deficiency enhances progression in an amyotrophic lateral sclerosis mouse model. Neurobiol Dis. Jun. 2009;34(3):511-7. doi: 10.1016/j.nbd.2009.03.005. Epub Mar. 28, 2009. |
Ule et al., CLIP Identifies Nova-Regulated RNA Networks in the Brain. Science. 2003;302: 1212-5. doi: 10.1126/science.1090095. |
Ule et al., CLIP: A method for identifying protein-RNA interaction sites in living cells. Methods. 2005;37:376-86. |
Valen et al., Genome-wide detection and analysis of hippocampus core promoters using DeepCAGE. Genome Res. Feb. 2009;19(2):255-65. doi: 10.1101/gr.084541.108. Epub Dec. 11, 2008. |
Van Peer et al., miRBase Tracker: keeping track of microRNA annotation changes. Database (Oxford). Aug. 25, 2014;2014. pii:bau080. doi: 10.1093/database/bau080. Print 2014. |
Varela et al., Natural Antisense Makes Sense for Gene-specific Activation in Brain. Mol Ther Nucleic Acids. May 15, 2012;1:e24. doi: 10.1038/mtna.2012.17. |
Veldink et al., SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS. Neurology. Sep. 27, 2005;65(6):820-5. Epub Aug. 10, 2005. |
Venter et al., The sequence of the human genome. Science. Feb. 16, 2001;291(5507): 1304-51. Erratum in: Science Jun. 5, 2001;292(5523): 1838. |
Vickers et al., Fully modified 2′ MOE oligonucleotides redirect polyadenylation. Nucleic Acids Res. Mar. 15, 2001;29(6):1293-9. |
Wahlestedt, Natural antisense and noncoding RNA transcripts as potential drug targets. Drug Discov Today. Jun. 2006;1 1(11-12):503-8. |
Wahlestedt, Targeting long non-coding RNA to therapeutically upregulate gene expression. Nature Rev Drug Disc. Jun. 2013;12:433-46. Review. |
Wan et al., Regulation of imprinting in clusters: noncoding RNAs versus insulators. Adv Genet. 2008;61:207-23. Review. |
Wang et al., Correlation between Dnase I hypersensitive site distribution and gene expression in HeLa S3 cells. PLoS One. 2 012;7(8):e42414. doi: 10.1371/journal.pone.0042414. Epub Aug. 10, 2012. |
Wang et al., Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol. Jul. 2012;41(1):276-84. |
Wang et al., Molecular mechanisms of long noncoding RNAs. Cell Press. Sep. 16, 2011; 43(6):904-14. |
Wang et al., Multifunctional transcription factor YY1: a therapeutic target in human cancer? Expert Opin Ther Targets. 2006;10(2):253-66. |
Whitehead et al., Variation in tissue-specific gene expression among natural populations. Genome Biol. 2005;6(2):R13. Epub Jan. 26, 2005. |
Williams et al., Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J Neurosci. Jun. 17, 2009;29(24):7633-8. doi: 10.1523/JNEUROSCI.0950-09.2009. |
Williamson et al., Identification of an imprinting control region affecting the expression of all transcripts in the Gnas cluster. Nat Genet. Mar. 2006;38(3):350-5. |
Wilusz et al., A triple helix stabilizes the 3′ ends of long noncoding RNAs that lack poly(A) tails. Genes Dev. Nov. 1, 2012;26(21):2392-407. doi: 10.1101/gad.204438.112. Epub Oct. 16, 2012. |
Wilusz et al., Long noncoding RN As: functional surprises from the RNA world. Genes Dev. Jul. 1, 2009;23(13):1494-504. doi: 10.1101/gad.1800909. |
Woo et al., A Region of the Human HOXD Cluster that Confers Polycomb-Group Responsiveness. Cell. Jan. 8, 2010;140:99-110. |
Woo et al., Gene activation of SMN by selective disruption of IncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophy. Proc Natl Acad Sci US A. Feb. 21, 2017;114(8):E1509-E1518. doi:10.1073/pnas.1616521114. Epub Feb. 13, 2017. |
Wu et al., Binding interactions between long noncoding RNA Hot Air and PRC2 proteins. Biochemistry, Dec. 31, 2013;52(52):9519-27. doi: 10.1021/bi401085h. |
Wutz et al., A Shift from Reversible to Irreversible X Inactivation Is Triggered during ES Cell Differentiation. Malec Cell. Apr. 2000;5:695-705. |
Xiong et al., Polycomb antagonizes p300/CREB-binding protein associated factor to silence FOXP3 in a Kruppel-like factor-dependent manner. J Biol Chem. Oct. 5, 2012;287(41):34372-85. doi: 10.1074/jbc.M1 11.325332. Epub Aug. 15, 2012. |
Yakali et al., Supramolecular chirality-sensing DNA-mimicry of a norbornane derivative decorated with isoxazoline and methylpyrolidine-2,5-dione ring. J Mol Structure. Jun. 10, 2013;1041: 164-174. |
Yamazaki et al., FUS-SMN protein interactions link the motor neuron diseases ALS and SMA. Cell Rep. Oct. 25, 2012;2(4):799-806. doi:10.1016/j.celrep.2012.08.025. Epub Sep. 27, 2012. |
Yang et al., High fidelity PCR with an off/on switch mediated by proofreading polymerases combining with phosphorothioate-modified primer. Biochem Biophys Res Commun. Mar. 4, 2005;328(1):265-72. Erratum in: Biochem Biophys Res Commun. Jun. 3, 2005;331(2):682. Zhang, Jia [removed]; Li, Kai [removed]. |
Yang et al., Long noncoding RN As: fresh perspectives into the RNA world. Trends Biochem Sci. Jan. 2014;39(1):35-43. doi: 10.1016/j.tibs.2013.10.002. Epub Nov. 27, 2013. Review. |
Yang et al., The histone code regulating expression of the imprinted mouse Igf2r gene. Endocrinology. Dec. 2003;144(12):5658-70. |
Yap et al., Molecular interplay of the noncoding RNA ANRIL and methylated his tone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. Jun. 11, 2010 ;38(5):662-74. doi: 10.1016/j.molcel.2010.03.021. Epub Jun. 11, 2011. 23 pages. |
Yatsuki et al., Sequence-based structural features between Kvlqt1 and Tapa1 on mouse chromosome 7F4/F5 corresponding to the Beckwith-Wiedemann syndrome region on human 11p15.5: long-stretches of unusually well conserved intronic sequences of kvlqt1 between mouse and human. DNA Res. Jun. 30, 2000;7(3): 195-206. |
Yu et al., Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell. Aug. 31, 2012;150(5):895-908. doi: 10.1016/j.cell.2012.08.002. |
Zara Vinos et al., Yin yang 1 expression in human tumors. Cell Cycle. Feb. 1, 2010;9(3):512-22. |
Zhang et al., Long noncoding RNA-mediated intrachromosomal interactions promote imprinting at the Kcnq1 locus. J Cell Biol. 2014;204(1):61-75. |
Zhang et al., NATsDB: Natural Antisense Transcripts DataBase. Nucleic Acids Res. Jan. 2007;35(Database issue):D156-61. Epub Nov. 1, 2006. |
Zhang et al., Perinucleolar Targeting of the Inactive X during S Phase: Evidence for a Role in the Maintenance of Silencing. Cell. May 18, 2007; 129:693-706. |
Zhao et al., Genome-wide identification of polycomb-associated RNAs by RIP-seq. Mol Cell. Dec. 22, 2010;40(6):939-53. |
Zhao et al., Polycomb proteins targeted by a short repeat RNA to the mouse X-chromosome. Science. 2008; 322(5902):750-756. doi:10.1126/science.1163045. E-pub version. |
Zhou et al., Targeting RNA-splicing for SMA treatment. Mol Cells. Mar. 2012;33(3):223-8. doi: 10.1007 /s10059-012-0005-6. |
Also Published As
Publication number | Publication date |
---|---|
CA2873779A1 (en) | 2013-11-21 |
EP2850190A4 (en) | 2016-02-10 |
AU2013262709A1 (en) | 2015-01-22 |
US10655128B2 (en) | 2020-05-19 |
EP2850190A1 (en) | 2015-03-25 |
WO2013173608A1 (en) | 2013-11-21 |
EA201492116A1 (en) | 2015-05-29 |
US20210102203A1 (en) | 2021-04-08 |
EP2850190B1 (en) | 2020-07-08 |
US20150152410A1 (en) | 2015-06-04 |
US20180223282A1 (en) | 2018-08-09 |
JP2015518712A (en) | 2015-07-06 |
CN104583402A (en) | 2015-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11788089B2 (en) | Compositions and methods for modulating MECP2 expression | |
US10058623B2 (en) | Compositions and methods for modulating UTRN expression | |
US10174323B2 (en) | Compositions and methods for modulating ATP2A2 expression | |
US10174315B2 (en) | Compositions and methods for modulating hemoglobin gene family expression | |
US10059941B2 (en) | Compositions and methods for modulating SMN gene family expression | |
US20150159161A1 (en) | Compositions and methods for modulating pten expression | |
US20150191722A1 (en) | Compositions and methods for modulating apoa1 and abca1 expression | |
US20160122760A1 (en) | Compositions and methods for modulating foxp3 expression | |
EP2849800A1 (en) | Compositions and methods for modulating bdnf expression | |
US10837014B2 (en) | Compositions and methods for modulating SMN gene family expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: HOWARD HUGHES MEDICAL INSTITUTE, MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LEE, JEANNIE T.;REEL/FRAME:053511/0465 Effective date: 20130514 Owner name: THE GENERAL HOSPITAL CORPORATION D/B/A/ MASSACHUSETTS GENERAL HOSPITAL, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HOWARD HUGHES MEDICAL INSTITUTE;REEL/FRAME:053511/0469 Effective date: 20130514 Owner name: RANA THERAPEUTICS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KRIEG, ARTHUR M.;SUBRAMANIAN, ROMESH;MCSWIGGEN, JAMES;REEL/FRAME:053511/0442 Effective date: 20130423 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
AS | Assignment |
Owner name: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TRANSLATE BIO MA, INC;REEL/FRAME:055419/0935 Effective date: 20210206 |
|
AS | Assignment |
Owner name: RANA DEVELOPMENT, INC., MASSACHUSETTS Free format text: CHANGE OF NAME;ASSIGNOR:RANA THERAPEUTICS, INC.;REEL/FRAME:056062/0179 Effective date: 20161110 Owner name: TRANSLATE BIO MA, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RANA DEVELOPMENT, INC.;REEL/FRAME:056062/0195 Effective date: 20170626 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction |